<SEC-DOCUMENT>0001193125-22-246784.txt : 20220919
<SEC-HEADER>0001193125-22-246784.hdr.sgml : 20220919
<ACCEPTANCE-DATETIME>20220919081034
ACCESSION NUMBER:		0001193125-22-246784
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220915
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220919
DATE AS OF CHANGE:		20220919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		221249439

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d401810d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:virx="http://viracta.com/20220915" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-09-15_to_2022-09-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-09-15_to_2022-09-15">0001061027</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="virx-20220915.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-09-15_to_2022-09-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001061027</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-15</xbrli:startDate> <xbrli:endDate>2022-09-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-09-15_to_2022-09-15">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt:datemonthdayyearen">September&#160;15, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-09-15_to_2022-09-15">VIRACTA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-09-15_to_2022-09-15">000-51531</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-09-15_to_2022-09-15">94-3295878</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">Identification No.)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-09-15_to_2022-09-15">2533 S Coast Hwy 101</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-09-15_to_2022-09-15">Suite 210</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-09-15_to_2022-09-15">Cardiff</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-09-15_to_2022-09-15">92007</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-09-15_to_2022-09-15">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-09-15_to_2022-09-15">400-8470</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-09-15_to_2022-09-15">Common Stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-09-15_to_2022-09-15">VIRX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-09-15_to_2022-09-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Succession of Chief Executive Officer and President; Appointment of Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On September&#160;15, 2022, the Board of Directors (&#8220;Board&#8221;) of Viracta Therapeutics, Inc. (the &#8220;Company&#8221;) appointed Mark Rothera to serve as Chief Executive Officer (&#8220;CEO&#8221;) and President of the Company, effective September&#160;19, 2022. In addition, also on September&#160;15, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mr.&#160;Rothera to serve as a Class&#160;I director of the Company, also effective September&#160;19, 2022, with a term expiring at the annual meeting of stockholders to be held in 2025. Mr.&#160;Rothera will succeed Ivor Royston, M.D., in the positions of CEO and President, and Dr.&#160;Royston&#8217;s tenure as an officer and employee of the Company is ending effective September&#160;19, 2022. Dr.&#160;Royston will continue to serve as a Class&#160;III director of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Most recently, Mr.&#160;Rothera, 60, served as President, Chief Executive Officer and as a member of the board of directors at Silence Therapeutics plc, a pharmaceutical company, from September 2020 until February 2022. From August 2017 to March 2020, Mr.&#160;Rothera served as President and Chief Executive Officer and member of the board of Orchard Therapeutics plc, a biotechnology company. From 2013 to August 2017, Mr.&#160;Rothera served as Chief Commercial Officer of PTC Therapeutics, a biotechnology company. From 2012 to 2013, he served as Global President of Aegerion Pharmaceuticals Inc., a biotechnology company, and from 2006 to 2012 as Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies, Inc., a pharmaceutical company, in Europe, the Middle East and Africa. Mr.&#160;Rothera served as Area VP Europe, Middle East and Africa for Chiron BioPharmaceuticals, a biotechnology company, from 2000 to 2005 and previously held various global strategic and operational marketing and sales roles with French and U.K. operations of Glaxo Wellcome, a pharmaceutical company. Mr.&#160;Rothera currently sits on the board of GenPharm. Mr.&#160;Rothera received an M.A. in Natural Sciences from Cambridge University, an M.B.A. from the European Institute for Business Administration (INSEAD) and a Diploma in Company Direction from Institute of Directors, United Kingdom. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mark Rothera Compensation Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Also on September&#160;15, 2022, upon the recommendation of the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;) and the approval of the Board, the Company entered into an executive compensation agreement with Mr.&#160;Rothera (the &#8220;employment agreement&#8221;), to be effective on September&#160;19, 2022, Mr.&#160;Rothera&#8217;s first day of employment (the &#8220;effective date&#8221;). Mr.&#160;Rothera&#8217;s employment under the employment agreement is at will and may be terminated at any time by the Company or by Mr.&#160;Rothera. Pursuant to the employment agreement, Mr.&#160;Rothera will receive an annual base salary of $580,650 and a discretionary annual target bonus of up to fifty-five percent (55%) of his annual base salary (the &#8220;target bonus&#8221;), based on the achievement of performance objectives to be determined by the Board or an authorized committee thereof. Under the employment agreement, for the Company&#8217;s 2022 fiscal year, Mr.&#160;Rothera is guaranteed to receive not less than the target bonus, prorated for the portion of the year that Mr.&#160;Rothera is employed by the Company. The employment agreement also provides for a <span style="white-space:nowrap">sign-on</span> bonus of $100,000 <span style="white-space:nowrap">(&#8220;sign-on</span> bonus&#8221;) and reimbursement for certain travel and other expenses related to his potential relocation to San Diego, California, subject to full or partial repayment in the event Mr.&#160;Rothera terminates his employment without &#8220;good reason&#8221; (as defined in the employment agreement) prior to the second anniversary of the effective date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the employment agreement, Mr.&#160;Rothera will also receive an initial grant of time-based <span style="white-space:nowrap">non-statutory</span> stock options to purchase 1,375,000 shares of the Company common stock (the &#8220;initial option&#8221;) with an exercise price per share equal to the per share fair market value of the Company&#8217;s common stock on the date of grant. The initial option will vest with respect to twenty-five percent (25%) of the total number of shares granted on the first anniversary of the Effective Date, and with respect to <span style="white-space:nowrap">one-forty-eighth</span> (1/48) of the total number of shares granted on the last day of each <span style="white-space:nowrap">one-month</span> period to Mr.&#160;Rothera&#8217;s service thereafter. The initial option will be subject to the terms and conditions of the Viracta Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If the Company terminates Mr.&#160;Rothera&#8217;s employment other than for &#8220;cause,&#8221; death or &#8220;disability&#8221; or Mr.&#160;Rothera resigns for &#8220;good reason&#8221; outside the period beginning three (3)&#160;months prior to a &#8220;change in control&#8221; (as all such terms are defined in the employment agreement) and ending twelve (12)&#160;months following a change in control (such period, the &#8220;change in control period&#8221;), Mr.&#160;Rothera will be entitled to: (i)&#160;continued payment of his base salary, in effect immediately prior to his termination date, for a period of fifteen (15)&#160;months; (ii) reimbursement by the Company for the cost of continuation of health coverage for each officer and their eligible dependents pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;), for up to fifteen (15)&#160;months; (iii) any actual bonus for the fiscal year preceding the termination date that have not been paid as of the date of termination; (iv)&#160;the <span style="white-space:nowrap">pro-rated</span> target bonus for the fiscal year of the Company in which the termination date occurs; and (v)&#160;the right to exercise his stock options until the close of business on the earliest of the twelve (12)&#160;months after his termination of employment or the term/expiration date of the stock option. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If the Company terminates Mr.&#160;Rothera&#8217;s employment other than for cause, death or disability, or Mr.&#160;Rothera resigns for good reason during the change in control period, Mr.&#160;Rothera will be entitled to: (i)&#160;a lump sum payment equal to eighteen (18)&#160;months of base salary in effect immediately prior to Mr.&#160;Rothera&#8217;s termination date; (ii)&#160;reimbursement by the Company for the cost of premiums for continued coverage under COBRA for up to eighteen (18)&#160;months; (iii) any actual bonus for the fiscal preceding the termination date that have not been paid as of the date of termination; (iv)&#160;lump sum payment of one hundred and fifty percent (150%) of the target bonus for the fiscal year of the Company in which the termination date occurs; and (v)&#160;acceleration of the unvested portion of any service-vesting stock option or other equity awards held by Mr.&#160;Rothera immediately prior to termination (with any performance-based vesting assumed at target performance). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If Mr.&#160;Rothera&#8217;s employment with the Company terminates due to Mr.&#160;Rothera&#8217;s death or disability, Mr.&#160;Rothera or his estate will receive a payment equal to the target bonus in the year of termination, <span style="white-space:nowrap">pro-rated</span> to reflect the number of days in the fiscal year of termination that he provided service, and Mr.&#160;Rothera will be eligible for the separation equity rights described above with respect to a termination within or outside of the change in control period, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing benefits are conditioned upon Mr.&#160;Rothera signing and not revoking a release of claims within 60 days following his employment termination date and his continuing compliance with the terms of a confidentiality and information agreement, which includes (i)&#160;a twelve (12)&#160;month <span style="white-space:nowrap">non-competition</span> provision applicable to him, (ii)&#160;a twelve (12)&#160;month <span style="white-space:nowrap">non-solicitation</span> provision applicable to him, and (iii)&#160;a mutual <span style="white-space:nowrap">non-disparagement</span> provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If any of the payments provided for under the employment agreement or otherwise payable to Mr.&#160;Rothera would constitute &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Internal Revenue Code and would be subject to the related excise tax under Section&#160;4999 of the Internal Revenue Code, then he will be entitled to receive either full payment of benefits or such lesser amount that would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of after tax benefits to the participant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Rothera will receive no additional compensation for his service on the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The summary of Mr.&#160;Rothera&#8217;s executive employment agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the executive employment agreement, which is attached to this Current Report on Form <span style="white-space:nowrap">8-K</span> as Exhibit 10.1 and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">In addition, the Company has entered into its standard form of indemnification agreement with Mr.&#160;Rothera. The form indemnification agreement was filed with the Securities and Exchange Commission on December&#160;23, 2004, as Exhibit 10.5 to the Company&#8217;s Registration Statement on <span style="white-space:nowrap">Form&#160;S-1&#160;and</span> is incorporated herein by reference. Mr.&#160;Rothera has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item&#160;404(a) of Regulation <span style="white-space:nowrap">S-K</span> promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed. There is no arrangement or understanding between Mr.&#160;Rothera or any other person pursuant to which Mr.&#160;Rothera was selected as an officer or director. There are no family relationships between Mr.&#160;Rothera and any of the Company&#8217;s directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Ivor Royston Separation Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">In connection with Dr.&#160;Royston&#8217;s termination of employment as CEO and President, on September&#160;15, 2022, Dr.&#160;Royston and the Company entered into a separation agreement and release of claims related to Dr.&#160;Royston&#8217;s employment with the Company (the &#8220;separation agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The separation agreement provides that, subject to (a)&#160;Dr.&#160;Royston&#8217;s execution of the separation agreement and release, (b)&#160;the separation agreement and release becoming effective, and (c)&#160;Dr.&#160;Royston&#8217;s continued compliance with the terms of the separation agreement, the Company will (i)&#160;provide for&#160;the continuation of payments of his base salary at the rate of $47,250 per month, less applicable withholdings, for fifteen (15)&#160;months from the employment termination date; (ii)&#160;provide for the continuation of healthcare coverage payments in the amount of $3,064.18 per month, less applicable withholdings, for fifteen (15)&#160;months from the employment termination date; (iii)&#160;reimburse Dr.&#160;Royston for the amounts he pays for COBRA coverage to continue his vision, dental and life insurance benefits for a period of up to 15 months, provided Dr.&#160;Royston timely elects and pays for continued coverage pursuant to COBRA; (iv)&#160;pay a <span style="white-space:nowrap">pro-rated</span> portion of Dr.&#160;Royston&#8217;s target bonus for the 2022 fiscal year based on the number of days between the start of the 2022 fiscal year and September&#160;30, 2022, subject to the Board or Compensation Committee determining that any applicable performance objectives have been achieved; and (v)&#160;extend the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">
post-termination exercise period of Dr.&#160;Royston&#8217;s stock options that are outstanding and vested as of date he is no longer a service provider to the Company (including as a member of the Board, advisor, or otherwise) to the date that is two years following such separation date, or, if earlier, the maximum term of each applicable stock option. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The summary of Dr.&#160;Royston&#8217;s separation agreement and release set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the separation agreement and release, which is attached to this Current Report on Form <span style="white-space:nowrap">8-K</span> as Exhibit 10.2 and incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Increase in Shares Reserved Under Inducement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On September&#160;15, 2022, in connection with the appointment of Mr.&#160;Rothera as the CEO and President of the Company and the approval of his employment agreement, the Board approved increasing the number of shares of common stock reserved under the 2021 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;) by 1,375,000 shares, to a new total of 2,375,000 shares of common stock. As previously disclosed, the Board adopted the Inducement Plan without stockholder approval pursuant to Rule 5635(c)(4) and Rule 5635(c)(3) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees <span style="white-space:nowrap">or&#160;non-employee&#160;directors</span> of the Company (or following such individuals&#8217; bona fide period <span style="white-space:nowrap">of&#160;non-employment&#160;with</span> the Company), as an inducement material to the individuals&#8217; entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the NASDAQ Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">As described above, Mr.&#160;Rothera&#8217;s initial option will be granted out of and subject to the terms of the Inducement Plan. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On September&#160;19, 2022, the Company issued a press release announcing the succession and appointments described in this Current Report on Form <span style="white-space:nowrap">8-K.</span> A copy of the press release is furnished herewith as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The information set forth under this Item&#160;7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d) Exhibits </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d401810dex101.htm">Executive Employment Agreement by and between the Company and Mark Rothera, dated September&#160;15, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d401810dex102.htm">Separation Agreement and Release by and between the Company and Ivor Royston, dated September&#160;15, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d401810dex991.htm">Press Release dated September&#160;19, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September&#160;19, 2022 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:9%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:90%"></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Chevallard</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Daniel Chevallard</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Operating Officer and Chief Financial Officer</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d401810dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIRACTA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Executive Employment Agreement (this &#147;<B>Agreement</B>&#148;) by and between Viracta Therapeutics, Inc. (the
&#147;<B>Company</B>&#148;) and Mark Rothera (&#147;<B>Executive</B>&#148;) is effective as of September&nbsp;19, 2022 (the &#147;<B>Effective Date</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Duties and Scope of Employment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Positions, Authority and Duties</U>. Executive will serve as Chief Executive Officer and President of the Company. Executive will have
the authority, responsibilities and duties as are customary for the Chief Executive Officer of a publicly traded company in the United States, and such additional authority, responsibilities and duties, consistent with Executive&#146;s position
within the Company, as will reasonably be assigned to Executive by the Company&#146;s Board of Directors (the &#147;<B>Board</B>&#148;). The period of Executive&#146;s employment from the Effective Date is referred to herein as the
&#147;<B>Employment Term</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Board Membership</U>. Executive shall be appointed to the Board as of the Effective Date and
shall serve as a member of the Board during the Employment Term, subject to any required shareholder approval. For each annual meeting of the shareholders at which Executive&#146;s term expires that occurs during the Employment Term, Executive will
be nominated for <FONT STYLE="white-space:nowrap">re-election</FONT> as a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Obligations</U>. During the
Employment Term, Executive shall perform Executive&#146;s duties faithfully and to the best of Executive&#146;s ability and shall devote substantially all of Executive&#146;s business efforts and time to the Company. For the duration of the
Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration which would conflict or interfere with the performance of such services without the prior
approval of the Board. Notwithstanding the foregoing, Executive may participate fully in social, charitable, civic and investment activities (including service as an officer or a director of an entity related to such activities). In addition to
being permitted to engage in such social, charitable, civic and investment activities, Executive shall have the right, with the prior written consent of the Board, to serve as a member of the board of directors or comparable governing bodies
(including any board committees) of up to two <FONT STYLE="white-space:nowrap">for-profit</FONT> businesses, one of which shall be satisfied by Executive&#146;s continued service on the board of GenPharm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Work Location</U>. Executive&#146;s primary work location will be his home office in New Hampshire. Executive shall allocate sufficient
time working in person at the Company&#146;s headquarters in Cardiff, California, while incorporating considerations such as pandemic lockdowns, travel restrictions, social distancing measures, virtual conferences and internet-based meetings against
business impact and timely execution on deliverables. To such an end, Executive shall dedicate a minimum of a third (1/3rd) of his time on a quarterly basis for the conduct of <FONT STYLE="white-space:nowrap">on-site</FONT> work-related endeavors,
including, but not limited to working at the Company&#146;s headquarters, medical, scientific and investor conferences, fund raising, clinical trials and vendor related activities as well as travel related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. The parties agree that Executive&#146;s employment with the Company
will be <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither Executive&#146;s job performance nor promotions,
commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&#146;s employment with the Company. However, as described in this
Agreement, Executive may be entitled to severance benefits depending on the circumstances of Executive&#146;s termination of employment with the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Compensation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Base Compensation</U>. During the Employment Term, the Company will pay Executive an annual salary of five hundred eighty thousand six
hundred fifty Dollars ($580,650.00) as compensation for Executive&#146;s services (the &#147;<B>Base Salary</B>&#148;), which will be paid periodically in accordance with the Company&#146;s normal payroll practice, subject to Section&nbsp;19.
Executive&#146;s salary will be subject to review and adjustments may be made in the Company&#146;s sole discretion, except that Executive&#146;s Base Salary may not be reduced without notice and written consent of Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Sign on Bonus and Relocation Reimbursement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Sign on Bonus</U>. Executive will be paid a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $100,000 (the
&#147;<B><FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus</B>&#148;), subject to Section&nbsp;19. The <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus will be paid within 30 business days following the Effective Date. If Executive
voluntarily terminates his employment with the Company, other than for Good Reason, before the date that is eighteen (18)&nbsp;months after the Effective Date, Executive agrees to repay to the Company a prorated portion of the amount of the <FONT
STYLE="white-space:nowrap">Sign-on</FONT> Bonus within (thirty) 30 days following his last day with the Company. The amount of such repayment would represent the portion of the <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus received by
Executive that has not been earned as of the date of the voluntary termination. For clarity, the <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus will be earned based on the number of days that Executive has been employed by the Company divided
by the number of days in the (eighteen) <FONT STYLE="white-space:nowrap">18-month</FONT> period beginning on the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Relocation Reimbursement</U>. The Company will reimburse Executive for reasonable and bona fide costs for up to three
(3)&nbsp;exploratory trips to the San Diego, California metropolitan area, for Executive and his family (namely, Sahel Golestan), up to a combined maximum of $7,500. If (x)&nbsp;Executive notifies the Company during the first twelve (12)&nbsp;months
of the Employment Term of his intent to relocate his current principal place of residence to the San Diego, California metropolitan area and (y)&nbsp;so relocates his current principle place of residence no later than the date that is (eighteen) 18
months after the Effective Date, subject to Section&nbsp;19, the Company will reimburse reasonable qualified relocation costs of temporary housing and a rental car for up to three (3)&nbsp;months (the &#147;<B>Relocation Reimbursement</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Executive voluntarily terminates Executive&#146;s employment with the Company other than for Good Reason before the first anniversary
of the start of Executive&#146;s employment with the Company, Executive agrees to repay to the Company 100% of the amount of the Relocation Reimbursement within thirty (30)&nbsp;days following the Executive&#146;s last day with the Company. If
Executive voluntarily terminates Executive&#146;s employment with the Company other than for Good Reason after the first anniversary but before the second anniversary of the start of the Executive&#146;s employment with the Company, Executive agrees
to repay to the Company a prorated portion of 50% of the amount of the Relocation Reimbursement within thirty (30)&nbsp;days following the Executive&#146;s last day with the Company. The amount of such repayment would represent the portion of the
Relocation Reimbursement received by Executive that has not been earned as of the date of the voluntary termination. For clarity, the Relocation Reimbursement will be earned based on the number of days that Executive has been employed by the Company
divided by the number of days in the <FONT STYLE="white-space:nowrap">two-year</FONT> period beginning on the date Executive&#146;s employment begins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the first anniversary of the employment start date, Executive will have to make a special request to the Board for any financial
assistance with respect to relocation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Employee Benefits</U>. During the Employment Term, Executive will be entitled to
participate in the employee benefit plans and programs currently and hereafter maintained by the Company of general applicability to other senior executives of the Company, including, without limitation, the Company&#146;s 401(k) retirement plan,
group medical, dental, vision, disability, life insurance, and flexible-spending account plans, if any, pursuant to the terms and conditions of such plans. The Company reserves the right to cancel or change the benefit plans and programs it offers
to its employees at any time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Paid Time Off/Vacation</U>. During the Employment Term, Executive will be entitled to
accrue twenty-five (25)&nbsp;days of paid <FONT STYLE="white-space:nowrap">time-off/vacation</FONT> annually, in accordance with the Company&#146;s paid-time off policies. Accrued and unused vacation will carry over from year to year, as required by
applicable California law, up to a cap of no more than 30 days. Notwithstanding such policies, (i)&nbsp;Executive&#146;s full twenty-five (25)&nbsp;days of paid <FONT STYLE="white-space:nowrap">time-off/vacation</FONT> for Executive&#146;s first
year of employment will accrue on the Effective Date; and (ii)&nbsp;paid <FONT STYLE="white-space:nowrap">time-off/vacation</FONT> to be used at the discretion of the Executive, subject to business needs and approval of the Board Chairman. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Target Bonus</U>. During the Employment Term, Executive will be eligible to receive an annual bonus of up to fifty-five percent (55%)
of Executive&#146;s Base Salary (the &#147;<B>Target Bonus</B>&#148;), subject to Section&nbsp;19, upon achievement of performance objectives to be determined by the Board or an authorized committee thereof (the &#147;<B>Committee</B>&#148;) in its
sole discretion but in consultation with Executive. Any bonus payable (the &#147;<B>Actual Bonus</B>&#148;)<B> </B>will be paid as soon as practicable after the Board or Committee determines such bonus has been earned, but in no event will any such
bonus be paid after March&nbsp;15 following the calendar year in which such bonus is earned. Except as set forth in Section&nbsp;5 below, in order to earn any bonus, Executive must be employed by the Company on the date the bonus is paid. Except as
set forth in Section&nbsp;5 below, Executive will not be eligible for a bonus if Executive&#146;s employment with the Company terminates prior to the payment date, regardless of whether Executive or the Company initiates the termination, and
independent of whether the termination is with or without cause. For the Company&#146;s 2022 fiscal year, Executive is guaranteed not less than the Target Bonus, prorated for the portion of the year that the Executive was employed by the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Equity</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)
<U>Inducement Option</U>. As soon as practicable following the Effective Date, subject to approval by the Compensation Committee of the Board, as a material inducement to Executive&#146;s acceptance of employment with the Company, Executive will be
granted a <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock option to purchase 1,375,000 shares of the Company&#146;s common stock, with an exercise price per share equal to the per share fair market value of the Company&#146;s common
stock on the date of grant (the &#147;<B>Initial Option</B>&#148;). The Initial Option will be granted pursuant to the Viracta Therapeutics, Inc. 2021&nbsp;Inducement Equity Incentive Plan (the &#147;<B>Option Plan</B>&#148;). The Initial Option
will vest with respect to twenty-five percent (25%) of the total number of shares of the Company&#146;s common stock subject to the Initial Option on the first anniversary of the Effective Date, and with respect to
<FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> (1/48) of the total number of shares of the Company&#146;s common stock subject to the Initial Option on the last day of each <FONT STYLE="white-space:nowrap">one-month</FONT> period of
Executive&#146;s service to the Company thereafter. The Initial Option will be subject to the terms and conditions of the Option Plan and any form of stock option agreement issued thereunder, provided that in the event of any conflict between the
terms of thereof and this Agreement, including with respect to the acceleration rights described in Section&nbsp;5, this Agreement shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Additional Equity Awards</U>. Executive will be eligible to receive additional awards of stock options, restricted stock units, or
other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or the Committee will determine in its discretion whether Executive will be granted any such equity awards and the terms of any
such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.
<U>Expenses</U>. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&#146;s duties hereunder, in accordance with
the Company&#146;s expense reimbursement policy as in effect from time to time, subject to the following: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Air Travel</U>. Business class, or first class if business class is not available,
may be used for domestic air travel outside of California, Arizona, and Nevada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Train Travel</U>. All train travel may be booked
in business class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Lodging</U>. Guidelines for reimbursable lodging expenses, including taxes, target a maximum of $375 per night
except in high priced cities (i.e., New York, Boston, Miami, Chicago, San Francisco Bay area, San Diego, Los Angeles, Washington, D.C., and Vancouver) and outside of North America where they should target a maximum of $475 per night. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Business Meals</U>. Reasonable business-related travel dining expenses (including taxes and gratuity not to exceed 20%) are
reimbursable. Costs of providing meals to actual or prospective customers, suppliers, applicants, candidates, or other <FONT STYLE="white-space:nowrap">non-Company</FONT> individuals for business purposes are reimbursable. Personal meals and
incidental expenses incurred while traveling on business are reimbursable, including taxes and tips, up to the following daily maximums: $150 (North America/Europe/Latina America); $200 (Asia Pacific, not including Japan); and $225 (Japan/UK). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Severance Benefits; Change in Control Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U><FONT STYLE="white-space:nowrap">Non-CIC</FONT> Qualified Termination</U>. If the Company terminates Executive&#146;s employment with
the Company outside of the Change in Control Period (as defined below) other than for Cause (as defined below), death or Disability (as defined in the Company&#146;s 2021 Equity Incentive Plan (the &#147;<B>Plan</B>&#148;)), or Executive resigns
from Executive&#146;s employment with the Company for Good Reason (as defined below) (such a termination, a &#147;<B>Qualified Termination</B>&#148;), then, subject to Section&nbsp;6, Executive will be entitled to the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) continued payment of Executive&#146;s annual Base Salary, at the level in effect immediately prior to Executive&#146;s
termination date, for a period of fifteen (15)&nbsp;months following the date of the Qualified Termination, with the first payment payable through the Company payroll within thirty (30)&nbsp;days following the effective date of the Release (as
defined below) (and to include any amounts that otherwise would have been paid between the termination date and the payment date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) reimbursement by the Company for the cost of premiums for Executive and Executive&#146;s covered dependents, if any, for
group health insurance continuation coverage under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<B>COBRA</B>&#148;) for up to fifteen (15)&nbsp;months following Executive&#146;s termination of employment
(the &#147;<B>COBRA Premium Reimbursement</B>&#148;), provided that (x)&nbsp;Executive and Executive&#146;s covered dependents timely elect and remain eligible for continued coverage under COBRA and (y)&nbsp;such COBRA Premium Reimbursement does not
result in excise tax penalties for the Company under applicable laws (including, without limitation, Section&nbsp;2716 of the Public Health Service Act). Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot
provide COBRA reimbursement benefits without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), the Company will instead provide the Executive a taxable payment in an amount
equal to the monthly COBRA premium that the Executive would be required to pay to continue the Executive&#146;s group health coverage in effect on the date of termination of employment (which amount will be based on the premium for the first month
of COBRA coverage), which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and continue for the period of months indicated in this
section; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) payment of any Actual Bonus with respect to a fiscal year of the
Company preceding the termination date that has not been paid as of the termination with the payment paid on the first Company payroll date following the effective date of the Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) payment of the Target Bonus for the fiscal year of the Company in which the termination date occurs, at the level in
effect immediately prior to Executive&#146;s termination date, <FONT STYLE="white-space:nowrap">pro-rated</FONT> to reflect the number of days in such fiscal year that Executive provided service, payable in a lump sum on the first Company payroll
date following the effective date of the Release; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) the right to exercise Executive&#146;s stock options granted by
the Company until the close of business on the date that is the earlier of (x)&nbsp;twelve (12) months after executive&#146;s termination date or (y)&nbsp;the term/expiration date of the stock option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>CIC Qualified Termination</U>. Upon a Qualified Termination occurring during the period beginning three (3)&nbsp;months prior to a
Change in Control (as defined in the Plan) and ending twelve (12)&nbsp;months following a Change in Control (the &#147;<B>Change in Control Period</B>&#148;), then, in lieu of the severance benefits described in Section&nbsp;5(a) above and subject
to Section&nbsp;6, Executive will be entitled to the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) a lump sum payment equal to eighteen (18)&nbsp;months
of Executive&#146;s annual Base Salary, at the level in effect immediately prior to Executive&#146;s termination date, paid on the first Company payroll date following the effective date of the Release (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) COBRA Premium Reimbursement for up to eighteen (18)&nbsp;months following Executive&#146;s termination of employment,
provided that (x)&nbsp;Executive and Executive&#146;s covered dependents timely elect and remain eligible for continued coverage under COBRA and (y)&nbsp;such COBRA Premium Reimbursement does not result in excise tax penalties for the Company under
applicable laws (including, without limitation, Section&nbsp;2716 of the Public Health Service Act). Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot provide COBRA reimbursement benefits without
potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), the Company will instead provide the Executive a taxable payment in an amount equal to the monthly COBRA premium that the
Executive would be required to pay to continue the Executive&#146;s group health coverage in effect on the date of termination of employment (which amount will be based on the premium for the first month of COBRA coverage), which payments will be
made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and continue for the period of months indicated in this section; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) payment of any Actual Bonus with respect to a fiscal year of the Company preceding the termination date that has not
been paid as of the termination, payable through the Company payroll within thirty (30)&nbsp;days following the effective date of the Release; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) payment of 150% of the Target Bonus for the fiscal year of the Company in which the termination date occurs, at the level
in effect immediately prior to Executive&#146;s termination date, payable in a lump sum on the first Company payroll date following the effective date of the Release; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) 100% of the unvested portion of any stock options or other equity award held by Executive that remain outstanding as of
immediately prior to the date of such Qualified Termination shall immediately vest and become exercisable (but, in no case, will more than 100% of the shares subject to any award vest and become exercisable); provided, however, that any stock
options or other equity award held by Executive that, at any time such equity award is outstanding, is subject to performance-based vesting, will vest assuming target performance. For purposes of clarity, any stock options or other equity award held
by Executive as of any Qualified Termination not within the Change in Control Period will remain outstanding for not less than three (3)&nbsp;months following such Qualified Termination (or, if longer, the period described in Section&nbsp;5(a)(v))
in order to give effect to this provision. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U><FONT STYLE="white-space:nowrap">Non-Duplication</FONT> of Payment or Benefits</U>.
For purposes of clarity, in the event of that a Change in Control occurs within three (3)&nbsp;months following a Qualified Termination, any severance payments and benefits to be provided to the Executive under Section&nbsp;5(b) will be reduced by
any amounts that already were provided to the Executive under Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Termination for Cause, Death or Disability;
Voluntary Resignation without Good Reason</U>. If Executive&#146;s employment with the Company terminates voluntarily by Executive for any reason (except upon resignation for Good Reason), for Cause by the Company or due to Executive&#146;s death or
Disability, then (i)&nbsp;all vesting will terminate immediately with respect to Executive&#146;s outstanding equity awards and (ii)&nbsp;all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to
amounts already earned, as described in Section&nbsp;5(e); provided, however,, if Executive&#146;s employment with the Company terminates due to Executive&#146;s death or Disability, then Executive or his estate will receive a payment equal to the
Target Bonus in the year of termination, <FONT STYLE="white-space:nowrap">pro-rated</FONT> to reflect the number of days in the fiscal year of termination that Executive provided service, and paid with the first payroll date following the date of
termination, and such termination shall be considered a Qualified Termination for purposes of Section&nbsp;5(a)(v) or 5(b)(v), as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Amounts Payable on All Terminations</U>. If Executive&#146;s employment with the Company terminates for any reason, Executive shall be
entitled to received, in addition to the amounts set forth above, all amounts already earned, including (i)&nbsp;Base Salary through the date of termination, (ii)&nbsp;vacation and paid time off earned but unused through the date of termination,
(iii)&nbsp;reimbursement of expenses properly incurred prior to termination, and (iv)&nbsp;any benefits paid or provided upon or following termination pursuant to any employee benefit plan or policy in accordance with the terms thereof. Except as
otherwise expressly provided herein, the Executive&#146;s rights with respect to the Initial Option and any other equity awards shall be governed by the terms of the applicable plan and award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>Conditions to Receipt of Payments; No Duty to Mitigate</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Separation Agreement and Release of Claims</U>. The receipt of any payments or benefits pursuant to Section&nbsp;5, other than the
amounts described in Section&nbsp;5(e), will be subject to Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company (the &#147;<B>Release</B>&#148;)<B> </B>and provided that
such Release becomes effective and irrevocable no later than sixty (60)&nbsp;days following the termination date (such deadline, the &#147;<B>Release Deadline</B>&#148;). Notwithstanding the foregoing, Executive will not be required to accept a
Release that (i)&nbsp;extends the post-employment restrictive covenants applicable to Executive, (ii)&nbsp;waives rights to seek indemnification under any D&amp;O policy, indemnification agreement between the parties, or the Company&#146;s bylaws or
(iii)&nbsp;waives rights as a shareholder of the Company. If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under this Agreement, other than as provided in Section&nbsp;5(e).
In no event will severance payments or benefits be paid or provided until the Release becomes effective and irrevocable, other than as provided in Section&nbsp;5(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Limitation on Payments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) In the event that the payments and benefits provided for in this Agreement or other payments and benefits payable or
provided to Executive (i)&nbsp;constitute &#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Code and (ii)&nbsp;but for this Section&nbsp;6(b), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code,
then Executive&#146;s payments and benefits under this Agreement or other payments or benefits (the &#147;280G Amounts&#148;) will be either: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) delivered in full, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y) delivered as to such lesser extent which would result in no portion of such payments and benefits being subject to the
excise tax under Section&nbsp;4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section&nbsp;4999 of the Code, results in Executive&#146;s
receipt on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of 280G Amounts, notwithstanding that all or some portion of the 280G Amounts may be taxable under Section&nbsp;4999 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Reduction Order</U>. In the event that a reduction of 280G Amounts is being made in accordance with this
Section&nbsp;6(b), the reduction will occur, with respect to the 280G Amounts considered parachute payments within the meaning of Section&nbsp;280G of the Code, in the following order: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the
occurrence of the event triggering the excise tax will be the first cash payment to be reduced); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) cancellation of
equity awards that were granted &#147;contingent on a change in ownership or control&#148; within the meaning of Code Section&nbsp;280G, or the vesting of which is based in whole or part on the attainment of performance goals, in the reverse order
of date of grant of the awards (that is, the most recently granted equity awards will be cancelled first); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(3) reduction
of the accelerated vesting of equity awards that vest solely based on continued employment, in the order of the portion of such awards that constitutes a parachute payment (that is, the awards the largest portion of which constitutes a parachute
payment will be reduced first); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(4) reduction of employee benefits in reverse chronological order (that is, the
benefit owed on the latest date following the occurrence of the event triggering the excise tax will be the first benefit to be reduced). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In no event will Executive have any discretion with respect to the ordering of payments or benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) <U>Firm</U>. Unless the Company and Executive otherwise agree in writing, any determination required under this
Section&nbsp;6(b) will be made in writing by a nationally recognized accounting or valuation firm (the &#147;Firm&#148;) selected by the Company, whose determination will be conclusive and binding upon Executive and the Company for all purposes. For
purposes of making the calculations required by this Section&nbsp;6(b), the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of
Sections 280G and 4999 of the Code. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section. The Company will bear all costs and make
all payments for the Firm&#146;s services relating to any calculations contemplated by this Section&nbsp;6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)
<U>Section</U><U></U><U>&nbsp;409A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Notwithstanding anything to the contrary in this Agreement, no severance pay
or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section&nbsp;409A of the Code, and
the final regulations and any guidance promulgated thereunder (&#147;<B>Section</B><B></B><B>&nbsp;409A</B>&#148;) (together, the &#147;<B>Deferred Compensation Separation Benefits</B>&#148;) will be paid or otherwise provided until Executive has a
&#147;separation from service&#148; within the meaning of Section&nbsp;409A. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Any severance payments or benefits under this Agreement that would be
considered Deferred Compensation Severance Benefits will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#146;s separation from service. Any installment payments that would have been
made to Executive during the sixty (60)&nbsp;day period immediately following Executive&#146;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#146;s separation from
service and the remaining payments shall be made as provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) Notwithstanding anything to the
contrary in this Agreement, if Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A at the time of Executive&#146;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are
payable within the first six (6)&nbsp;months following Executive&#146;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6)&nbsp;months and one (1)&nbsp;day following the date of
Executive&#146;s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the
contrary, if Executive dies following Executive&#146;s separation from service, but prior to the six (6)&nbsp;month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum
as soon as administratively practicable after the date of Executive&#146;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and
benefit payable under this Agreement, including the portion of the Executive&#146;s Base Salary that is paid on each payroll date pursuant to Section&nbsp;5(a)(i), is intended to constitute separate payments for purposes of <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)</FONT> of the Treasury Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) Any amount paid under
this Agreement that satisfies the requirements of the &#147;short-term deferral&#148; rule set forth in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> of the Treasury Regulations will not constitute Deferred Compensation
Separation Benefits for purposes of clause (i)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) Any amount paid under this Agreement that qualifies as a
payment made as a result of an involuntary separation from service pursuant to <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9)(iii)</FONT> of the Treasury Regulations that does not exceed the Section&nbsp;409A Limit (as defined below)
will not constitute Deferred Compensation Separation Benefits for purposes of clause (i)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) The foregoing
provisions are intended to comply with the requirements of Section&nbsp;409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section&nbsp;409A, and any ambiguities
herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of
any additional tax or income recognition prior to actual payment to Executive under Section&nbsp;409A. In no event will the Company have any liability or obligation to reimburse, indemnify, or hold harmless Executive (or any other person) for any
taxes or costs that may be imposed on or incurred by Executive (or any other person) as a result of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)
<U>Confidential Information Agreement</U>. Executive&#146;s receipt of any payments or benefits under Section&nbsp;6 will be subject to Executive continuing to comply with the terms of Confidential Information Agreement (as defined in
Section&nbsp;8). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>No Duty to Mitigate</U>. Executive will not be required to mitigate the amount of any
payment contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>Definitions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)
<U>Cause</U>. For purposes of this Agreement, &#147;<B>Cause</B>&#148; is defined as: (i)&nbsp;an act of dishonesty made by Executive in connection with Executive&#146;s responsibilities as an employee that materially discredits, or is materially
detrimental to, the Company; (ii)&nbsp;Executive&#146;s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude; (iii)&nbsp;a willful or reckless act made by Executive in
connection with Executive&#146;s responsibilities as an employee that involves (A)&nbsp;physical violence or the threat of physical violence, (B)&nbsp;sexual harassment, (C)&nbsp;damage to property, and (D)&nbsp;the influence of alcohol or drugs;
(iv)&nbsp;Executive&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive&#146;s relationship with the
Company; (v)&nbsp;Executive&#146;s material breach of any obligations under any written agreement or covenant with the Company; or (vi)&nbsp;Executive&#146;s willful, continued failure to perform Executive&#146;s assigned employment duties after
Executive has received a written demand of performance from the Company with specifically sets forth the factual basis for the Company&#146;s belief that Executive has not substantially performed Executive&#146;s duties and has failed to cure such <FONT
STYLE="white-space:nowrap">non-performance</FONT> to the Company&#146;s satisfaction within thirty (30)&nbsp;business days after receiving such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Good Reason</U>. For purposes of this Agreement, &#147;<B>Good Reason</B>&#148; means Executive&#146;s resignation within thirty
(30)&nbsp;days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive&#146;s consent: (i)&nbsp;the assignment to Executive of any duties, or the reduction of
Executive&#146;s duties,<I> </I>either of which results in a material diminution of Executive&#146;s authority, duties, or responsibilities; (ii)&nbsp;the Board fails to appoint the Executive to the Board, or to nominate Executive for election or
reelection to the Board; (iii)&nbsp;a material reduction of Executive&#146;s Base Salary (in other words, a reduction of more than 10% of Executive&#146;s Base Salary in any one year, unless pursuant to a salary reduction program applicable
generally to the Company&#146;s executives); (iv) a reduction of Executive&#146;s Target Bonus; (v)&nbsp;the failure of the Company to obtain assumption of this Agreement by any acquirer or successor; or (vi)&nbsp;the failure of the Compensation
Committee to approve the Initial Option on the terms set forth in Section&nbsp;3(a). Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#147;Good
Reason&#148; within ninety (90)&nbsp;days of the initial existence of the grounds for &#147;Good Reason&#148; and a reasonable cure period of not less than thirty (30)&nbsp;days following the date of such notice. Executive must resign effective not
later than sixty (60)&nbsp;days after the end of the Company cure period in the even such event(s), condition(s), or conduct is uncured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Section</U><U></U><U>&nbsp;409A Limit</U>. For purposes of this Agreement, &#147;<B>Section</B><B></B><B>&nbsp;409A Limit</B>&#148;
will mean two (2)&nbsp;times the lesser of: (i)&nbsp;Executive&#146;s annualized compensation based upon the annual rate of pay paid to Executive during the Company&#146;s taxable year preceding the Company&#146;s taxable year of Executive&#146;s
termination of employment as determined under Treasury Regulation <FONT STYLE="white-space:nowrap">1.409A-1(b)(9)(iii)(A)(1)</FONT> and any Internal Revenue Service guidance issued with respect thereto; or (ii)&nbsp;the maximum amount that may be
taken into account under a qualified plan pursuant to Section&nbsp;401(a)(17) of the Code for the year in which Executive&#146;s employment is terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>Confidential Information; Restrictive Covenants</U>. Executive agrees to enter into and abide by the Company&#146;s standard
Confidential Information, Invention Assignment and Arbitration Agreement attached hereto as <U>Exhibit A</U> (the &#147;<B>Confidential Information Agreement</B>&#148;) entered into on or about the Effective Date. Executive acknowledges that such
Confidential Information Agreement will provider for, subject to the limits per applicable law, (i)&nbsp;a twelve (12)&nbsp;month <FONT STYLE="white-space:nowrap">non-competition</FONT> provision applicable to Executive, (ii) a twelve
(12)&nbsp;month <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision applicable to Executive, and (iii)&nbsp;a mutual <FONT STYLE="white-space:nowrap">non-disparagement</FONT> provision. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>Cooperation</U>. The parties agree that certain matters in which the Executive will be
involved during the Employment Term may necessitate the Executive&#146;s cooperation in the future. Accordingly, following the termination of the Executive&#146;s employment for any reason, to the extent reasonably requested by the Company, the
Executive shall cooperate with the Company in connection with matters arising out of the Executive&#146;s service to the Company; provided that, the Company shall make reasonable efforts to minimize disruption of the Executive&#146;s other
activities. The Company shall reimburse the Executive for reasonable expenses incurred in connection with such cooperation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.
<U>Representation of the Executive</U>. The Executive represents and warrants to the Company that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Executive is not, as of the
Effective Date, currently employed or engaged as an independent contractor with any other entity, and Executive&#146;s acceptance of employment with the Company and the performance of his duties hereunder will not conflict with or result in a
violation of, a breach of, or a default under any contract, agreement or understanding to which he is a party or is otherwise bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)
The Executive&#146;s acceptance of employment with the Company and the performance of his duties hereunder will not violate any <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-competition</FONT> or
other similar covenant or agreement of a prior employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>Assignment</U>. This Agreement will be binding upon and inure to the
benefit of (a)&nbsp;the heirs, executors and legal representatives of Executive upon Executive&#146;s death and (b)&nbsp;any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of
this Agreement for all purposes. For this purpose, &#147;<B>successor</B>&#148; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or
substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution.
Any other attempted assignment, transfer, conveyance or other disposition of Executive&#146;s right to compensation or other benefits will be null and void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>Notices</U>. All notices, requests, demands and other communications called for hereunder will be in writing and will be deemed given
(i)&nbsp;on the date of delivery if delivered personally, (ii)&nbsp;one (1) day after being sent by a well-established commercial overnight service, or (iii)&nbsp;four (4) days after being mailed by registered or certified mail, return receipt
requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Company: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Viracta Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2533 S. Coast Hwy. 101, Suite 210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cardiff, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Attn</U>: Chairman of the Board of Directors </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to Executive: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">at the last residential address known by the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Severability</U>. In the event that any provision hereof becomes or is declared by a
court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. The parties further agree that any such court is expressly authorized to modify any such
unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language
to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties expressly agree that this Agreement as so
modified by the court shall be binding upon and enforceable against each of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>Professional Fees</U>. Company will reimburse
Executive&#146;s reasonable attorneys&#146; fees relating to the negotiation and preparation of this Agreement and any other agreement relating to Executive joining the Company not to exceed $15,000 in the aggregate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. <U>Arbitration</U>. Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company and any
employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive&#146;s service to the Company, will be subject to arbitration in accordance with
the provisions of the Confidential Information Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. <U>Integration</U>. This Agreement, together with the Option Plan, option
agreement thereunder, the Confidential Information Agreement, and the Indemnification Agreement (as defined in Section&nbsp;23) represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all
prior or contemporaneous agreements whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the parties that is designated as an amendment to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. <U>Modification: Waiver of Breach</U>. No provision of this Agreement may be amended or modified unless such amendment or modification is
agreed to in writing and signed by the Executive and by the Board or its designee. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will not operate as or be construed to be a waiver of any other previous
or subsequent breach of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. <U>Headings</U>. All captions and section headings used in this Agreement are for convenient
reference only and do not form a part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. <U>Tax Withholding</U>. All payments made pursuant to this Agreement will be
subject to withholding of applicable taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20. <U>Governing Law</U>. This Agreement will be governed by the laws of the State of New
Hampshire (with the exception of its conflict of laws provisions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21. <U>Acknowledgment</U>. Executive acknowledges that Executive has
had the opportunity to discuss this matter with and obtain advice from Executive&#146;s private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily
entering into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22. <U>Counterparts</U>. This Agreement may be executed in counterparts, and each counterpart will have the
same force and effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23.
<U>Indemnification Agreement</U>. The parties shall enter into an indemnification agreement in the form attached hereto as <U>Exhibit B</U> (the &#147;<B>Indemnification Agreement</B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24. <U>Survival</U>. The provisions of this Agreement shall survive the termination of the
Agreement, and of the Employment Period for any reason, to the extent necessary to enable the parties to enforce their respective rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Remainder of Page Intentionally Left Blank] </I></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, each of the parties has executed this Agreement (in the case of the
Company, by a duly authorized officer or director), effective as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">COMPANY:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VIRACTA THERAPEUTICS, INC.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Roger J. Pomerantz, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: September&nbsp;15, 2022</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Roger J. Pomerantz, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Chairman of the Board</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EXECUTIVE:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MARK ROTHERA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Mark Rothera</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: September&nbsp;15, 2022</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[SIGNATURE PAGE TO EMPLOYMENT AGREEMENT] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL INFORMATION AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>VIRACTA THERAPEUTICS, INC. </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT AND ARBITRATION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a condition of my employment with Viracta Therapeutics, Inc. (the &#147;<B>Company</B>&#148;), and in consideration of my
employment with the Company and my receipt of the compensation now and hereafter paid to me by the Company, I agree to the following provisions of this Confidential Information, Invention Assignment and Arbitration Agreement
(this&nbsp;&#147;<B>Agreement</B>&#148;): </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.
<U>A<SMALL>T</SMALL><FONT STYLE="white-space:nowrap">-W</FONT><SMALL>ILL</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I UNDERSTAND AND ACKNOWLEDGE THAT MY EMPLOYMENT WITH THE COMPANY IS FOR NO SPECIFIED TERM AND CONSTITUTES <FONT
STYLE="white-space:nowrap">&#147;AT-WILL&#148;</FONT> EMPLOYMENT. I ALSO UNDERSTAND THAT ANY REPRESENTATION TO THE CONTRARY IS UNAUTHORIZED AND NOT VALID UNLESS IN WRITING AND SIGNED BY THE PRESIDENT OR CEO OF THE COMPANY. ACCORDINGLY, I ACKNOWLEDGE
THAT MY EMPLOYMENT RELATIONSHIP MAY BE TERMINATED AT ANY TIME, WITH OR WITHOUT GOOD CAUSE OR FOR ANY OR NO CAUSE, AT MY OPTION OR AT THE OPTION OF THE COMPANY, WITH OR WITHOUT NOTICE. I FURTHER ACKNOWLEDGE THAT THE COMPANY MAY MODIFY JOB TITLES,
SALARIES, AND BENEFITS FROM TIME TO TIME AS IT DEEMS NECESSARY. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.
<U>C<SMALL>ONFIDENTI</SMALL></U><SMALL><U>ALITY</U></SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Definition of Company Confidential Information</I>.
&#147;<B>Company Confidential Information</B>&#148; means information (including any and all combinations of individual items of information) that the Company has or will develop, acquire, create, compile, discover or own, that has value in or to
the Company&#146;s business which is not generally known and which the Company wishes to maintain as confidential. Company Confidential Information includes both (i)&nbsp;information created by others that I learn or that becomes available to me
through the Company or its agents; and (ii)&nbsp;information I create that the Company owns pursuant to Section&nbsp;3 of this Agreement. By way of example, and without limitation, Company Confidential Information includes any and all <FONT
STYLE="white-space:nowrap">non-public</FONT> information that relates to the actual or anticipated business and/or products, research or development of the Company, or to the Company&#146;s technical data, trade secrets, or <FONT
STYLE="white-space:nowrap">know-how,</FONT> including, but not limited to, research, product plans, or other information regarding the Company&#146;s products or services and markets therefor, customer lists and customers (including, but not limited
to, customers of the Company on which I called or with which I may become acquainted during the term of my employment), software, developments, inventions, discoveries, ideas, processes, formulas, technology, designs, drawings, engineering, hardware
configuration information, marketing, finances, and other business information disclosed by the Company either directly or indirectly in writing, orally or by drawings or inspection of premises, parts, equipment, or other Company property.
Notwithstanding the foregoing, Company Confidential Information does not include general knowledge, skill, and experience I have acquired during the course of or in connection with my employment with the Company or a former employer. In addition,
Company Confidential Information shall not include any such information which I can establish (i)&nbsp;was publicly known or made generally available prior to the time of disclosure by the Company to me; (ii)&nbsp;becomes publicly known or made
generally available after disclosure by the Company to me through no wrongful action or omission by me; or (iii)&nbsp;is in my rightful possession, without confidentiality obligations, at the time of disclosure by the Company as shown by my
then-contemporaneous written records; provided that any combination of individual items of information shall not be deemed to be within any of the foregoing exceptions merely because one or more of the individual items are within such exception,
unless the combination as a whole is within such exception. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I>Nonuse and Nondisclosure</I>. During and after my
employment with the Company, I will hold in the strictest confidence and take all reasonable precautions to prevent any unauthorized use or disclosure of Company Confidential Information. I will not (i)&nbsp;use Company Confidential Information for
any purpose whatsoever other than for the benefit of the Company in the course of my employment, or (ii)&nbsp;disclose Company Confidential Information to any third party without the prior written authorization of the President, CEO, or the Board of
Directors of the Company. Prior to disclosure, when compelled by applicable law, I shall<I> </I>provide prior written notice to the President, CEO, and General Counsel of the Company (as applicable). I agree that I obtain no title to any Company
Confidential Information, and that the Company retains all Confidential Information as the sole property of the Company. I understand that my unauthorized use or disclosure of Company Confidential Information during my employment may lead to
disciplinary action, up to and including, immediate termination and legal action by the Company. I understand that my obligations under this section shall continue after termination of my employment and also that nothing in this Agreement prevents
me from engaging in protected conduct, as described in the Protected Activity Not Prohibited section below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. <I>Former Employer Confidential Information</I>. I agree that during my
employment with the Company, I will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any former employer or other person or entity with which I have an obligation to keep such proprietary
information or trade secrets in confidence. I further agree that I will not bring onto the Company&#146;s premises or transfer onto the Company&#146;s technology systems any unpublished document, proprietary information, or trade secrets belonging
to any such third party unless disclosure to, and use by, the Company has been consented to, in writing, by such third party and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. <I>Third Party Information</I>. I recognize that the Company has received, and in the future may receive, from third parties
(for example, customers, suppliers, licensors, licensees, partners, and collaborators) as well as its subsidiaries and affiliates (&#147;<B>Associated Third Parties</B>&#148;), information which the Company is required to maintain and treat as
confidential or proprietary information of such Associated Third Parties (&#147;<B>Associated Third Party Confidential Information</B>&#148;), and I agree to use such Associated Third Party Confidential Information only as directed by the Company
and to not use or disclose such Associated Third Party Confidential Information in a manner that would violate the Company&#146;s obligations to such Associated Third Parties. By way of example, Associated Third Party Confidential Information may
include the habits or practices of Associated Third Parties, the technology of Associated Third Parties, requirements of Associated Third Parties, and information related to the business conducted between the Company and such Associated Third
Parties. I agree at all times during my employment with the Company and thereafter, that I owe the Company and its Associated Third Parties a duty to hold all such Associated Third Party Confidential Information in the strictest confidence, and not
to use it or to disclose it to any person, firm, corporation, or other third party except as necessary in carrying out my work for the Company consistent with the Company&#146;s agreement with such Associated Third Parties. I further agree to comply
with any and all Company policies and guidelines that may be adopted from time to time regarding Associated Third Parties and Associated Third Party Confidential Information. I understand that my unauthorized use or disclosure of Associated Third
Party Confidential Information or violation of any Company policies during my employment may lead to disciplinary action, up to and including, immediate termination and legal action by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3. <U>O<SMALL>WNERSHIP</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Assignment of Inventions</I>. As between the Company and myself, I agree that all right, title, and interest in and to
any and all copyrightable material, notes, records, drawings, designs, logos, inventions, improvements, developments, discoveries, ideas and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by me, solely or
in collaboration with others, during the period of time I am in the employ of the Company (including during my <FONT STYLE="white-space:nowrap">off-duty</FONT> hours), or with the use of the Company&#146;s equipment, supplies, facilities, or Company
Confidential Information, and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing, except as provided in<B> </B>Section&nbsp;3.G below (collectively,
&#147;<B>Inventions</B>&#148;), are the sole property of the Company. I also agree to promptly make full written disclosure to the Company of any Inventions, and to deliver and assign and hereby irrevocably assign fully to the Company all of my
right, title and interest in and to Inventions. I agree that this assignment includes a present conveyance to the Company of ownership of Inventions that are not yet in existence. I further acknowledge that all original works of authorship that are
made by me (solely or jointly with others) within the scope of and during the period of my employment with the Company and that are protectable by copyright are &#147;works made for hire,&#148; as that term is defined in the United States Copyright
Act. I understand and agree that the decision whether or not to commercialize or market any Inventions is within the Company&#146;s sole discretion and for the Company&#146;s sole benefit, and that no royalty or other consideration will be due to me
as a result of the Company&#146;s efforts to commercialize or market any such Inventions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I><FONT
STYLE="white-space:nowrap">Pre-Existing</FONT> Materials</I>. I will inform the Company, in writing, before incorporating any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other
proprietary information or intellectual property rights owned by me or in which I have an interest prior to, or separate from, my employment with the Company, including, without limitation, any such inventions that meet the criteria set forth herein
under Section&nbsp;3.G, (&#147;<B>Prior Inventions</B>&#148;) into any Invention or otherwise utilizing any Prior Invention in the course of my </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
employment with the Company; and the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right to grant and authorize
sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such incorporated or utilized Prior Inventions, without restriction,
including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. I will not incorporate any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade
secrets and other proprietary information or intellectual property rights owned by any third party into any Invention without the Company&#146;s prior written permission. I have attached hereto, as <U>Exhibit A</U> a list describing all Prior
Inventions that relate to the Company&#146;s current or anticipated business, products, or research and development or, if no such list is attached, I represent and warrant that there are no such Prior Inventions. Furthermore, I represent and
warrant that if any Prior Inventions are included on <U>Exhibit A</U>, they will not materially affect my ability to perform all obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. <I>Moral Rights</I>. Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity,
modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as &#147;moral rights,&#148; &#147;artist&#146;s rights,&#148; &#147;droit moral,&#148; or the like (collectively, &#147;<B>Moral
Rights</B>&#148;). To the extent that Moral Rights cannot be assigned under applicable law, I hereby waive and agree not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent
permitted under applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. <I>Maintenance of Records</I>. I agree to keep and maintain adequate, current,
accurate, and authentic written records of all Inventions made by me (solely or jointly with others) during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any
other format that may be specified by the Company. As between the Company and myself, the records are and will be available to and remain the sole property of the Company at all times. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">E. <I>Further Assurances</I>. I agree to assist the Company, or its designee, at the Company&#146;s expense, in every proper
way to secure the Company&#146;s rights in the Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths,
assignments, and all other instruments that the Company shall deem proper or necessary in order to apply for, register, obtain, maintain, defend, and enforce such rights, and in order to deliver, assign and convey to the Company, its successors,
assigns, and nominees the sole and exclusive rights, title, and interest in and to all Inventions, and testifying in a suit or other proceeding relating to such Inventions. I further agree that my obligations under this Section&nbsp;3.E<B> </B>shall
continue after the termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">F.
<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-in-Fact</FONT></FONT></I>. I agree that, if the Company is unable because of my unavailability, mental or physical incapacity, or for any other reason to secure my
signature with respect to any Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to
the Company in Section&nbsp;3.A, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> to act for and on my behalf to execute and file any papers and oaths, and to do all other lawfully permitted acts with respect to such Inventions to
further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by me. This power of attorney shall be deemed coupled with an interest, and shall be irrevocable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">G. <I>Exception to Assignments</I>. I UNDERSTAND THAT THE PROVISIONS OF THIS AGREEMENT REQUIRING ASSIGNMENT OF INVENTIONS (AS
DEFINED UNDER SECTION 3.A ABOVE) TO THE COMPANY DO NOT APPLY TO ANY INVENTION FOR WHICH NO EQUIPMENT SUPPLIES, FACILITY, OR TRADE SECRET INFORMATION OF THE COMPANY WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON MY OWN TIME (AN &#147;<B>OTHER
INVENTION</B>&#148;) EXCEPT FOR THOSE OTHER INVENTIONS THAT RELATE: (A)&nbsp;DIRECTLY TO THE BUSINESS OF THE COMPANY; (B)&nbsp;TO THE COMPANY&#146;S ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT; OR (C)&nbsp;RESULT FROM ANY WORK I
PERFORM FOR THE COMPANY. I WILL NOT INCORPORATE, OR PERMIT TO BE INCORPORATED, ANY OTHER INVENTION OWNED BY ME OR IN WHICH I HAVE AN INTEREST INTO A COMPANY PRODUCT, PROCESS OR SERVICE WITHOUT THE COMPANY&#146;S PRIOR WRITTEN CONSENT. I WILL ADVISE
THE COMPANY PROMPTLY IN WRITING OF ANY INVENTIONS THAT I BELIEVE MEET THE ABOVE CRITERIA AND ARE NOT OTHERWISE DISCLOSED ON <U>EXHIBIT A</U> TO PERMIT A DETERMINATION OF OWNERSHIP BY THE COMPANY. ANY SUCH DISCLOSURE WILL BE RECEIVED IN CONFIDENCE.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4. <U>C<SMALL>ONFLICTING</SMALL>
</U><U>O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Current Obligations. </I>I agree that during the term of my
employment with the Company, I will not engage in or undertake any other employment, occupation, consulting relationship, or commitment that is directly related to the business in which the Company is now involved or becomes involved or has plans to
become involved, nor will I engage in any other activities that conflict with my obligations to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I>Prior
Relationships</I>. Without limiting Section&nbsp;4.A, I represent and warrant that I have no other agreements, relationships, or commitments to any other person or entity that conflict with the provisions of this Agreement, my obligations to the
Company under this Agreement, or my ability to become employed and perform the services for which I am being hired by the Company. I further agree that if I have signed a confidentiality agreement or similar type of agreement with any former
employer or other entity, I will comply with the terms of any such agreement to the extent that its terms are lawful under applicable law. I represent and warrant that after undertaking a careful search (including searches of my computers, cell
phones, electronic devices, and documents), I have returned all property and confidential information belonging to all prior employers (and/or other third parties I have performed services for in accordance with the terms of my applicable
agreement). Moreover, I agree to fully indemnify the Company, its directors, officers, agents, employees, investors, shareholders, administrators, affiliates, divisions, subsidiaries, predecessor and successor corporations, and assigns for all
verdicts, judgments, settlements, and other losses incurred by any of them resulting from my breach of my obligations under any agreement with a third party to which I am a party or obligation to which I am bound, as well as any reasonable
attorneys&#146; fees and costs if the plaintiff is the prevailing party in such an action, except as prohibited by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5. <U>R<SMALL>ETURN</SMALL> <SMALL>OF</SMALL> C<SMALL>OMPANY</SMALL> </U><U>M<SMALL>ATERIALS</SMALL></U><SMALL></SMALL>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Definition of Electronic Media Equipment and Electronic Media Systems. </I>&#147;<B>Electronic Media
Equipment</B>&#148; includes, but is not limited to, computers, external storage devices, thumb drives, mobile devices (including, but not limited to, smart phones, tablets, and <FONT STYLE="white-space:nowrap">e-readers),</FONT> telephone
equipment, and other electronic media devices. &#147;<B>Electronic Media Systems</B>&#148; includes, but is not limited to, computer servers, messaging and email systems or accounts, applications for computers or mobile devices, and <FONT
STYLE="white-space:nowrap">web-based</FONT> services (including cloud-based information storage accounts). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I>Return of
Company Property.</I> I understand that anything that I created or worked on for the Company while working for the Company belongs solely to the Company and that I cannot remove, retain, or use such information without the Company&#146;s express
written permission. Accordingly, upon separation from employment with the Company or upon the Company&#146;s request at any other time, I will immediately deliver to the Company, and will not keep in my possession (or custody or control), recreate,
or deliver to anyone else, any and all Company property, including, but not limited to, Company Confidential Information, Associated Third Party Confidential Information, all Company equipment including all Electronic Media Equipment that was
provided to me by or that I used on behalf of the Company, all tangible embodiments of the Inventions, all electronically stored information and passwords to access such information, Company credit cards, records, data, notes, notebooks, reports,
files, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, photographs, charts, any other documents and property, and reproductions of any of the foregoing items including, without limitation, those records
maintained pursuant to Section&nbsp;3.D. Notwithstanding the foregoing, I understand that I am allowed to keep a copy of the Company&#146;s employee handbook and personnel records relating to my employment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. <I>Return of Company Information on Company Electronic Media Equipment. </I>In connection with my obligation to return
information to the Company, I agree that I will not copy, delete, or alter any information, including personal information voluntarily created or stored, contained in Company Electronic Media Equipment before I return the information or property to
the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. <I>Return of Company Information on Personal Electronic Media Equipment
or Personal Electronic Media Systems.</I> If I have used any personal Electronic Media Equipment or personal Electronic Media Systems to create, receive, store, review, prepare, or transmit any Company information, including, but not limited to,
Company Confidential Information, I agree to make a prompt and reasonable search for such information in good faith, including reviewing any personal Electronic Media Equipment or personal Electronic Media Systems to locate such information and, if
I locate such information, I agree to notify the Company of that fact and then provide the Company with a computer-useable copy of all such Company information from those equipment and systems. I agree to cooperate reasonably with the Company to
verify that the necessary copying is completed (including upon request providing a sworn declaration confirming the return of property and deletion of information), and, upon confirmation of compliance by the Company, I agree to delete and expunge
all Company information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">E. <I>No Expectation of Privacy in Company Property.</I> I understand that I have no expectation
of privacy in Company property, and I agree that any Company property is subject to inspection by Company personnel at any time with or without further notice. As to any personal Electronic Media Equipment or personal Electronic Media Systems that I
have used for Company purposes, I agree that the Company, at its sole discretion, may have reasonable access, as determined by the Company in good faith, to such personal Electronic Media Equipment or personal Electronic Media Systems to review,
retrieve, destroy, or ensure the permanent deletion of Company information from such equipment or systems or to take such other actions necessary to protect the Company or Company property, as determined by the Company reasonably and in good faith.
I also consent to an exit interview and an audit to confirm my compliance with this Section&nbsp;5, and I will certify in writing that I have complied with the requirements of this Section&nbsp;5. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>6. <U>T<SMALL>ERMINATION</SMALL> C<SMALL>ERTIFICATION</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon separation from employment with the Company, I agree to immediately sign and deliver to the Company the &#147;Termination
Certification&#148; attached hereto as <U>Exhibit C</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>7. <U>N<SMALL>OTIFICATION</SMALL> <SMALL>OF</SMALL>
N<SMALL>EW</SMALL> E<SMALL>MPLOYER</SMALL></U><SMALL></SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that I leave the employ of the Company, I
hereby grant consent to notification by the Company to my new employer about my obligations under this Agreement. I also agree to keep the Company advised of my home and business address for a period of three (3)&nbsp;years after termination of my
employment with the Company, so that the Company can contact me regarding my continuing obligations provided by this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>8. <U>C<SMALL>OVENANT</SMALL> N<SMALL>OT</SMALL> <SMALL>TO</SMALL> C<SMALL>OMPETE</SMALL> <SMALL>AND</SMALL>
N<SMALL>O</SMALL> S<SMALL>OLICITATION</SMALL></U><SMALL></SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Covenant Not to Compete. </I>I agree that
during the course of my employment, and for a period of twelve (12)&nbsp;months immediately following the termination of my relationship with the Company if I resign voluntarily without Good Reason or if I am terminated by the Company involuntarily
with Cause, I will not, without the prior written consent of the Company, whether paid or not: (i)&nbsp;serve as a partner, principal, licensor, licensee, employee, consultant, officer, director, manager, agent, representative, advisor, promoter,
associate, investor, or otherwise for (except for passive ownership of one percent (1%) or less of any entity whose securities have been registered under the Securities Act of 1933, as amended, or Section&nbsp;12 of the Securities Exchange Act of
1934, as amended); (ii) directly or indirectly, own, purchase, organize or take preparatory steps for the organization of; or (iii)&nbsp;build, design, finance, acquire, lease, operate, manage, control, invest in, work or consult for or otherwise
join, participate in any business whose business, products or operations are in any respect involved in the Covered Business.&nbsp;For purposes of this Agreement, &#147;<B>Covered Business</B>&#148; shall mean any business in which the Company is
engaged or in which the Company has plans to be engaged, or any service that the Company provides or has plans to provide. The foregoing covenant shall cover my activities in every part of the Territory.&nbsp;&#147;<B>Territory</B>&#148; shall mean
(i)&nbsp;all counties in the State of New Hampshire; (ii)&nbsp;all other states of the United States of America in which the Company provided goods or services, had customers, or otherwise conducted business at any time during the <FONT
STYLE="white-space:nowrap">two-year</FONT> period prior to the date of the termination of my relationship with the Company; and (iii)&nbsp;any other countries from which the Company provided goods or services, had customers, or otherwise conducted
business at any time during the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to the date of the termination of my relationship with the Company. Should I obtain other employment during my employment with the Company, or within
twelve (12)&nbsp;months immediately following the termination of my relationship with the Company if this Section&nbsp;8.A is in effect, I agree to provide written notification to the Company as to the name and address of my new employer, the
position that I expect to hold, and a general description of my duties and responsibilities, at least three (3)&nbsp;business days prior to starting such employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I>No Solicitation. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) <I><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> of Customers.</I> I agree that for a period of twelve
(12)&nbsp;months immediately following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I shall not contact, or cause to be contacted, directly or indirectly, or engage
in any form of oral, verbal, written, recorded, transcribed, or electronic communication with any Customer for the purposes of conducting business that is competitive or similar to that of the Company or for the purpose of disadvantaging the
Company&#146;s business in any way. For purposes of foregoing, &#147;<B>Customer</B>&#148; means all persons or entities that have purchased, used or inquired of the Company&#146;s products or services at any time during the <FONT
STYLE="white-space:nowrap">two-year</FONT> period preceding the termination of my employment with the Company and with whom I had material contact during such period. For purposes of the foregoing, &#147;<B>material contact</B>&#148; means
(A)&nbsp;I dealt with such Customer on behalf of the Company; (B)&nbsp;such Customer&#146;s dealings with the Company were coordinated or supervised by me, in whole or in part; or (C)&nbsp;I obtained confidential information regarding such Customer,
including, without limitation any Company Confidential Information or Associated Third-Party Confidential Information. I acknowledge and agree that the Customers did not use or inquire of the Company&#146;s services solely as a result of my efforts,
and that the efforts of other Company personnel and resources are responsible for the Company&#146;s relationship with the Customers. I further acknowledge and agree that the identity of the Customers is not readily ascertainable or discoverable
through public sources, and that the Company&#146;s list of Customers was cultivated with great effort and secured through the expenditure of considerable time and money by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) <I><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> of Employees.</I> I agree that for a period of twelve
(12)&nbsp;months immediately following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I will not directly or indirectly hire, solicit, or recruit, or attempt to hire,
solicit, or recruit, any employee of the Company to leave their employment with the Company, nor will I contact any employee of the Company, or cause an employee of the Company to be contacted, for the purpose of leaving employment with the Company.
For purposes of the foregoing, the term &#147;<B>employee</B>&#148; shall be limited to those employees with whom I interacted during the last two (2)&nbsp;years of my employment with the Company or about whom I obtained personnel information or
other Company Confidential Information about such employee as a result of my position with the Company during the last two (2)&nbsp;years of my employment with the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(3) <I><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> of Others.</I> I agree that for a period of twelve
(12)&nbsp;months immediately following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I will not solicit, encourage, or induce, or cause to be solicited, encouraged or
induced, directly or indirectly, any Business Partner to terminate or adversely modify any business relationship with the Company or not to proceed with, or enter into, any business relationship with the Company, nor shall I otherwise interfere with
any business relationship between the Company and any Business Partner. For purposes of the foregoing, &#147;<B>Business Partner</B>&#148; means any business partner, franchisee, joint venture, supplier, vendor or contractor who conducted business
with the Company at any time during the <FONT STYLE="white-space:nowrap">two-year</FONT> period preceding the termination of my employment with the Company and with whom I had material contact during such period. For purposes of the foregoing,
&#147;<B>material contact</B>&#148; means (A)&nbsp;I dealt with such Business Partner on behalf of the Company; (B)&nbsp;such Business Partner&#146;s dealings with the Company were coordinated or supervised by me, in whole or in part; or (C)&nbsp;I
obtained confidential information regarding such Business Partner, including, without limitation, Company Confidential Information or Associated Third-Party Confidential Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. <I>Acknowledgements.</I> I acknowledge that I will derive significant value from the Company&#146;s agreement to provide me
with Company Confidential Information to enable me to optimize the performance of my duties to the Company.&nbsp;I further acknowledge that my fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation
neither to disclose nor to use Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to compete and not to solicit contained in subsections (A)&nbsp;and (B) above, is necessary to protect Company
Confidential Information and, consequently, to preserve the value and goodwill of the Company.&nbsp;I also acknowledge the time, geographic and scope limitations of my obligations under subsections (A)&nbsp;and (B) above are fair and reasonable in
all respects, especially in light of the Company&#146;s need to protect Company Confidential Information and the scope and nature of the Company&#146;s business, and that I will not be precluded from gainful employment if I am obligated not to
compete with the Company or solicit its customers, employees, or others during the period and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
within the Territory as described above. In the event of my breach or violation of this <B>Section</B><B></B><B>&nbsp;8</B>, or good faith allegation by the Company of my breach or violation of
this <B>Section</B><B></B><B>&nbsp;8</B>, to the maximum extent permitted by law the restricted periods set forth in this <B>Section</B><B></B><B>&nbsp;8</B> shall be tolled until such breach or violation, or dispute related to an allegation by the
Company that I have breached or violated this <B>Section</B><B></B><B>&nbsp;8</B>, has been duly cured or resolved, as applicable. I agree that nothing in this <B>Section</B><B></B><B>&nbsp;8</B> shall affect my continuing obligations under this
Agreement during and after this twelve (12)&nbsp;month period, including, without limitation, my obligations under <B>Section</B><B></B><B>&nbsp;2</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>D.</I> <I>Separate Covenants</I>. The covenants contained in subsections (A)&nbsp;and (B) above shall be construed as a
series of separate covenants, one for each city, county and state of any geographic area in the Territory.&nbsp;Except for geographic coverage, each such separate covenant shall be deemed identical in terms to the covenant contained in subsections
(A)&nbsp;and (B) above.&nbsp;If, in any judicial or arbitral proceeding, a court or arbitrator refuses to enforce any of such separate covenants (or any part thereof), then such unenforceable covenant (or such part) shall be revised, or if revision
is not permitted it shall be eliminated from this Agreement, to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced.&nbsp;In the event that the provisions of subsections (A)&nbsp;and (B) above are
deemed to exceed the time, geographic or scope limitations permitted by applicable law, then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the case may be, then permitted by such law. In the event that
the applicable court or arbitrator does not exercise the power granted to it in the prior sentence, I and the Company agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve,
to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.<I> </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>9.
<U>C<SMALL>ONFLICT</SMALL> <SMALL>OF</SMALL> I<SMALL>NTEREST</SMALL> G<SMALL>UIDELINES</SMALL></U><SMALL></SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I
agree to diligently adhere to all policies of the Company, including the Company&#146;s insider trading policies and the Company&#146;s Conflict of Interest Guidelines. A copy of the Company&#146;s current Conflict of Interest Guidelines is attached
as <U>Exhibit D</U> hereto, but I understand that these Conflict of Interest Guidelines may be revised from time to time during my employment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>10. <U>R<SMALL>EPRESENTATIONS</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Without limiting my obligations under Section&nbsp;3.E above, I agree to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. I represent and warrant that my performance of all the terms of this Agreement will not breach any agreement to maintain the confidentiality of information acquired by me in confidence or in trust
prior to my employment by the Company. I hereby represent and warrant that I have not entered into, and I will not enter into, any oral or written agreement in conflict herewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>11. <U>A<SMALL>UDIT</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that I have no reasonable expectation of privacy in any Company Electronic Media Equipment or Company Electronic
Media Systems. All information, data, and messages created, received, sent, or stored in Company Electronic Media Equipment or Company Electronic Media Systems are, at all times, the property of the Company. As such, the Company has the right to
audit and search all such items and systems, without further notice to me, to ensure that the Company is licensed to use the software on the Company&#146;s devices in compliance with the Company&#146;s software licensing policies, to ensure
compliance with the Company&#146;s policies, and for any other business-related purposes in the Company&#146;s sole discretion. I understand that I am not permitted to add any unlicensed, unauthorized, or
<FONT STYLE="white-space:nowrap">non-compliant</FONT> applications to the Company&#146;s technology systems, including, without limitation, open source or free software not authorized by the Company, and that I shall refrain from copying unlicensed
software onto the Company&#146;s technology systems or using <FONT STYLE="white-space:nowrap">non-licensed</FONT> software or websites. I understand that it is my responsibility to comply with the Company&#146;s policies governing use of the
Company&#146;s documents and the internet, email, telephone, and technology systems to which I will have access in connection with my employment. In addition, as to any personal Electronic Media Equipment or personal Electronic Media Systems or
other personal property that I have used for Company purposes, I agree that the Company may have reasonable access to such personal Electronic Media Equipment or personal Electronic Media Systems or other personal property to review, retrieve,
destroy, or ensure the permanent deletion of Company information from such equipment or systems or property or take such other actions that are needed to protect the Company or Company property, as determined by the Company reasonably and in good
faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I am aware that the Company has or may acquire software and systems that are
capable of monitoring and recording all Company network traffic to and from any Company Electronic Media Equipment or Company Electronic Media Systems. The Company reserves the right to access, review, copy, and delete any of the information, data,
or messages accessed through Company Electronic Media Equipment or Company Electronic Media Systems, with or without notice to me and/or in my absence. This includes, but is not limited to, all <FONT STYLE="white-space:nowrap">e-mail</FONT> messages
sent or received, all website visits, all chat sessions, all news group activity (including groups visited, messages read, and postings by me), and all file transfers into and out of the Company&#146;s internal networks. The Company further reserves
the right to retrieve previously deleted messages from <FONT STYLE="white-space:nowrap">e-mail</FONT> or voicemail and monitor usage of the Internet, including websites visited and any information I have downloaded. In addition, the Company may
review Internet and technology systems activity and analyze usage patterns, and may choose to publicize this data to assure that technology systems are devoted to legitimate business purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>12. <U>A<SMALL>RBITRATION</SMALL> <SMALL>AND</SMALL> E<SMALL>QUITABLE</SMALL> R<SMALL>ELIEF</SMALL> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Arbitration</I>. IN CONSIDERATION OF MY EMPLOYMENT WITH THE COMPANY, THE COMPANY&#146;S PROMISE TO ARBITRATE ALL
EMPLOYMENT-RELATED DISPUTES WITH ME, AND MY RECEIPT OF COMPENSATION AND OTHER BENEFITS PAID OR PROVIDED TO ME BY THE COMPANY AT PRESENT AND IN THE FUTURE, I AGREE THAT ANY AND ALL CONTROVERSIES, CLAIMS, OR DISPUTES THAT I MAY HAVE WITH THE COMPANY
(INCLUDING ANY COMPANY EMPLOYEE, OFFICER, DIRECTOR, TRUSTEE, OR BENEFIT PLAN OF THE COMPANY, IN THEIR CAPACITY AS SUCH OR OTHERWISE), ARISING OUT OF, RELATING TO, OR RESULTING FROM MY EMPLOYMENT OR RELATIONSHIP WITH THE COMPANY OR THE TERMINATION OF
MY EMPLOYMENT OR RELATIONSHIP WITH THE COMPANY, INCLUDING ANY BREACH OF THIS AGREEMENT, SHALL BE SUBJECT TO BINDING ARBITRATION PURSUANT TO THE FEDERAL ARBITRATION ACT (9 U.S.C. SEC. 1 ET SEQ.) (THE &#147;<B>FAA</B>&#148;). THE FAA&#146;S
SUBSTANTIVE AND PROCEDURAL PROVISIONS SHALL EXCLUSIVELY GOVERN AND APPLY WITH FULL FORCE AND EFFECT TO THIS ARBITRATION AGREEMENT, INCLUDING ITS ENFORCEMENT. ANY STATE COURT OF COMPETENT JURISDICTION SHALL STAY PROCEEDINGS PENDING ARBITRATION OR
COMPEL ARBITRATION IN THE SAME MANNER AS A FEDERAL COURT UNDER THE FAA. I FURTHER AGREE THAT, TO THE FULLEST EXTENT PERMITTED BY LAW, I MAY BRING ANY ARBITRATION PROCEEDING ONLY IN MY INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF, REPRESENTATIVE, OR
CLASS MEMBER IN ANY PURPORTED CLASS, COLLECTIVE, OR REPRESENTATIVE LAWSUIT OR PROCEEDING. <B>I AGREE TO ARBITRATE ANY AND ALL COMMON LAW AND/OR STATUTORY CLAIMS UNDER LOCAL, STATE, OR FEDERAL LAW, INCLUDING, BUT NOT LIMITED TO, CLAIMS UNDER THE NEW
HAMPSHIRE LAW AGAINST DISCRIMINATION; THE NEW HAMPSHIRE CIVIL RIGHTS ACT; TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, THE OLDER WORKERS BENEFIT PROTECTION
ACT, THE WORKER ADJUSTMENT AND RETRAINING NOTIFICATION ACT, THE FAIR LABOR STANDARDS ACT, THE FAIR CREDIT REPORTING ACT, THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AND THE FAMILY AND MEDICAL LEAVE ACT, CLAIMS RELATING TO EMPLOYMENT STATUS,
COMPENSATION (CASH, EQUITY, BONUS, OR OTHERWISE), OR CLASSIFICATION, AND CLAIMS OF HARASSMENT, DISCRIMINATION, RETALIATION, WRONGFUL TERMINATION, AND BREACH OF CONTRACT</B><B>, EXCEPT AS PROHIBITED BY LAW. TO THE FULLEST EXTENT PERMITTED BY LAW, I
ALSO AGREE TO ARBITRATE ANY AND ALL DISPUTES ARISING OUT OF OR RELATING TO THE INTERPRETATION OR APPLICATION OF THIS AGREEMENT TO ARBITRATE, BUT NOT DISPUTES ABOUT THE ENFORCEABILITY, REVOCABILITY OR VALIDITY OF THIS AGREEMENT TO ARBITRATE </B><B>OR
THE CLASS, COLLECTIVE, AND REPRESENTATIVE PROCEEDING WAIVER HEREIN</B><B>. WITH RESPECT TO ALL SUCH CLAIMS AND DISPUTES THAT I AGREE TO ARBITRATE, I HEREBY EXPRESSLY AGREE TO WAIVE, AND DO WAIVE, ANY RIGHT TO A TRIAL BY JURY.</B> I FURTHER
UNDERSTAND THAT THIS AGREEMENT TO ARBITRATE ALSO APPLIES TO ANY DISPUTES THAT THE COMPANY MAY HAVE WITH ME. I UNDERSTAND THAT NOTHING IN THIS AGREEMENT REQUIRES ME TO ARBITRATE CLAIMS THAT CANNOT BE ARBITRATED UNDER APPLICABLE LAW, SUCH AS THE
SARBANES-OXLEY ACT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I>Administration of Arbitration</I>. I AGREE THAT ANY ARBITRATION WILL
BE ADMINISTERED BY JAMS, PURSUANT TO ITS EMPLOYMENT ARBITRATION RULES&nbsp;&amp; PROCEDURES (THE &#147;<B>JAMS EMPLOYMENT RULES</B>&#148;), WHICH ARE AVAILABLE AT http://www.jamsadr.com/rules-employment-arbitration/ AND FROM THE COMPANY. IF THE JAMS
EMPLOYMENT RULES CANNOT BE ENFORCED AS TO THE ARBITRATION, THEN THE PARTIES AGREE THAT THEY WILL ARBITRATE THIS DISPUTE UTILIZING THE JAMS COMPREHENSIVE ARBITRATION RULES AND PROCEDURES OR SUCH RULES AS THE ARBITRATOR MAY DEEM MOST APPROPRIATE FOR
THE DISPUTE (THE RULES UNDER WHICH THE ARBITRATION IS ADMINISTERED, WHETHER THE JAMS EMPLOYMENT RULES OR OTHERWISE, ARE REFERRED TO HEREIN AS THE &#147;<B>JAMS RULES</B>&#148;). IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THIS <B>SECTION 12
</B>AND THE JAMS RULES, THIS <B>SECTION 12 </B>SHALL TAKE PRECEDENCE. I AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION, AND
MOTIONS TO DISMISS, APPLYING THE STANDARDS SET FORTH FOR SUCH MOTIONS UNDER APPLICABLE NEW HAMPSHIRE LAW, INCLUDING THE NEW HAMPSHIRE CIVIL PROCEDURE RULES. I AGREE THAT THE ARBITRATOR SHALL ISSUE A WRITTEN DECISION ON THE MERITS. I ALSO AGREE THAT
THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES AVAILABLE UNDER APPLICABLE LAW, AND THAT THE ARBITRATOR MAY AWARD ATTORNEYS&#146; FEES AND COSTS TO THE PREVAILING PARTY, WHERE PERMITTED BY APPLICABLE LAW. I AGREE THAT THE DECREE OR AWARD
RENDERED BY THE ARBITRATOR MAY BE ENTERED AS A FINAL AND BINDING JUDGMENT IN ANY COURT HAVING JURISDICTION THEREOF. I UNDERSTAND THAT THE COMPANY WILL PAY FOR ANY ADMINISTRATIVE OR HEARING FEES CHARGED BY THE ARBITRATOR OR JAMS EXCEPT THAT I SHALL
PAY ANY FILING FEES ASSOCIATED WITH ANY ARBITRATION THAT I INITIATE, BUT ONLY SO MUCH OF THE FILING FEES AS I WOULD HAVE INSTEAD PAID HAD I FILED A COMPLAINT IN A COURT OF LAW THAT WOULD HAVE HAD JURISDICTION OVER SUCH COMPLAINT. I AGREE THAT THE
ARBITRATOR SHALL APPLY SUBSTANTIVE NEW HAMPSHIRE LAW TO ANY DISPUTE OR CLAIM. TO THE EXTENT THAT THE JAMS RULES CONFLICT WITH SUBSTANTIVE NEW HAMPSHIRE LAW, NEW HAMPSHIRE LAW SHALL TAKE PRECEDENCE. I AGREE THAT ANY ARBITRATION UNDER THIS AGREEMENT
SHALL BE CONDUCTED IN HILLSBOROUGH COUNTY, NEW HAMPSHIRE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. <I>Remedy</I>. EXCEPT FOR THE PURSUIT OF ANY PROVISIONAL
REMEDY PERMITTED UNDER THE FAA, OR AS OTHERWISE PROVIDED BY THIS AGREEMENT, I AGREE THAT ARBITRATION SHALL BE THE SOLE, EXCLUSIVE, AND FINAL REMEDY FOR ANY DISPUTE BETWEEN ME AND THE COMPANY. WHETHER IN ARBITRATION OR IN ACCORDANCE WITH THE
PROVISIONAL REMEDIES PERMITTED UNDER THE FAA, AND WHERE DEEMED APPROPRIATE BY THE JUDGE OR ARBITRATOR, BOTH PARTIES CONSENT TO THE ISSUANCE OF A TEMPORARY RESTRAINING ORDER OR PRELIMINARY INJUNCTION (INCLUDING IN THE EVENT OF ANY BREACH OR
THREATENED BREACH OF THIS AGREEMENT, WHICH WILL CAUSE IRREPARABLE INJURY AND FOR WHICH MONEY DAMAGES ALONE WILL NOT PROVIDE AN ADEQUATE REMEDY), WHICH, IN THE CASE OF A PARTY ALLEGING OR CLAIMING A VIOLATION OF AN AGREEMENT REGARDING TRADE SECRETS,
CONFIDENTIAL INFORMATION, NONCOMPETITION OR NONSOLICITATION, SHALL BE ISSUED WITHOUT THE POSTING OF A BOND. IN THE EVENT EITHER PARTY SEEKS SUCH INJUNCTIVE RELIEF, THE PREVAILING PARTY SHALL BE ENTITLED TO RECOVER REASONABLE COSTS AND
ATTORNEYS&#146; FEES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. <I>Administrative Relief</I>. I UNDERSTAND THAT THIS AGREEMENT DOES NOT PROHIBIT ME FROM PURSUING
AN ADMINISTRATIVE CLAIM WITH A LOCAL, STATE, OR FEDERAL ADMINISTRATIVE BODY OR GOVERNMENT AGENCY THAT IS AUTHORIZED TO ENFORCE OR ADMINISTER LAWS RELATED TO EMPLOYMENT, INCLUDING, BUT NOT LIMITED TO, THE NEW HAMPSHIRE COMMISSION FOR HUMAN RIGHTS,
THE EQUAL EMPLOYMENT OPPORTUNITY COMMISSION, THE NATIONAL LABOR RELATIONS BOARD, THE SECURITIES AND EXCHANGE COMMISSION, OR THE WORKERS&#146; COMPENSATION BOARD. THIS AGREEMENT DOES, HOWEVER, PRECLUDE ME FROM PURSUING A COURT ACTION REGARDING ANY
SUCH CLAIM, EXCEPT AS PERMITTED BY LAW. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 9 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">E. <I>Voluntary Nature of Agreement</I>. I ACKNOWLEDGE AND AGREE THAT I AM
EXECUTING THIS AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE BY THE COMPANY OR ANYONE ELSE. I FURTHER ACKNOWLEDGE AND AGREE THAT I HAVE CAREFULLY READ THIS AGREEMENT AND THAT I HAVE ASKED ANY QUESTIONS NEEDED FOR ME TO UNDERSTAND
THE TERMS, CONSEQUENCES, AND BINDING EFFECT OF THIS AGREEMENT AND FULLY UNDERSTAND IT, INCLUDING THAT <B><I>I AM WAIVING MY RIGHT TO A JURY TRIAL</I></B>. I AGREE THAT I HAVE BEEN PROVIDED AN OPPORTUNITY TO SEEK THE ADVICE OF AN ATTORNEY OF MY
CHOICE BEFORE SIGNING THIS AGREEMENT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>13. <U>M<SMALL>ISCELLANEOUS</SMALL></U><SMALL></SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. <I>Governing Law; Consent to Personal Jurisdiction</I>. With the exception of the arbitration requirements set forth in
Section&nbsp;12 above (which are governed by the FAA), this Agreement will be governed by the laws of the State of New Hampshire without regard to New Hampshire&#146;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflicts-of-law</FONT></FONT> rules that may result in the application of the laws of any jurisdiction other than New Hampshire. To the extent that any lawsuit is permitted under
this Agreement, I hereby expressly consent to the personal and exclusive jurisdiction and venue of the state and federal courts located in New Hampshire for any<B><I> </I></B>lawsuit filed against me by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. <I>Waiver of Trial by Jury</I>. TO THE EXTENT THAT ANY LAWSUIT IS PERMITTED UNDER THIS AGREEMENT, I IRREVOCABLY AND
UNCONDITIONALLY WAIVE MY RIGHT TO A TRIAL BY JURY IN ANY LAWSUIT DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR MY RELATIONSHIP WITH THE COMPANY AND ACKNOWLEDGE THAT I AM KNOWINGLY AND VOLUNTARILY WAIVING MY RIGHT TO A TRIAL
BY JURY. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. <I>Mutual <FONT STYLE="white-space:nowrap">Non-Disparagement.</FONT> </I>Subject to the Protected Activity Not
Prohibited section, I agree that following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I shall refrain from any disparagement of the Company. The Company agrees
that, following the termination of my relationship with the Company, it shall refrain from making any disparaging statements about me. I understand that the Company&#146;s obligations under this Section&nbsp;13.C extend only to the Company&#146;s
executive officers and members of its Board of Directors at the time of my separation from the Company and only for so long as each officer or member is an employee or Director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. <I>Assignability</I>. This Agreement will be binding upon my heirs, executors, assigns, administrators, and other legal
representatives, and will be for the benefit of the Company, its successors, and its assigns. The Associated Third Parties are intended third-party beneficiaries to this Agreement with respect to my obligations in Section&nbsp;2.D. Notwithstanding
anything to the contrary herein, the Company may assign this Agreement and its rights and obligations under this Agreement to any successor to all, or substantially all, of the Company&#146;s relevant assets, whether by merger, consolidation,
reorganization, reincorporation, sale of assets or stock, or otherwise. For the avoidance of doubt, the Company&#146;s successors and assigns are authorized to enforce the Company&#146;s rights under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">E. <I>Entire Agreement</I>. This Agreement, together with the Exhibits herein and any executed written offer letter between me
and the Company, to the extent such materials are not in conflict with this Agreement, sets forth the entire agreement and understanding between the Company and me with respect to the subject matter herein and supersedes all prior written and oral
agreements, discussions, or representations between us, including, but not limited to, any representations made during my interview(s) or relocation negotiations. I represent and warrant that I am not relying on any statement or representation not
contained in this Agreement. Any subsequent change or changes in my duties, salary, compensation, conditions or any other terms of my employment will not affect the validity or scope of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">F. <I>Headings</I>. Headings are used in this Agreement for reference only and shall not be considered when interpreting this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">G. <I>Severability</I>. If a court or other body of competent jurisdiction finds, or the parties to this
Agreement mutually believe, any provision of this Agreement, or portion thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this
Agreement will continue in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 10 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">H. <I>Modification, Waiver. </I>No modification of or amendment to this
Agreement, nor any waiver of any rights under this Agreement, will be effective unless in a writing signed by the President or CEO of the Company and me. Waiver by the Company of a breach of any provision of this Agreement will not operate as a
waiver of any other or subsequent breach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I. <I>Survivorship. </I>The rights and obligations of the parties to this
Agreement will survive termination of my employment with the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>14. <U>P<SMALL>ROTECTED</SMALL>
A<SMALL>CTIVITY</SMALL> N<SMALL>OT</SMALL> P<SMALL>ROHIBITED</SMALL></U><SMALL></SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I understand that nothing in
this Agreement limits or prohibits me from filing and/or pursuing a charge or complaint with, or otherwise communicating or cooperating with or participating in any investigation or proceeding that may be conducted by, any federal, state or local
government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board
<B>(</B><B>&#147;</B><B>Government Agencies</B><B>&#148;</B>), including disclosing documents or other information as permitted by law, without giving notice to, or receiving authorization from, the Company. In addition, I understand that nothing in
this Agreement, including its definition of Company Confidential Information, (i)&nbsp;limits employees&#146; rights to discuss or disclose the terms, wages, and working conditions of their employment, nor (ii)&nbsp;prevents me from discussing or
disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that I have reason to believe is unlawful. Notwithstanding the preceding, I agree to take all reasonable precautions to prevent
any unauthorized use or disclosure of any Company trade secrets, proprietary information, or confidential information that does not involve unlawful acts in the workplace or the activity otherwise protected herein. I further understand that I am not
permitted to disclose the Company&#146;s attorney-client privileged communications or attorney work product. In addition, I hereby acknowledge that the Company has provided me with notice in compliance with the Defend Trade Secrets Act of 2016
regarding immunity from liability for limited disclosures of trade secrets. The full text of the notice is attached in Exhibit B.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: September&nbsp;19, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mark Rothera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name of Employee (typed or printed)</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 11 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF PRIOR INVENTIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND ORIGINAL WORKS OF AUTHORSHIP </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identifying Number or Brief Description</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No inventions or improvements </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional Sheets Attached </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: September&nbsp;19, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mark Rothera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name of Employee (typed or printed)</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 12 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 7 OF THE DEFEND TRADE SECRETS ACT OF 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147; . . . An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a
trade secret that&#151;(A) is made&#151;(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation
of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law
may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual&#151;(A) files any document containing the trade secret under seal; and (B)&nbsp;does not disclose the
trade secret, except pursuant to court order.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 13 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION CERTIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is to certify that I do not have in my possession, custody, or control, nor have I failed to return, any devices,
records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, any other documents or property, or reproductions of any and all aforementioned items belonging to Viracta
Therapeutics, Inc. (the &#147;<B>Company</B>&#148;). Notwithstanding the foregoing, I understand that I may keep a copy of the Company&#146;s employee handbook and personnel records relating to me. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I further certify that I have complied with all the terms of the Company&#146;s Confidential Information, Invention Assignment
and Arbitration Agreement (the &#147;<B>Agreement</B>&#148;) signed by me, including the reporting of any inventions and original works of authorship (as defined therein) conceived or made by me (solely or jointly with others), as covered by that
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I understand that pursuant to the Agreement, and subject to its protected activity exclusion, I am obligated
to preserve, as confidential, all Company Confidential Information and Associated Third Party Confidential Information, including trade secrets, confidential knowledge, data, or other proprietary information relating to products, processes, <FONT
STYLE="white-space:nowrap">know-how,</FONT> designs, formulas, developmental or experimental work, computer programs, databases, other original works of authorship, customer lists, business plans, financial information, or other subject matter
pertaining to any business of the Company or any of its employees, clients, consultants, or licensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I also acknowledge
that under the Agreement, for twelve (12)&nbsp;months from this date, I will not engage in the activities prohibited by <B>Section</B><B></B><B>&nbsp;8 </B>or <B>Section</B><B></B><B>&nbsp;13.C</B> of the Agreement. After leaving the Company&#146;s
employment, I will be employed by _______________________________________________________________ in the position of _______________________________________________________________. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: _____________________________________</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mark Rothera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name of Employee (typed or printed)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address for Notifications:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 14 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT D </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFLICT OF INTEREST GUIDELINES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is the policy of Viracta Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) to conduct its affairs in strict compliance
with the letter and spirit of the law and to adhere to the highest principles of business ethics. Accordingly, all officers, employees, and independent contractors must avoid activities that are in conflict, or give the appearance of being in
conflict, with these principles and with the interests of the Company. The following are potentially compromising situations that must be avoided: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. Revealing confidential information to outsiders or misusing confidential information. Unauthorized divulging of information
is a violation of this policy whether or not for personal gain and whether or not harm to the Company is intended. (The Confidential Information, Invention Assignment and Arbitration Agreement (&#147;<B>Confidentiality Agreement</B>&#148;), to which
this Exhibit D was attached, elaborates on this principle and is a binding agreement.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. Accepting or offering
substantial gifts, excessive entertainment, favors, or payments that may be deemed to constitute undue influence or otherwise be improper or embarrassing to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. Participating in civic or professional organizations that might involve divulging confidential information of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. Initiating or approving personnel actions affecting reward or punishment of employees or applicants where there is a
family relationship or is, or appears to be, a personal or social involvement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. Initiating or approving any form of
personal or social harassment of employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. Investing or holding outside directorship in suppliers, customers, or
competing companies, including financial speculations, where such investment or directorship might influence in any manner a decision or course of action of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. Borrowing from or lending to employees, customers, or suppliers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. Acquiring real estate of interest to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. Improperly using or disclosing to the Company any proprietary information or trade secrets of any other employer or other
person or entity with whom obligations of confidentiality exist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. Unlawfully discussing prices, costs, customers,
sales, or markets with competing companies or their employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. Making any unlawful agreement with distributors with
respect to prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. Improperly using or authorizing the use of any inventions that are the subject of patent claims of
any other person or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. Engaging in any conduct that is not in the best interest of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each officer, employee, and independent contractor must take every necessary action to ensure compliance with these guidelines
and to bring problem areas to the attention of higher management for review. Violations of this conflict of interest policy may result in immediate termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Nothing in these guidelines limits or prohibits employees from engaging in any protected activities described in the section
of the Confidentiality Agreement entitled &#147;Protected Activity Not Prohibited.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 15 of 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>VIRACTA THERAPEUTICS, INC. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEMNIFICATION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Indemnification Agreement (the &#147;<U>Agreement</U>&#148;) is made as of September&nbsp;19, 2022, by and between
Viracta Therapeutics, Inc.(formerly known as Sunesis Pharmaceuticals, Inc.), a Delaware corporation (the &#147;<U>Company</U>&#148;), and Mark Rothera (the &#147;<U>Indemnitee</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and
key employees, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance.&nbsp;The Company and Indemnitee further recognize the substantial increase in corporate litigation in general,
subjecting directors, officers and key employees to expensive litigation risks at the same time as the availability and coverage of liability insurance has been severely limited.&nbsp;Indemnitee does not regard the current protection available as
adequate under the present circumstances, and Indemnitee and agents of the Company may not be willing to continue to serve as agents of the Company without additional protection.&nbsp;The Company desires to attract and retain the services of highly
qualified individuals, such as Indemnitee, and to indemnify its directors, officers and key employees so as to provide them with the maximum protection permitted by law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In consideration of the mutual promises made in this Agreement, and for other good and valuable consideration, receipt of
which is hereby acknowledged, the Company and Indemnitee hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.
<B><U>Indemnification</U></B><B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B><U>Third Party Proceedings</U></B><B>.</B>&nbsp;The Company shall indemnify
Indemnitee if Indemnitee is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of
the Company) by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by
reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in connection with such action, suit
or proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe
Indemnitee&#146;s conduct was unlawful.&nbsp;The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that
Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal action or proceeding, that Indemnitee had reasonable cause to
believe that Indemnitee&#146;s conduct was unlawful. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B><U>Proceedings By or in the Right of the
Company</U></B><B>.</B>&nbsp;The Company shall indemnify Indemnitee if Indemnitee was or is a party or is threatened to be made a party to any threatened, pending or completed action or proceeding by or in the right of the Company or any subsidiary
of the Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee
while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys&#146; fees) and, to the fullest extent permitted by law, amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld), in each case to the
extent actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests
of the Company and its stockholders, except that no indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudicated by court order or judgment to be liable to the Company in the
performance of Indemnitee&#146;s duty to the Company and its stockholders unless and only to the extent that the court in which such action or proceeding is or was pending shall determine upon application that, in view of all the circumstances of
the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <B><U>Mandatory Payment of Expenses</U></B><B>.</B>&nbsp;To the extent that Indemnitee has been successful on the merits or
otherwise in defense of any action, suit or proceeding referred to in Section&nbsp;1(a) or Section&nbsp;1(b) or the defense of any claim, issue or matter therein, Indemnitee shall be indemnified against expenses (including attorneys&#146; fees)
actually and reasonably incurred by Indemnitee in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <B><U>No Employment
Rights</U></B><B>.</B>&nbsp;Nothing contained in this Agreement is intended to create in Indemnitee any right to continued employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <B><U>Expenses; Indemnification Procedure</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B><U>Advancement of Expenses</U></B><B>.</B>&nbsp;The Company shall advance all expenses incurred by Indemnitee in
connection with the investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referred to in Section&nbsp;l(a) or Section&nbsp;1(b) hereof (including amounts actually paid in settlement of any such action, suit
or proceeding).&nbsp;Indemnitee hereby undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B><U>Notice/Cooperation by Indemnitee</U></B><B>.</B>&nbsp;Indemnitee
shall, as a condition precedent to his or her right to be indemnified under this Agreement, give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this
Agreement.&nbsp;Notice to the Company shall be directed to the Chief Executive Officer of the Company and shall be given in accordance with the provisions of Section&nbsp;12(d) below.&nbsp;In addition, Indemnitee shall give the Company such
information and cooperation as it may reasonably require and as shall be within Indemnitee&#146;s power. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)
<B><U>Procedure</U></B><B>.</B>&nbsp;Any indemnification and advances provided for in Section&nbsp;1 and this Section&nbsp;3 shall be made no later than twenty (20)&nbsp;days after receipt of the written request of Indemnitee.&nbsp;If a claim under
this Agreement, under any statute, or under any provision of the Company&#146;s Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company within twenty (20)&nbsp;days after a written request for payment
thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and, subject to Section&nbsp;11 of this Agreement, Indemnitee shall
also be entitled to be paid for the expenses (including attorneys&#146; fees) of bringing such action.&nbsp;It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in connection with any
action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed, but the burden of
proving such defense shall be on the Company and Indemnitee shall be entitled to receive interim payments of expenses pursuant to Section&nbsp;3(a) unless and until such defense may be finally adjudicated by court order or judgment from which no
further right of appeal exists.&nbsp;It is the parties&#146; intention that if the Company contests Indemnitee&#146;s right to indemnification, the question of Indemnitee&#146;s right to indemnification shall be for the court to decide, and neither
the failure of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is proper in the
circumstances because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent
legal counsel, or its stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <B><U>Notice to Insurers</U></B><B>.</B>&nbsp;If, at the time of the receipt of a notice of a claim pursuant to
Section&nbsp;3(b) hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective
policies.&nbsp;The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <B><U>Selection of Counsel</U></B><B>.</B>&nbsp;In the event the Company
shall be obligated under Section&nbsp;3(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, upon the
delivery to Indemnitee of written notice of its election so to do.&nbsp;After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this
Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that (i)&nbsp;Indemnitee shall have the right to employ counsel in any such proceeding at Indemnitee&#146;s expense; and (ii)&nbsp;if
(A)&nbsp;the employment of counsel by Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any
such defense or (C)&nbsp;the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then the fees and expenses of Indemnitee&#146;s counsel shall be at the expense of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <B><U>Additional Indemnification Rights; Nonexclusivity</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B><U>Scope</U></B><B>.</B>&nbsp;Notwithstanding any other provision of this Agreement, the Company hereby agrees to
indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Company&#146;s Certificate of Incorporation, the Company&#146;s
Bylaws or by statute.&nbsp;In the event of any change, after the date of this Agreement, in any applicable law, statute, or rule which expands the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such
changes shall be deemed to be within the purview of Indemnitee&#146;s rights and the Company&#146;s obligations under this Agreement.&nbsp;In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware
corporation to indemnify a member of its board of directors or an officer, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties&#146;
rights and obligations hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B><U>Nonexclusivity</U></B><B>.</B>&nbsp;The indemnification provided by this
Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company&#146;s Certificate of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested members of the Company&#146;s Board
of Directors, the General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee&#146;s official capacity and as to action in another capacity while holding such office.&nbsp;The indemnification provided under this
Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he or she may have ceased to serve in any such capacity at the time of any action, suit or other covered proceeding.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <B><U>Partial Indemnification</U></B><B>.</B>&nbsp;If Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred in the investigation, defense, appeal or settlement of any civil or criminal action, suit or proceeding, but not,
however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <B><U>Mutual Acknowledgment</U></B><B>.</B>&nbsp;Both the Company and
Indemnitee acknowledge that in certain instances, Federal law or public policy may override applicable state law and prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise.&nbsp;For example, the Company
and Indemnitee acknowledge that the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) has taken the position that indemnification is not permissible for liabilities arising under certain federal securities laws, and federal legislation
prohibits indemnification for certain ERISA violations. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the SEC to submit the question of indemnification to a court in
certain circumstances for a determination of the Company&#146;s right under public policy to indemnify Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.
<B><U>Officer and Director Liability Insurance</U></B><B>.</B>&nbsp;The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance
with reputable insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company&#146;s performance of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage.&nbsp;In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such
a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company&#146;s directors, if Indemnitee is a director; or of the Company&#146;s officers, if Indemnitee is not a director of the
Company but is an officer; or of the Company&#146;s key employees, if Indemnitee is not an officer or director but is a key employee.&nbsp;Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if
the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by
exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained by a parent or subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <B><U>Severability</U></B><B>.</B>&nbsp;Nothing in this Agreement is intended to require or shall be construed as requiring
the Company to do or fail to do any act in violation of applicable law.&nbsp;The Company&#146;s inability, pursuant to court order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement.&nbsp;The provisions
of this Agreement shall be severable as provided in this Section&nbsp;8.&nbsp;If this Agreement or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee
to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <B><U>Exceptions</U></B><B>.</B>&nbsp;Any other provision herein to the contrary notwithstanding, the Company shall not be
obligated pursuant to the terms of this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B><U>Claims Initiated by Indemnitee</U></B><B>.</B>&nbsp;To
indemnify or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification
under this Agreement or any other statute or law or otherwise as required under Section&nbsp;145 of the Delaware General Corporation Law, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the
Board of Directors finds it to be appropriate; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B><U>Lack of Good Faith</U></B><B>.</B>&nbsp;To indemnify Indemnitee
for any expenses incurred by Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by Indemnitee in such
proceeding was not made in good faith or was frivolous; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <B><U>Insured Claims</U></B>.&nbsp;To indemnify Indemnitee for
expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent such expenses or liabilities have been paid directly to Indemnitee by an
insurance carrier under a policy of officers&#146; and directors&#146; liability insurance maintained by the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <B><U>Claims under Section</U></B><B><U></U></B><B><U>&nbsp;16(b)</U></B><B>.</B>&nbsp;To indemnify Indemnitee for expenses
or the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <B><U>Construction of Certain Phrases</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) For purposes of this Agreement, references to the &#147;<U>Company</U>&#148; shall include, in addition to the resulting
corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and
employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to
such constituent corporation if its separate existence had continued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) For purposes of this Agreement, references to
&#147;<U>other enterprises</U>&#148; shall include employee benefit plans; references to &#147;<U>fines</U>&#148; shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to &#147;<U>serving at
the request of the Company</U>&#148; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit
plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to
have acted in a manner &#147;<U>not opposed to the best interests of the Company</U>&#148; as referred to in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <B><U>Attorneys&#146; Fees</U></B><B>.</B>&nbsp;In the event that any action is instituted by Indemnitee under this
Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys&#146; fees, incurred by Indemnitee with respect to such action, unless as a part of such
action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
were not made in good faith or were frivolous.&nbsp;In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this
Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including attorneys&#146; fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee&#146;s counterclaims and cross-claims made in
such action), unless as a part of such action the court determines that each of Indemnitee&#146;s material defenses to such action were made in bad faith or were frivolous. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <B><U>Miscellaneous</U></B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B><U>Governing Law</U></B><B>.</B>&nbsp;This Agreement and all acts and transactions pursuant hereto and the rights and
obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflict of law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B><U>Entire Agreement; Enforcement of Rights</U></B><B>.</B>&nbsp;This Agreement sets forth the entire agreement and
understanding of the parties relating to the subject matter herein and merges all prior discussions between them.&nbsp;No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in
writing signed by the parties to this Agreement.&nbsp;The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <B><U>Construction</U></B><B>.</B>&nbsp;This Agreement is the result of negotiations between and has been reviewed by each
of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <B><U>Notices</U></B><B>.</B>&nbsp;Any notice, demand or request required or permitted to be given under this Agreement
shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or forty-eight (48)&nbsp;hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party
to be notified at such party&#146;s address as set forth below or as subsequently modified by written notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)
<B><U>Counterparts</U></B><B>.</B>&nbsp;This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <B><U>Successors and Assigns</U></B><B>.</B>&nbsp;This Agreement shall be binding upon the Company and its successors and
assigns, and inure to the benefit of Indemnitee and Indemnitee&#146;s heirs, legal representatives and assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g)
<B><U>Subrogation</U></B>.&nbsp;In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all
acts that may be necessary to secure such rights and to enable the Company to effectively bring suit to enforce such rights. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties hereto have executed this Agreement as of the day and year set
forth on the first page of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VIRACTA THERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roger J. Pomerantz, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman of the Board</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address: &nbsp;2533 S. Coast Hwy 101, Suite 210</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cardiff,
California 92007</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AGREED TO AND ACCEPTED:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Rothera</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d401810dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Separation Agreement and Release (&#147;Agreement&#148;) is made by and between Ivor Royston (&#147;Executive&#148;) and
Viracta Therapeutics, Inc. (the &#147;Company&#148;) (collectively referred to as the &#147;Parties&#148; or individually referred to as a &#147;Party&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Executive was employed by the Company as its Chief Executive Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Executive signed an Executive Employment Agreement effective as of April&nbsp;3, 2017, as amended on August&nbsp;12,
2021 (together, the &#147;Employment Agreement&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Executive signed an
<FONT STYLE="white-space:nowrap">At-Will</FONT> Employment, Confidential Information, Invention Assignment, and Arbitration Agreement<B> </B>with the Company (the &#147;Confidentiality Agreement&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Executive&#146;s employment with the Company is being terminated effective September&nbsp;19, 2022 (the
&#147;Separation Date&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the Parties wish to resolve any and all disputes, claims, complaints,
grievances, charges, actions, petitions, and demands that the Executive may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to
Executive&#146;s employment with or separation from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the mutual promises
made herein, the Company and Executive hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Consideration</U>. Subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of
this Agreement, and Executive&#146;s continued compliance with the terms of this Agreement and the Confidentiality Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. <I>Severance Payment</I>. The Company agrees to pay Executive a total of Seven Hundred and Eight Thousand Seven Hundred and
Fifty Dollars ($708,750), at the rate of Forty Seven Thousand Two Hundred and Fifty Dollars ($47,250) per month, less applicable withholdings, for fifteen (15)&nbsp;months from the Separation Date, in accordance with the Company&#146;s regular
payroll practices, with the first payment paid on the first regular payroll date following the Effective Date and to include any amounts that that otherwise would have been paid between the Separation Date and the first payment date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. <I>Health Care Coverage Payment</I>. The Company agrees to pay Executive a total of Forty Five Thousand Nine Hundred <FONT
STYLE="white-space:nowrap">Sixty-Two</FONT> Dollars and Seventy Cents ($45,962.70), at the rate of Three Thousand Sixty-Four Dollars and Eighteen Cents ($3,064.18) per month, less applicable withholdings, for fifteen (15)&nbsp;months from the
Separation Date, in accordance with the Company&#146;s regular payroll practices, with the first payment paid on the first regular payroll date following the Effective Date and to include any amounts that that otherwise would have been paid between
the Separation Date and the first payment date. In addition, the Company agrees to reimburse the Executive for the amounts he pays to continue his other Company provided health and welfare benefits (vision, dental, and life insurance) under
applicable law (COBRA) for fifteen (15)&nbsp;months, provided Executive timely elects and pays for continued coverage pursuant to COBRA, with such reimbursement to be made within thirty (30)&nbsp;days of submission of proof of payment, but only if
proof of payment is submitted within thirty (30)&nbsp;days of Executive paying the applicable premium. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. <I>Bonus</I>. The Company agrees to pay Executive a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> Target Bonus (as defined in the Employment Agreement) for the 2022 fiscal year, where the proration is based on the number of days between the start of the 2022 fiscal year and September&nbsp;30, 2022.
Payment pursuant to this Section&nbsp;1.c will be subject to the Company&#146;s Board of Directors (the &#147;Board&#148;) (or an authorized committee of the Board) determining, in good faith, that any applicable performance objectives have been
achieved and, if earned, paid to Executive on the same day that 2022 annual bonuses are paid to continuing Company employees, but in no event will any such annual bonus be paid after the later of (i)&nbsp;the fifteenth (15th) day of the third (3rd)
month following the close of the Company&#146;s fiscal year in which such bonus is earned or (ii)&nbsp;March&nbsp;15 following the calendar year in which such bonus is earned. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. <I>Post-Termination Exercise Period</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">i. <I>Extension of Exercise Period</I>. The Company agrees that, effective as of the Effective Date, the equity awards set
forth on <U>Exhibit A</U> (the &#147;Options&#148;) will each be amended to provide that Executive has the right to exercise the vested portion of each Option until the earlier of (x)&nbsp;two (2) years following the date that he is no longer a
Service Provider to the Company (as defined in the applicable equity incentive plan), or (y)&nbsp;the expiration of the term of such Option, subject in each case to earlier termination in accordance with the terms of the applicable equity incentive
plan (the &#147;Options Amendment&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ii. <I>Tax Implications</I>. Executive acknowledges and agrees that the Options
Amendment is a &#147;modification&#148; of the Options resulting in the deemed <FONT STYLE="white-space:nowrap">re-grant</FONT> of the Options for purposes of the rules governing Incentive Stock Options under Section&nbsp;422 of the Code.&nbsp;As a
result, the Options otherwise characterized as Incentive Stock Options have converted into Nonstatutory Stock Options for tax purposes as of the Effective Date.&nbsp;Upon the exercise of any of the Options, Executive will be treated as having
received compensation income from the Company (taxable at ordinary income tax rates) equal to the excess, if any, of the aggregate fair market value of the exercised shares on the date of exercise over their aggregate exercise price.&nbsp;In that
case, in addition to the payment of the aggregate exercise price, Executive&#146;s exercise of any Options is conditioned on payment to the Company of applicable federal, state and other withholding obligations incurred upon exercise.&nbsp;Executive
acknowledges and agrees that Executive remains solely responsible for all employee-related withholdings associated with the exercise of the unexercised Options.&nbsp;The Company has advised the Executive to consult with Executive&#146;s own tax
advisor regarding the tax status of the Options and the tax consequences to the Executive of Executive&#146;s exercise of the Options and disposition of any shares acquired upon such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. <I>Reimbursement of Costs and Fees</I>. The Company shall reimburse Executive for reasonable costs and attorney&#146;s fees
in connection with the preparation of this Agreement not to exceed $15,000 in the aggregate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. <I>Acknowledgement</I>.
Executive acknowledges that without this Agreement, Executive is otherwise not entitled to the consideration listed in this Section&nbsp;1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Termination</U>. Executive&#146;s employment with the Company is being terminated as of the Separation Date. Executive
agrees to&nbsp;promptly&nbsp;execute any&nbsp;instruments,&nbsp;forms or other documents&nbsp;evidencing the termination of his employment as a matter of state, federal, or foreign law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Board Position</U>. The Parties agree that Executive shall continue to be a member of the Board following the Separation
Date until the expiration of the term for which he was elected and any subsequent term for which he is nominated and elected to the Board, or until Executive&#146;s earlier death, resignation or removal, and shall continue to vest in any outstanding
equity awards from the Company pursuant to the terms and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">conditions of any applicable equity agreements between Executive and the Company.
Furthermore, in the event Executive otherwise would incur a termination of Continuous Service (as defined in the Company&#146;s Amended 2011 Equity Incentive Plan) or cease to be a Service Provider (as defined in the Company&#146;s 2021 Equity
Incentive Plan) prior to the vesting of all of the Stock Options set forth on <U>Exhibit A</U> due to the Executive&#146;s removal from the Board for any reason other than his voluntary resignation, his death, or for Cause, the Company shall appoint
Executive to its Scientific Advisory Board so that Executive shall not have a termination of Continuous Service and shall continue as a Service Provider for purposes of continued vesting of the Stock Options, with Executive remaining in Continuous
Service as a Service Provider pursuant to his services as a member of the Scientific Advisory Board though the date on which the Stock Options have vested in full or his earlier voluntary resignation from the Scientific Advisory Board, death or
removal from the Scientific Advisory Board for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;an act of dishonesty made by Executive in connection with Executive&#146;s responsibilities as a member of the Board or the
Scientific Advisory Board; (ii)&nbsp;Executive&#146;s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude; (iii)&nbsp;Executive&#146;s gross misconduct;
(iv)&nbsp;Executive&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive&#146;s relationship with the
Company; (v)&nbsp;Executive&#146;s willful breach of any obligations under any written agreement or covenant with the Company; or (vi)&nbsp;Executive&#146;s continued failure to perform Executive&#146;s Board or Scientific Advisory Board duties
after Executive has received a written demand of performance from the Company with specifically sets forth the factual basis for the Company&#146;s belief that Executive has not substantially performed Executive&#146;s duties and has failed to cure
such <FONT STYLE="white-space:nowrap">non-performance</FONT> to the Company&#146;s satisfaction within 10 business days after receiving such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Payment of Salary and Receipt of All Benefits</U>. Executive&#146;s participation in all benefits and incidents of
employment, including, but not limited to, the accrual of bonuses, vacation, and paid time off, will cease as of the Separation Date. Other than (i)&nbsp;the base salary otherwise payable to Executive for employment on and after September&nbsp;1,
2022, (ii) Executive&#146;s wellness (gym) benefit reimbursement for September, and (iii)&nbsp;payment for Executive&#146;s accrued, but unused, vacation/paid-time off, (all of the foregoing amounts to be paid in the ordinary course), Executive
acknowledges and represents that the Company has paid or provided all salary, wages, bonuses, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, and any and all
other benefits and compensation due to Executive as of the signature date below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Release of Claims</U>. Executive
agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders,
administrators, affiliates, benefit plans, plan administrators, professional employer organization or <FONT STYLE="white-space:nowrap">co-employer,</FONT><B> </B>insurers, trustees, divisions, subsidiaries, predecessor and successor corporations,
and assigns (collectively, the &#147;Releasees&#148;). Executive, on Executive&#146;s own behalf and on behalf of Executive&#146;s respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and
agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or
unsuspected, that Executive may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the date Executive signs this Agreement, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. any and all claims relating to or arising from Executive&#146;s employment relationship with the Company and the termination
of that relationship; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. any and all claims relating to, or arising from, Executive&#146;s right to purchase, or actual
purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. any and all claims for wrongful discharge of employment, termination in
violation of public policy, discrimination, harassment, retaliation, breach of contract (both express and implied), breach of covenant of good faith and fair dealing (both express and implied), promissory estoppel, negligent or intentional
infliction of emotional distress, fraud, negligent or intentional misrepresentation, negligent or intentional interference with contract or prospective economic advantage, unfair business practices, defamation, libel, slander, negligence, personal
injury, assault, battery, invasion of privacy, false imprisonment, conversion, and disability benefits; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. any and all
claims for violation of any federal, state, or municipal statute, including, but not limited to, Title&nbsp;VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Rehabilitation Act of 1973, the Americans with Disabilities Act of
1990, the Equal Pay Act, the Fair Labor Standards Act, the Fair Credit Reporting Act, the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act of 1974, the Worker
Adjustment and Retraining Notification Act, the Family and Medical Leave Act, the Immigration Reform and Control Act, the National Labor Relations Act, the California Family Rights Act, the California Labor Code, the California Workers&#146;
Compensation Act, and the California Fair Employment and Housing Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. any and all claims for violation of the federal
or any state constitution; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. any and all claims arising out of any other laws and regulations relating to employment or
employment discrimination; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g. any claim for any loss, cost, damage, or expense arising out of any dispute over the
nonwithholding or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">h.
any and all claims for attorneys&#146; fees and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Executive agrees that the release set forth in this section shall be and remain in
effect in all respects as a complete general release as to the matters released. This release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released as a matter of law. This
release does not waive any rights available to Executive under the Indemnification Agreement signed between the Parties on February&nbsp;24, 2021 (the &#147;Indemnification Agreement&#148;). This release does not release claims Executive may have in
connection with his status as a stockholder. Any and all disputed wage claims that are released herein shall be subject to binding arbitration in accordance with this Agreement, except as required by applicable law. This release does not extend to
any right Executive may have to unemployment compensation benefits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>Acknowledgment of Waiver of Claims under
ADEA</U>. Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#147;ADEA&#148;), and that this waiver and release is knowing and voluntary. Executive
agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Executive signs this Agreement. Executive acknowledges that the consideration given for this waiver and release is in addition to
anything of value to which Executive was already entitled. Executive further acknowledges that Executive has been advised by this writing that: (a)&nbsp;Executive should consult with an attorney <U>prior</U> to executing this Agreement;
(b)&nbsp;Executive has <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days within which to consider this Agreement; (c)&nbsp;Executive has seven (7)&nbsp;days following Executive&#146;s execution of this Agreement to revoke this
Agreement; (d)&nbsp;this Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
shall not be effective until after the revocation period has expired; and (e)&nbsp;nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good
faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Agreement and returns it to the
Company in less than the <FONT STYLE="white-space:nowrap">21-day</FONT> period identified above, Executive hereby acknowledges that Executive has knowingly and voluntarily chosen to waive the time period allotted for considering this Agreement.
Executive acknowledges and understands that revocation must be accomplished by a written notification to the person executing this Agreement on the Company&#146;s behalf that is received prior to the Effective Date. The Parties agree that changes,
whether material or immaterial, do not restart the running of the <FONT STYLE="white-space:nowrap">21-day</FONT> period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>California Civil Code Section</U><U></U><U>&nbsp;1542</U>. Executive acknowledges that Executive has been advised to
consult with legal counsel and is familiar with the provisions of California Civil Code Section&nbsp;1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR
HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Executive, being aware of said code section, agrees to expressly waive any rights Executive may have thereunder, as well as under any other
statute or common law principles of similar effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>No Pending or Future Lawsuits</U>. Executive represents that
Executive has no lawsuits, claims, or actions pending in Executive&#146;s name, or on behalf of any other person or entity, against the Company or any of the other Releasees. Executive also represents that Executive does not currently intend to
bring any claims on Executive&#146;s own behalf or on behalf of any other person or entity against the Company or any of the other Releasees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>Application for Employment</U>. Executive understands and agrees that, as a condition of this Agreement, Executive shall
not be entitled to any employment with the Company, and Executive hereby waives any right, or alleged right, of employment or <FONT STYLE="white-space:nowrap">re-employment</FONT> with the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>Trade Secrets and Confidential Information/Company Property</U>. Executive agrees at all times hereafter to hold in the
strictest confidence, and not to use or disclose to any person or entity, any Confidential Information of the Company. Executive understands that &#147;Confidential Information&#148; means any Company or associated third party proprietary
information, technical data, trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> including, but not limited to, research, product plans, products, services, customer lists and customers (including, but not limited to, customers of the
Company on whom Executive has called or with whom Executive became acquainted during the term of Executive&#146;s employment), markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware
configuration information, marketing, finances, or other business information disclosed to Executive by the Company either directly or indirectly, in writing, orally, or by drawings or observation of parts or equipment. Executive further understands
that Confidential Information does not include any of the foregoing items that have become publicly known and made generally available through no wrongful act of Executive&#146;s or of others who were under confidentiality obligations as to the item
or items involved or improvements or new versions thereof. Executive hereby grants consent to notification by the Company to any new employer about Executive&#146;s obligations under this section. Executive represents that Executive has not to date
misused or disclosed Confidential Information to any unauthorized party. Executive acknowledges that the Company will not enforce the post-employment <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions in the Confidentiality
Agreement; provided, however, that Executive remains bound by all other continuing </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
obligations under the Confidentiality Agreement, including Executive&#146;s confidentiality obligations thereof. Executive&#146;s signature below constitutes Executive&#146;s certification under
penalty of perjury that Executive has returned all documents and other items provided to Executive by the Company, developed or obtained by Executive in connection with Executive&#146;s employment with the Company, or otherwise belonging to the
Company, except as stated herein. Specifically, Executive may retain a copy of the Employee Handbook and personnel documents specifically relating to Executive. In addition, during the period in which Executive continues to serve as a member of the
Board or is otherwise a Company service provider, subject to his continuing obligations under the Confidentiality Agreement (as amended herein) and this Agreement, applicable Company security and cybersecurity policies as may be amended or adopted
from time to time, and other applicable legal obligations, Executive will: (i)&nbsp;have access to, and may continue using, his Company-provided email account, (ii)&nbsp;retain his Company-issued desktop computer and have continued access to the
Company&#146;s Active Directory Controlled Network accessible folder, and (iii)&nbsp;retain his Company-issued phone and phone number. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>Invention Assignment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. <I>Inventions Defined</I>. &#147;Inventions&#148; means inventions, original works of authorship, developments, concepts,
improvements, designs, discoveries, ideas, <FONT STYLE="white-space:nowrap">know-how,</FONT> trademarks, and trade secrets, whether or not patentable or registrable under copyright or similar laws, that Executive solely or jointly authored,
conceived, developed, or reduced to practice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. <I>Assignment of Inventions and Works Made for Hire</I>. Executive hereby
assigns to Company, or its designee, all of Executive&#146;s right, title, and interest (including all related intellectual property rights) in all Inventions that Executive created during the period of time Executive was in the employ of the
Company (including during <FONT STYLE="white-space:nowrap">off-duty</FONT> hours) (&#147;Company Inventions&#148;). In addition, Executive acknowledges that all original works of authorship that were made by Executive (solely or jointly with others)
within the scope of and during the period of Executive&#146;s employment with Company and that are protectable by copyright are &#147;works made for hire,&#148; as that term is defined in the United States Copyright Act, and in accordance, the
Company is considered the author of these works. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. <I>Exception to Assignments</I>. EXECUTIVE ACKNOWLEDGES AND
UNDERSTANDS THAT THE PROVISIONS OF THIS AGREEMENT REQUIRING ASSIGNMENT OF INVENTIONS TO COMPANY DO NOT APPLY TO ANY INVENTION THAT QUALIFIES FULLY UNDER THE PROVISIONS OF CALIFORNIA LABOR CODE SECTION 2870. California Labor Code section 2870
provides: &#147;(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee
developed entirely on his or her own time without using the employer&#146;s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1)&nbsp;Relate at the time of conception or reduction to practice of
the invention to the employer&#146;s business, or actual or demonstrably anticipated research or development of the employer; or (2)&nbsp;Result from any work performed by the employee for the employer. (b)&nbsp;To the extent a provision in an
employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. <I>Outside Inventions.</I>&nbsp;Executive acknowledges that Executive has not incorporated any inventions, discoveries,
ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by any third party into any Company Invention without the Company&#146;s prior written permission.
Executive acknowledges that Executive has informed the Company, in writing, before incorporating any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or
intellectual property </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rights owned by Executive or in which Executive has an interest prior to, or separate from, Executive&#146;s employment with the Company, including, without limitation, any such inventions that
are subject to California Labor Code Section&nbsp;2870 (&#147;Outside Inventions&#148;) into any Company Invention or otherwise utilizing any Outside Invention in the course of Executive&#146;s employment with the Company; and the Company is hereby
granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare
derivative works of, display, perform, and otherwise exploit any such incorporated or utilized Outside Inventions, without restriction, including, without limitation, as part of, or in connection with, such Invention, and to practice any method
related thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. <I>Moral Rights</I><I>. </I>Any assignment to the Company of Company Inventions includes all rights of
attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as &#147;moral rights,&#148; &#147;artist&#146;s rights,&#148; or the like (collectively,
&#147;Moral Rights&#148;). If Moral Rights cannot be assigned under applicable law, Executive hereby waives and agrees not to enforce any and all Moral Rights, including any limitation on subsequent modification, to the extent permitted under
applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. <I>Further Assurances.</I> Executive will assist the Company, or its designee, at Company&#146;s
expense, in every proper way to secure and protect the Company&#146;s rights in Company Inventions and any related copyrights, patents, mask work rights, or other intellectual property rights in any and all countries. Executive will disclose to
Company all pertinent information and data. Executive will execute all applications, specifications, oaths, assignments, and all other instruments that Company deems necessary in order to apply for and obtain these rights and in order to deliver,
assign, and convey to Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to Company Inventions, and any related copyrights, patents, mask work rights, or other intellectual property rights.
Executive will testify in a suit or other proceeding relating to such Company Inventions and any rights relating thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>No Cooperation</U>. Subject to the Protected Activity Not Prohibited section, Executive agrees that Executive will not
knowingly encourage, counsel, or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against any of the Releasees, unless under a
subpoena or other court order to do so or upon written request from an administrative agency or the legislature or as related directly to the ADEA waiver in this Agreement Executive agrees both to immediately notify the Company upon receipt of any
such subpoena or court order or written request from an administrative agency or the legislature, and to furnish, within three (3)&nbsp;business days of its receipt, a copy of such subpoena or other court order or written request from an
administrative agency or the legislature. If approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Releasees, Executive shall
state no more than that Executive cannot provide counsel or assistance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Protected Activity Not Prohibited</U>.
Executive understands that nothing in this Agreement shall in any way limit or prohibit Executive from engaging in any Protected Activity. Protected Activity includes: (i)&nbsp;filing and/or pursuing a charge, complaint, or report with, or otherwise
communicating, cooperating, or participating in any investigation or proceeding that may be conducted by any federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity
Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (&#147;Government Agencies&#148;); and/or (ii)&nbsp;discussing or disclosing information about unlawful acts in the workplace, such as harassment
or discrimination or any other conduct that Executive has reason to believe is unlawful. Executive understands that in connection with such Protected Activity, Executive is permitted to disclose documents or other information as permitted by law,
without giving notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, Executive agrees to take all reasonable </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
precautions to prevent any unauthorized use or disclosure of any Company trade secrets, proprietary information, or confidential information that does not involve unlawful acts in the workplace
or the activity otherwise protected herein. Executive further understands that Protected Activity does not include the disclosure of any Company attorney-client privileged communications or attorney work product. Any language in the Confidentiality
Agreement regarding Executive&#146;s right to engage in Protected Activity that conflicts with, or is contrary to, this section is superseded by this Agreement. In addition, pursuant to the Defend Trade Secrets Act of 2016, Executive is notified
that an individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i)&nbsp;is made in confidence to a federal, state, or local government official (directly or
indirectly) or to an attorney <I>solely</I> for the purpose of reporting or investigating a suspected violation of law, or (ii)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is
made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the individual&#146;s attorney and use the trade secret information in the
court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>Mutual Nondisparagement</U>. Subject to the Protected Activity Not Prohibited section, Executive agrees to refrain from
any disparagement, defamation, libel, or slander of any of the Releasees, and agrees to refrain from any tortious interference with the contracts and relationships of any of the Releasees. Similarly, the Company agrees to refrain from any
disparagement, defamation, libel or slander of Executive. Executive understands that the Company&#146;s obligations under this paragraph extend only to the Company&#146;s current executive officers and members of its Board of Directors and only for
so long as each officer or member is an employee or director of the Company. Executive shall direct any inquiries by potential future employers to the Company&#146;s human resources department. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. <U>Breach</U>. In addition to the rights provided in the &#147;Attorneys&#146; Fees&#148; section below, Executive
acknowledges and agrees that any material breach of this Agreement, unless such breach constitutes a legal action by Executive challenging or seeking a determination in good faith of the validity of the waiver herein under the ADEA, or of any
provision of the Confidentiality Agreement (as amended herein) shall entitle the Company immediately to recover and/or cease providing the consideration provided to Executive under this Agreement and to obtain damages, except as provided by law.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. <U>No Admission of Liability</U>. Executive understands and acknowledges that with respect to all claims released
herein, this Agreement constitutes a compromise and settlement of any and all actual or potential disputed claims by Executive unless such claims were explicitly not released by the release in this Agreement. No action taken by the Company hereto,
either previously or in connection with this Agreement, shall be deemed or construed to be (a)&nbsp;an admission of the truth or falsity of any actual or potential claims or (b)&nbsp;an acknowledgment or admission by the Company of any fault or
liability whatsoever to Executive or to any third party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. <U>ARBITRATION</U>. EXCEPT AS PROHIBITED BY LAW, THE PARTIES
AGREE THAT ANY AND ALL DISPUTES ARISING OUT OF THE TERMS OF THIS AGREEMENT, THEIR INTERPRETATION, EXECUTIVE&#146;S EMPLOYMENT WITH THE COMPANY OR THE TERMS THEREOF, OR ANY OF THE MATTERS HEREIN RELEASED, SHALL BE SUBJECT TO ARBITRATION UNDER THE
FEDERAL ARBITRATION ACT (THE &#147;FAA&#148;) AND THAT THE FAA SHALL GOVERN AND APPLY TO THIS ARBITRATION AGREEMENT WITH FULL FORCE AND EFFECT; HOWEVER, WITHOUT LIMITING ANY PROVISIONS OF THE FAA, A MOTION OR PETITION OR ACTION TO COMPEL ARBITRATION
MAY ALSO BE BROUGHT IN STATE COURT UNDER THE PROCEDURAL PROVISIONS OF SUCH STATE&#146;S LAWS RELATING TO MOTIONS OR PETITIONS OR ACTIONS TO COMPEL ARBITRATION. EXECUTIVE AGREES THAT, TO THE FULLEST EXTENT PERMITTED BY </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
LAW, EXECUTIVE MAY BRING ANY SUCH ARBITRATION PROCEEDING ONLY IN EXECUTIVE&#146;S INDIVIDUAL CAPACITY. ANY ARBITRATION WILL OCCUR IN SAN DIEGO COUNTY, BEFORE JAMS, PURSUANT TO ITS EMPLOYMENT
ARBITRATION RULES&nbsp;&amp; PROCEDURES (&#147;JAMS RULES&#148;), EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION. THE PARTIES AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING
MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION, AND MOTIONS TO DISMISS AND DEMURRERS, APPLYING THE STANDARDS SET FORTH UNDER THE CALIFORNIA CODE OF CIVIL PROCEDURE. THE PARTIES AGREE THAT THE ARBITRATOR SHALL ISSUE A WRITTEN DECISION ON THE
MERITS. THE PARTIES ALSO AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES AVAILABLE UNDER APPLICABLE LAW, AND THAT THE ARBITRATOR MAY AWARD ATTORNEYS&#146; FEES AND COSTS TO THE PREVAILING PARTY, WHERE PERMITTED BY APPLICABLE
LAW. THE ARBITRATOR MAY GRANT INJUNCTIONS AND OTHER RELIEF IN SUCH DISPUTES. THE DECISION OF THE ARBITRATOR SHALL BE FINAL, CONCLUSIVE, AND BINDING ON THE PARTIES TO THE ARBITRATION. THE PARTIES AGREE THAT THE PREVAILING PARTY IN ANY ARBITRATION
SHALL BE ENTITLED TO INJUNCTIVE RELIEF IN ANY COURT OF COMPETENT JURISDICTION TO ENFORCE THE ARBITRATION AWARD. THE PARTIES TO THE ARBITRATION SHALL EACH PAY AN EQUAL SHARE OF THE COSTS AND EXPENSES OF SUCH ARBITRATION, AND EACH PARTY SHALL
SEPARATELY PAY FOR ITS RESPECTIVE COUNSEL FEES AND EXPENSES; PROVIDED, HOWEVER, THAT THE ARBITRATOR MAY AWARD ATTORNEYS&#146; FEES AND COSTS TO THE PREVAILING PARTY, EXCEPT AS PROHIBITED BY LAW. THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE
ANY DISPUTE BETWEEN THEM RESOLVED IN A COURT OF LAW BY A JUDGE OR JURY. NOTWITHSTANDING THE FOREGOING, THIS SECTION WILL NOT PREVENT EITHER PARTY FROM SEEKING INJUNCTIVE RELIEF (OR ANY OTHER PROVISIONAL REMEDY) FROM ANY COURT HAVING JURISDICTION
OVER THE PARTIES AND THE SUBJECT MATTER OF THEIR DISPUTE RELATING TO THIS AGREEMENT AND THE AGREEMENTS INCORPORATED HEREIN BY REFERENCE. SHOULD ANY PART OF THE ARBITRATION AGREEMENT CONTAINED IN THIS SECTION CONFLICT WITH ANY OTHER ARBITRATION
AGREEMENT BETWEEN THE PARTIES, INCLUDING, BUT NOT LIMITED TO THE ARBITRATION SECTION OF THE CONFIDENTIALITY AGREEMENT, THE PARTIES AGREE THAT THIS ARBITRATION AGREEMENT IN THIS SECTION SHALL GOVERN. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. <U>Tax Consequences</U>. The Company makes no representations or warranties with respect to the tax consequences of the
payments and any other consideration provided to Executive or made on Executive&#146;s behalf under the terms of this Agreement. The Parties agree and acknowledge that the payments made pursuant to section 1 of this Agreement are not related to
sexual harassment or sexual abuse and not intended to fall within the scope of 26 U.S.C. Section&nbsp;162(q). The Company shall withhold on the payments to be made hereunder in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. <U>Section 409A.</U> It is intended that this Agreement comply with, or be exempt from, Code Section&nbsp;409A and the
final regulations and official guidance thereunder (&#147;Section&nbsp;409A&#148;) and any ambiguities herein will be interpreted to so comply and/or be exempt from Section&nbsp;409A. Each payment and benefit to be paid or provided under this
Agreement is intended to constitute a series of separate payments for purposes of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)</FONT> of the Treasury Regulations. The Company and Executive will work together in good faith to consider
either (i)&nbsp;amendments to this Agreement; or (ii)&nbsp;revisions to this Agreement with respect to the payment of any awards, which are necessary or appropriate to avoid imposition of any additional tax or income recognition prior to the actual
payment to Executive under Section&nbsp;409A. In no event will the Releasees reimburse Executive for any taxes that may be imposed on Executive as a result of Section&nbsp;409A. The parties acknowledge and agree that the termination of
Executive&#146;s employment constitutes a &#147;separation from service&#148; under Section&nbsp;409A of the Code. Notwithstanding anything to the contrary in this Agreement, if Executive is a </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
&#147;specified employee&#148; within the meaning of Section&nbsp;409A at the time of Executive&#146;s termination of employment (other than due to death), and if necessary to avoid the
imputation of additional tax, whether in the form of excise taxes or otherwise, pursuant to Section&nbsp;409A, then all amounts payable hereunder that are considered deferred compensation under Section&nbsp;409A (&#147;Deferred Compensation
Separation Benefits&#148;) that are payable within the first six (6)&nbsp;months following Executive&#146;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6)&nbsp;months and one
(1)&nbsp;day following the date of Executive&#146;s separation from service. Notwithstanding anything herein to the contrary, if Executive dies following Executive&#146;s separation from service, but prior to the six (6)&nbsp;month anniversary of
the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#146;s death and all other Deferred Compensation Separation
Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20.
<U>Authority</U>. The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through it to the terms and conditions of this Agreement. Executive represents
and warrants that Executive has the capacity to act on Executive&#146;s own behalf and on behalf of all who might claim through Executive to bind them to the terms and conditions of this Agreement. Each Party warrants and represents that there are
no liens or claims of lien or assignments in law or equity or otherwise of or against any of the claims or causes of action released herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21. <U>Severability</U>. In the event that any provision or any portion of any provision hereof or any surviving agreement made
a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22. <U>Attorneys</U><U>&#146;</U><U> Fees</U>. Except with regard to a legal action challenging or seeking a determination in
good faith of the validity of the waiver herein under the ADEA, in the event that either Party brings an action to enforce or effect its rights under this Agreement, the prevailing Party shall be entitled to recover its costs and expenses, including
the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys&#146; fees incurred in connection with such an action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23. <U>Entire Agreement</U>. This Agreement represents the entire agreement and understanding between the Company and Executive
concerning the subject matter of this Agreement and Executive&#146;s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings
concerning the subject matter of this Agreement and Executive&#146;s relationship with the Company, including, but not limited to, the Employment Agreement, with the exception of the Confidentiality Agreement and the Indemnification Agreement,
except as amended herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24. <U>No Oral Modification</U>. This Agreement may only be amended in a writing signed by
Executive and the Company&#146;s Chairman of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25. <U>Governing Law</U>. This Agreement shall be governed by the
laws of the State of California, without regard for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> provisions, except that any dispute regarding the enforceability of the arbitration section of this
Agreement shall be governed by the FAA. Executive consents to personal and exclusive jurisdiction and venue in the State of California. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26. <U>Effective Date</U>. Executive understands that this Agreement shall be null and void if not executed by Executive within
<FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days. Each Party has seven (7)&nbsp;days after that Party signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Executive signed this
Agreement, so long as it has been signed by the Parties and has not been revoked by either Party before that date (the &#147;Effective Date&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27. <U>Counterparts</U>. This Agreement may be executed in counterparts and
each counterpart shall be deemed an original and all of which counterparts taken together shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned.&nbsp;The
counterparts of this Agreement may be executed and delivered by facsimile, photo, email PDF, or other electronic transmission or signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28. <U>Voluntary Execution of Agreement</U>. Executive understands and
agrees that Executive executed this Agreement voluntarily and without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#146;s claims against the Company and any
of the other Releasees. Executive acknowledges that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Executive has read this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Executive has a right to consult with an attorney regarding this Agreement, and has been represented in the
preparation, negotiation, and execution of this Agreement by an attorney of Executive&#146;s own choice or has elected not to retain an attorney; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Executive understands the terms and consequences of this Agreement and of the releases it contains;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Executive is fully aware of the legal and binding effect of this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Executive has not relied upon any representations or statements made by the Company that are not
specifically set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the Parties have executed this Agreement on the
respective dates set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IVOR ROYSTON, M.D., an individual</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dated: September&nbsp;15, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Ivor Royston, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ivor Royston, M.D.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VIRACTA THERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dated: September&nbsp;15, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Roger J. Pomerantz, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roger J. Pomerantz, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman of the Board</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Plan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Subject<BR>to Original<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Previously<BR>Exercised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding<BR>Shares&nbsp;Subject<BR>to Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/13/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2016&nbsp;Plan</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">01/08/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2016 Plan</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/26/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021 Plan</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/17/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021 Plan</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d401810dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g401810dsp57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of
the Company&#146;s Strategic Development and Growth </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Viracta Therapeutics&#146; Board of Directors appoints Mark Rothera as
President and Chief Executive Officer </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of
Viracta&#146;s Board of Directors </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>PR Newswire, San Diego, September</I><I></I><I>&nbsp;19, 2022 &#150; </I><U>Viracta</U>
Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession of its President and Chief Executive Officer, Ivor Royston, M.D. to Mark Rothera, who was appointed as President
and CEO and member of the Board of Directors, effective today. Dr.&nbsp;Royston will support the leadership transition and continue to serve as a member of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;We are pleased to welcome Mark as Viracta&#146;s new President and Chief Executive Officer, given his demonstrated strategic execution,
deep commercialization experience and proven global leadership skills, as the Company advances Nana-val towards later-stage clinical development, marketing approval and important global strategic positioning,&#148; said Roger J. Pomerantz, M.D.,
F.A.C.P, Chairman of the Board of Directors at Viracta. &#147;On behalf of the Viracta Board of Directors, we would like to thank Ivor for his visionary leadership in advancing a new and potentially disruptive modality in the treatment of
Epstein-Barr virus-associated cancers, and look forward to his continued service on the Board.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;I am thrilled to be joining
Viracta at this exciting time, as the company progresses Nana-val across multiple indications with the ambition of representing a tumor-agnostic approach to Epstein-Barr virus-associated cancers,&#148; said Mr.&nbsp;Rothera. &#147;I appreciate the
solid foundation Ivor has established at Viracta, the strong team that he has assembled and the opportunity to expand on the promising clinical data in <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma. I view this transition as a
passing of the baton and look forward to leveraging my strategic and global commercial experience to optimally position Nana-val to help patients suffering from some of the most aggressive forms of cancer, whilst maintaining a clear focus on driving
shareholder value.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record
of commercial and global leadership, including driving the successful build of multiple biotech companies, predominantly in the field of rare or specialty diseases. Prior to joining Viracta, Mr.&nbsp;Rothera served as President and CEO of Silence
Therapeutics (NASDAQ: SLN), a clinical-stage organization focused on developing RNA therapies for hematology, cardiovascular and rare diseases. He previously served as CEO of Orchard Therapeutics (NASDAQ: ORTX), where he oversaw its transformation
from a small U.K.-based, privately held company with two clinical-stage programs into a leading gene therapy company with seven clinical-stage programs and fully integrated capabilities. During his tenure, Orchard Therapeutics secured more than
$600&nbsp;million </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in financing and grew from a market capitalization of $250&nbsp;million to more than $1.7&nbsp;billion at its peak. Prior to Orchard, Mr.&nbsp;Rothera served as Chief Commercial Officer of PTC
Therapeutics (NASDAQ: PTCT), where he helped it evolve into a commercial company with a global footprint, including the successful launch of two rare disease therapies. Previously, he served as Global President of Aegerion Pharmaceuticals Inc. and
Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Mr.&nbsp;Rothera received an M.A. in Natural Sciences from Cambridge University and an M.B.A. from the European
Institute for Business Administration (INSEAD). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;As the Company progresses in its transition from development stage towards
commercialization, Viracta will benefit from Mark&#146;s over 30 years of global leadership experience in the biopharmaceutical industry, having driven the strategic advancement of multiple biotechnology companies from development stage to
commercialization,&#148; stated Dr.&nbsp;Royston. &#147;I am fortunate to have been involved in building a superb management team that will continue our vision of creating new therapies for virus-associated cancers. With this transition, I look
forward to supporting the advancement of the Company as a Viracta board member and I am confident and excited about Viracta&#146;s future under Mark&#146;s leadership.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Nana-val (Nanatinostat and Valganciclovir) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific
isoforms of Class&nbsp;I HDACs, which is key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent
valganciclovir as an <FONT STYLE="white-space:nowrap">all-oral</FONT> combination therapy, Nana-val, in various subtypes of <FONT STYLE="white-space:nowrap">EBV-associated</FONT> malignancies. Ongoing trials include a pivotal, global, multicenter,
open-label Phase 2 basket trial in multiple subtypes of relapsed/refractory EBV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>&nbsp;lymphoma <FONT STYLE="white-space:nowrap">(NAVAL-1)</FONT> as well as a multinational Phase&nbsp;1b/2 trial in
patients with EBV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>&nbsp;recurrent or metastatic nasopharyngeal carcinoma and other EBV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>&nbsp;solid tumors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">EBV-Associated</FONT> Cancers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approximately 90% of the world&#146;s adult population is infected with Epstein-Barr virus (EBV). Infections are commonly asymptomatic or
associated with mononucleosis. Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patient&#146;s life. Cells containing latent virus are increasingly susceptible to malignant transformation.
Patients who are immunocompromised are at an increased risk of developing EBV<SUP STYLE="font-size:75%; vertical-align:top">+ </SUP>lymphomas. EBV is estimated to be associated with approximately 2% of the global cancer burden including lymphoma,
nasopharyngeal carcinoma and gastric cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Viracta is a precision oncology company targeting virus-associated malignancies. Viracta&#146;s lead product candidate is an <FONT
STYLE="white-space:nowrap">all-oral</FONT> combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple
ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>)
lymphoma <FONT STYLE="white-space:nowrap">(NAVAL-1),</FONT> as well as a multinational Phase 1b/2 trial for the treatment of EBV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>&nbsp;recurrent or metastatic nasopharyngeal carcinoma and other
EBV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>&nbsp;solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For additional information please visit <U>www.viracta.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
communication contains &#147;forward-looking&#148; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for
Viracta&#146;s ongoing trials and updates regarding the same, the announced changes to management, statements concerning or implying Viracta&#146;s future performance, goals and potential, and the ability of management personnel to contribute to the
execution of Viracta&#146;s vision, performance, goals and potential. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not
limited to: Viracta&#146;s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta&#146;s plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and
valganciclovir; the timing of initiation of Viracta&#146;s planned clinical trials; the timing of the availability of data from Viracta&#146;s clinical trials; previous preclinical and clinical results may not be predictive of future clinical
results; the timing of any planned investigational new drug application or new drug application; Viracta&#146;s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and
market acceptance of Viracta&#146;s product candidates; Viracta&#146;s ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; Viracta&#146;s ability to identify additional products or product
candidates with significant commercial potential; developments and projections relating to Viracta&#146;s competitors and its industry; the impact of government laws and regulations; Viracta&#146;s ability to protect its intellectual property
position; and Viracta&#146;s estimates regarding future expenses, capital requirements and need for additional financing in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These risks and uncertainties may be amplified by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has caused significant
economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could
cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#147;Risk Factors&#148; and elsewhere in Viracta&#146;s reports and other documents that Viracta has
filed, or will file, with the SEC from time to time and available at&nbsp;<U>www.sec.gov</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The forward-looking statements included in this communication are made only as of the date
hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ashleigh
Barreto </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Head of Investor Relations&nbsp;&amp; Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Viracta Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>abarreto@viracta.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">SOURCE Viracta Therapeutics, Inc. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>virx-20220915.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/19/2022 12:24:13 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:virx="http://viracta.com/20220915"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://viracta.com/20220915"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="virx-20220915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="virx-20220915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>virx-20220915_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/19/2022 12:24:13 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>virx-20220915_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/19/2022 12:24:13 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="virx-20220915.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g401810dsp57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401810dsp57.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  B 'L# 2(  A$! Q$!_\0
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M+C<BQ^#A[3$T^57M?3>U^_;KL=F7<2Y9CZGLL)54I6YK:[7MKIIKT>I\[_\
M!=[]A?\ X:A_9B/C30;+SO&OPUCDOH5C7,E_IY&;FW]25"B5!ZQLH&7KS?\
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M/^S)\-? GARSL]#\.:]K5Q<W=GI\"VT#BTA0Q1[$ 7;NE#8QUC4]J\-UX_\
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?:SBLX1'%%'%&O144*!^ HHK&MO+U.G#_  Q_PH__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146947879296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VIRACTA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3295878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2533 S Coast Hwy 101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cardiff<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-8470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d401810d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="virx-20220915.xsd" xlink:type="simple"/>
    <context id="duration_2022-09-15_to_2022-09-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061027</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-09-15_to_2022-09-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-09-15_to_2022-09-15"
      id="Hidden_dei_EntityCentralIndexKey">0001061027</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-09-15_to_2022-09-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-09-15_to_2022-09-15">2022-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-09-15_to_2022-09-15">VIRACTA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-09-15_to_2022-09-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-09-15_to_2022-09-15">000-51531</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-09-15_to_2022-09-15">94-3295878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-09-15_to_2022-09-15">2533 S Coast Hwy 101</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-09-15_to_2022-09-15">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-09-15_to_2022-09-15">Cardiff</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-09-15_to_2022-09-15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-09-15_to_2022-09-15">92007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-09-15_to_2022-09-15">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-09-15_to_2022-09-15">400-8470</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-09-15_to_2022-09-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-09-15_to_2022-09-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-09-15_to_2022-09-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-09-15_to_2022-09-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-09-15_to_2022-09-15">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-09-15_to_2022-09-15">VIRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-09-15_to_2022-09-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-09-15_to_2022-09-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
M-5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K
M!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1U
MW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@
M;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 4$$S5660>9(9
M 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL
M6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4
M'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I
M>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY
M'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?K
MT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;
M@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"
M% ,4    " !003-5!T%-8H$   "Q    $               @ $     9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %!!,U70>9NA[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %!!
M,U697)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 4$$S5?_;"-9D!   +1$  !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %!!
M,U6?H!OPL0(  .(,   -              "  :8,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ 4$$S59>*NQS     $P(   L              ( !@@\
M %]R96QS+RYR96QS4$L! A0#%     @ 4$$S51PX9>H_ 0  / (   \
M         ( !:Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %!!,U4D
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( %!!,U5ED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d401810d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d401810d8k.htm">d401810d8k.htm</File>
    <File>d401810dex101.htm</File>
    <File>d401810dex102.htm</File>
    <File>d401810dex991.htm</File>
    <File>virx-20220915.xsd</File>
    <File>virx-20220915_lab.xml</File>
    <File>virx-20220915_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d401810d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d401810d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "virx-20220915_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "virx-20220915_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "virx-20220915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "virx",
   "nsuri": "http://viracta.com/20220915",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d401810d8k.htm",
      "contextRef": "duration_2022-09-15_to_2022-09-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d401810d8k.htm",
      "contextRef": "duration_2022-09-15_to_2022-09-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viracta.com//20220915/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-22-246784-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-246784-xbrl.zip
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MA/ ?#;LT0^9\(IHC*?@7S'QZKMCG5R%PR-J(ZQ+I\NLRBYM8CIWVB9%882_
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M1=*)[J8E[A;:M#T[Z<* @2( B#(KE3>67V'=]%ZU=6V8%]W>B!3.[:NEX/
MUB[BT/G28#]V6GAVE,VY9%?<3_YIG8]U:-*J14GV7;K=__A&$&'XQ3BC=^G^
M+\4)*/ZFNGT)'M\)CUS^M^(I]IG++R)FGSX-5E9PG\*3/0Y<].X%&RV80T4%
MF/$+: U!+8B%3+X7,4 S1 BXZ(1-9'@=3S%(F&-VGT?,%6,O4(<'5'*UTV?E
M@TG9>:1MMHF,\/J $JQFL$?'#N9X[ !K4FM&&KU1,TUZK7<8:O6D!CJ,.DKS
M6V"V[G>N:C6=AM4X5U*D96EYZX&9X2--,%#O/UE,_+C8.1XOX4NL8U<RN5>J
M5$V!A84/H1NP<!!2()=$@D8!CG0]#&\)\:C4I8[N(TYH+7^!BU][L#2*0P#P
MP1,IKKP(W@/!X(&#&5WN.-BECX/QOA"72S=2E3!W:12YO<G3*-)FYY;-!2D%
M'J$^_8T<^E?E65VD_?X[L#Z5G"EF)<;$/UE.TD@ Z<%)\J_Y(MI09[OPII;4
MH8+@.I3[/^S1_P[,AN8WN11:6P.QO #^L#<Y?/]=*4GX_O3\:'C>')Q^^G1X
M=C'<-S]\W4G";K<R2\CH1V"D<OJKHL\W%C/%'?U6I]>J<&7LV9XKJ;?,WU?;
M/!+@I\:)I$#DR).@/$(9H0X: *P<;/(I=4_)Z( -?:5:<D,/V.%\'GI!C"E
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M&V%H@ Q;RWST0PC0\LKU4$PP= G868Y0$:G]VK64U([5>IU7>KT>+O(; %[
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M2L[+F_8H=!?P%_!F_7?_#U!+ P04    " !003-5]K6*T)6C  #B_P( $0
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MY(??BV0OF>,.YMEOC_#AW]=NV?[7IY8)4<L9<)&KF#@F$\J1V9)N9\.>,!W
M%8.=6#1W7%C;+ :&,%O-Y\R#A<XND[)JO98Q\1]^EE\P36YR(#T@FK**LRJ-
M:2CXHNWGEZLRS9*2!&U>5,S%*M@(?;%AV2^$P\+YT]KE+#:N.$:-H@0:8-JE
MBP&32;*K^"I!MHOD3+J PUY"HK2EO*0@7KJ:$PG3"+A:I"7\[92X&SZ59O+O
M(EFLLD3FR,1]FZ_FR.VS&;!_>1KH&SA5PNRY8M:'YQ)G$Q+.Q/GQSH+X*.FI
M?%7Q@\ BBVY'+UR-)D_S"A_&K9_J/8%QDRO@&U?NWBSBNV 9%Z! I4MD%7SD
ML"=E/H$S QD"%S6M@/DG\&]8]H3.)LUN@!1HMV4WD&AVTFPR7]$+9<YT;?"0
M1/[!?LENY2P-,SB&"O>R2.:Q<#06=V98$ J#S(@_> !O-+X#]FJ15O(C>YJ\
M9Q\^_>8E086 MHY,C] Y)=S\X+; MV=$&HYZ04<0TD+6,=M+E8M3(Q>)Q(#(
M"YQK<)7?)$6&B[S,IS"W;L?96R0Y'@%^03L FX2CK99T7V[S[1P.B&$/*&>6
M5LK@] [B1N0941_3K1$[)5!S.4MAOT':-^XP[ +<CA4*!#G[//,7^S+)SN$X
M%@^A8TZ)9[[)0>T_SB<Q<W9/O!J=J$A)E[O%9^?R+"M"L =HJESGBT1(&ND-
M7_LJ7BQ!9!=)4U[#_^$@R KQ)RE0"BB9R-OP#7B>, :0,JA8* A;M*CK))[^
M[PHN*<I*>+@/^YG.9B'\8Y["069I'.)9S7$ZD[Q8YLAW8&#2_Z;"A4JY5[!"
MN +) JX"3.S=-+]%E1MT46"*J$Y613H1/9PO$1 I\I$)CK@ 57!5((G<I$6%
M<AWY&7"P;"*Z)_&T+*GV+N,2:$'$/GQW%:=9"4LWO#Z%10(?5%:/')FW#AEN
M!@)D#IM(UZ$$M5#9 C*,:?.J@B*=TB[#54NS=+%:L+(-6BT0W\[!HZ?%E.X(
M'B#M/FYW(-N*FFT,JK)1X&%5T]6$KO36JY1G0)9HW_$]PE/=4VX&<TWB&[C?
M8;=C+G (=ZTB<31/%ZGP+R6&[200PJ;B8H&[E41.Z<QC:RRL]%!"8.GP51&G
M);UZ,H?M@1_#B</9\IG=P#3A5SIIAZ.C"9 @$9>60H1/HUY=Y0]QEQ.ZRUO/
MI5?MO8%;J^=2MW/)T$#)A\M$#8'URTT6A^'_<CIH-C%;V#H9-COB:@]_P6:&
M3LQY 1X&2F08$35?45GCBE@^\PR< LH>404F\:I,\ ,@)^!'+ON!8P=J00V
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M;BG:G-[% GY)PTCZ,R9@O@=YB]E<<.,G)'UYE"!!][?A .;C&>@E2!GOX'[
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M.G'P&C>\!)16U=O"X%I1;FD+S Z"UOX16QAZX,2-#%VTQ)W=#?%O9_).*JC
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MBL;7>VJ!&2@Z$%+WLW67V.9,&V;F0I:X]GF+VRAT>)+!!S*D9W"%%'\/!(2
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M4]I<3_*53NK'&@^L^WL_C ]B9AR[B>_% X//P0+UC3[W>P KN^%\<-OMW#
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MZ;8Z?QOB2UC+< _#G;<#A"98A>@OVREW22=B'QW]Q24;>%?0FEFAARJ9/H1
MG0@JQ<8D1/:S?Z"HW9*>IF.J$!:7/8KBH+K-@QT%YJ]H#90^S^60^<P19VM@
MX$G]]\&RJ'R"$H_IGC!:?"$T@ZC+S;P8)VNGQONT&(\@FWS$W$U/MC!%OT>@
MC\Y,GC%!X%:/>$O(9'M8IB42 \;>SH&)QZA3?8#^*W0C#Y%R5XF!S39IB<!6
M4+'WD_;1_5[ES&D]D:R=A\5?Y#AIT8'[+LG\*E&Q3$P8:\J@,VO#P3\^/L"
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MDU'64G_=DF_F50MU.]<Q2]]\B>@YJRSE<C*I"V$R$3DH:N#49,-/27-JUZM
M,MX0]Q$U/J0"(WQ;N4+%,"5Q@^6+5-@H!4A@K"5H@U,*#+NB^4\KOCF.U*9K
M^1R2(HSL[Z'4' ETF"Z_U.N2[67*X7OHJ_SDB21"K0@W AA,V4K;(M2,D*<<
M%?L;7CBQ:N=COA&$D$#!UA)D7M//P=I 7J17A QJ0B4.?$GLY*V'QC!U5!2K
M4U%TWAJE<H0D-!]@=Y]RTLQ:);.9=<;FMY?%NJ$[G&FL@?)A8^[I84ONZ89I
M.1WYOGLI/P<EL*=BM *[[R:>.^>^@9T(,93THV1-:E^W4V,_FI)E4U3.N41C
M<YZ? 6+A+&J6N*X>GZL#2$QD28&G#"^.B1LS[.OI[Q,Z\1^HSF+P^_\;$NZF
M]($XQW+K ;G>4@&"/X:3#P[!C'SW_U')'M5F?*?OS]#XX!2F/SZ-1J/@S:MH
M&)V]"#TVK%2$XM8(D1JU[]30;BNG[CMDNW.Z\KW8XNUAOQ'[>W9#MTFC4;SJ
MR?$U4> L'LFSMEV-W?I!RGEH%#B8<>_P. KZT?'QZ+S7'YR^_.L/CW^@O\][
M1T?ZMW? AV?#HVA(G\L<^),]H(KCWODH^E7_L?$HZN>&Y\Z4.Q[^+O\XTC<_
M_3/<E$?C(_O%:SE(7IJ=HCY8^_U?/G& @Q^W#=#VJZT_VC;MG_5S^']#9X-T
MYYV+FQ+$U:^,-_6!.U^;'% /T, 9DL0I7GNBM]K%T1D$/L4%ZV_H?2?3/SN!
M][[]%4G4W9/Z?BLA-Y_ ^3_D3^FP_(-R%NEL^*MH\/+5&([_)W^_W>%;GWGR
MF9]IF?%_(FF]'@Q[_7$O& .G[YU'%^-!?Q0&@]/^_O\M8OMZ!/;C0Q#8UR6J
MP[M/957W5G<.\*-+ZN!B/WJ/W<9@W_[K,?W/)^I#C\I'\!5FJ_YM/SC/%X@;
M6?T[#$[VCQ[NDCP<QT"=ZU?$&ZT0):H0D-1G8?#D\9,G9C_^C[#/TW@!F_'-
M4<>78*'_B<<W3JMYLB9/[A,/CRSFK[80GLRW\/^['6M.?:( ^&9W[W/<Z^\:
M\3?*$Z)_1GU0@U]'W\VM[\3UN8GKI#?\>S \(VOK.WG] 0VI!NE\2U;*25R\
M@^\Q"R/^;IELLDPP2$".WJ\10W0"&_]O!)_TQA?#*#COO8R"\5D0G9P?G[T]
MB4['0>_E,(KP7QC1^![-^%S!I N0Z:\&AP/8X(!0P>S>?LVS[Y^=OA@<P;8-
M>L?!X/3%V?"D-QZ<G=IC_W[JG_74U_LV[T,&7VY>ZP@!Y_8:/T::&"&G8*YP
M>A3TAD"^PR:Y?#PQ?]86+CU$?S#8@(3W>=< 5MA0:UC'T:(XH9.Y(,DXMBUN
M;-^C&>/K$1P6=V[[""Z/<,J;L_R6TX<2N"I4$:L8>HLZW!A,UW98\4M66X+_
MGPN*K-O9P?'$ M5=:LOPV(BY\O/7H 28V $GRO1^&YWTCH]_'__VB/^Q%=%B
M[XV 6,@O!\?'^ML@DL^,L#2CXAW0?\K#6^[$3U]C(P;!Q>E1-!R-Z?KB__7_
M?GKVYC@Z0K'_JC<.3MZZLO_-8/P*.54@P;Y@, J ,P2G9\'H/.H/7@RBHP!X
M[PD-!BQD-!Z,+\;1Z#[XVDPTO?'>&]A3IA7%"[%3V ?B[AV/SMR)TT1Q-L/H
M?!B-X"GF0:"W\%Q/@2L-:;(7I[V+\:NS(0@57O#IV9@4PR/XZABS"3"Q8#@8
M#TY?TO?(X.#1P[<T% Y/3#& 1?>CL^#LA;L=^[!__;,AQM^/W^(U=+:SVVG9
MSV%T3%,=O1J<!R>]M\%A1-LW /4+)\C+&@].HI#W'EZ+_SV[& <OS\Y@BWL7
MHP@_Q5/ 9_DPZ.,PX/>=G=-NX -CFJU^X,V]^0+8FD$_P@U_<3%$\=2D#I<4
M</HG9T>#%V^#OYT=PJ3'L)\AG'CON#<<P#]I/P^CT^C%8 QD,SP[H971,>%_
M>[#YX^ (Q,8H.(WZ<!AP:!MSZ+X6LWC"S*(O5]A(QK;K#3SE>#!^RU*O=M7;
MEW&?F_[)!</83FG@=$_ACD$L?M:) $Q8VM=6XE;D;7B^!L_B]GMP*JK\NJS%
MI>27D4S"5,N;=(K@A< A%O*9&697ZPO=AEB4^4\IG-/D)IGGRU#16,)@@ETT
M\+_P=#HG^)82L888U>46L])P0!SD)IYS>2PAE7.A4[T?@0*V<&$"(W<%%KV;
MRZXIH]3 ]=FJP/*:T]HP94R MBG96O=R?^N)2"=0K(K)L7FT(F:X&\TKIF1P
M,K(E(7H0S+$+$$-;Q)4I0XYOXG2ND)(++$V]+O+5E3]WJ>T 53VKRN<*-]GR
M\H&\OGE,L#'E>G39IVUE!H>P:3$UIDW>QZ ^"="EUBD3#JCH*O??.)?X[MOT
M874Y3R<JB]SETBJI%B\Q9572UX)R'T%[3)=\&DHY\.Y'7/:"D-2$_E+"P7#%
MG]"O6P9EE#K;R+<.>YQ,KC-J$#.-JSCTVZK0[^ZQ3J3<O>O\-K3+E.O*G80)
M(QPWG.IJ[*Q#70F5-_+KN,+&W2<L&"W6P3;K5A"4/-<I<FT+\,1W"5>[%0DA
MP4Z G6'T$J92"KJ??E0Z'*8Q92RX#IU'Z[UF%%YSH  ["IRG'W,Z.O7Y0]:"
M%]A'V^1RIII) 29!F<^JVQ@YD7.VV'Q:E>O2LB2J3 7JC4O:U8F R^ VKN;X
M(9UT/L^OL%D#U5GAKXL8=7L$#\M A"24[(]U",7TEGJ'$XNY6IF23D?%YQVF
MYT$P8)&G9-;7<+/<LY36.@U0SD#:4:S!QW*+MW+FEESRKO/GYSG%E^73LD@6
M*6V!Y/QCB[0E)QX;,M.W:X\C$%CUCMN2L<YM.^_!*TQ#5&$:RN #4V0"Y_H.
MY(U4(;Q'2'JJHQI(>\:)]')S" 2+W3G-E-;9A"-MVJ(U#AP3)20N%-X@,_ "
MH4E=7;\P3N]V5V; &]P3MG<A"PR&DQ4VMS$R<F2)1N)A16%L-PIS9HU8\7J0
M4RD,]S73_DPU*B(IY+8;44'5_DJW=X9])UO(6UX2J*3+<B#-/+O";F"QMB$Q
M;1T(EB%1P'4C] B4%XUV3$7'7RYSO*X,_: BRI7NU*G3MH8*%5!J^Y9@2?BU
MX+F@*P&^0U1%OQ17*V2Q#6DQ+6O8M(*7:72M>ZA:#K58$#$NJ92.%427,_]Z
MV7*R$N'SL(,['""U]&WIJ].8 I8IRNC<U$%'"Q$M1)I4)-Y*J+_7[74^)WS/
MUA]O,B*^BO9]2-KW*39CX5*D4[=%&>G9P1'S"M)-B'RW>(W0ON1Z)VSJ*JGL
M#%T/E]:0GM0^47=<1@DVV!/83"%>\5E1ESB&KF$(QVV]W;8QFWV='A*0X1TX
MU%8V-4/X1.+I# 4)IQM799Z0UDY,G_J'*.RD ZG9A%9P^*['815S3GN/B%#;
M/CFJD*)VF\54L&3UMG.U'G([T^Q--M'#+CY7P*8070BF]Y/B7G4[%OBJC@MY
MKKS4G@6AV&3L+)P+.%X=%G_ =UG[1@EGJ,U5FML(HZY/$FGHI8A!+-XKDWE]
MPQ&_P+YY=]^Z(=G^D'I*X+859C3I3LK/-S5%8.R$FD$!VBU"PA!1KSTM0=\K
M<P8'(@VAL:L#I^Z2W[/X'#= I;\OV0D $*L^T<3$ 5/8L0S+H%CTA,%J&4@S
M"4>A31? ?JE3M5N194%B16[5$;]:E]9L4$B6EY:2*YBZX$5)1QZ_#LQ?$]M3
MMH,YLN"KEB)TX3!EM[.0@EJ"L):'X7Q P:T(+)+Z]83<E:6<%.EE8EC<N7FL
MQW#H=\!-*_R8"@\36Q-/O=Z^UQ-^&5A!DF@O6"&-1"'=[$GR^8&Y'/<3<J2T
M+O@*8Z%T*:Z<.4$%LZFQXE)!5\MC>?MA74@54=?1M*VYP8"HC+[.6,*NF2C-
MV6OMV-\ER5*Z)]MI8-.&#?-@"T$D.&Y="_*:LS67M)EYUNXA4$/*!?A=^[ U
M,H/RKF2MC#0"4L )S'6:3U8L1-?L:]A<$%Y&M$^O"/S,V!VN'!4%S^&R6C2/
MQWAYYS=80)?=99)DVGA1'!.NG7G9\A+%X:F#(CZ8;GA$-VE,4SRG*;9<'-3J
MKS+L%M'J_]0^K28$23HY->YP>WR'!A9/MB--@!?O4 -&]; 9)PGVW4%I3O\$
MH9YD"(.K_TS4+,_H>_+$Y'.POA!\&Y[;1=Z-*, ,65<2QDH*$JS03JSQ;);.
M4_*<[=AX85GFDY0\9G9'4@18<\*L35O5T_M*OY>Z<;;BP5-/902$<"TS@:%I
M9Q#2Y&[=Q+;-_3[><HD<.U%;I/?UK]V@<C"02RE.F(:/!M7J*;?AK&I*S4>^
M4'J-9EDB?N7;? 7FB+87:.$OKO8!,]FXNZT^X ^=(EP 9+;L\, )7<>7*;L;
MEQCL)W\CO&#=)$)Q\!FVN/%9H3W&H]GX)%]5UTDZCRN+16V<;Z(-4?-:B^?E
MY@ZT[F&W8S91*0MI'U%%B"6U:J?KFDM(TD%H=/G;I/$8[NG::X*EU(RY0N8J
MPPQ\'+VMLW-Y1ZG+I%RAM H\<XD^$>FSMFV XUMTY8: X6/K:0-<@$(:<3<5
MF0_V\C8OWAG+U/2MQ(20LFK;8-/NPT'UT?X[ZV]%0QU@,'R$>S']7C3(81RD
MU,!#F"_V&$SF2%^!TR@PB*<Y@?6SF&#8&OZO]>"O/V),#?FPX_QHVZN=V#<Q
MQB)P&\QXK:+-SFPSV((O;J]M2I+Z6M%NQC<^DX#VF]-HB.D)7SB5Y3,%N)U,
M)3ADD\%4LA[5*]>RT,5=F<QGH6^CD+\,_;LANRR49V/?@9+[%F5LR/LA[>4=
M_8H<,-JF.D3.Q )BPLVG;>#&Q') O.2UX! 9/3>)A(W\(%(S<"1:CJMX _-1
MY5"?)T61;AC^B]]&W_/H'/^B_M(LCE1,LBL\)'<*Q6]0KCIZGPEF<. Y=.,?
MMMTP\1/8YX7IX4N7K>%.L@D#]EYN3<_*9[,]E#0:QKQ&]Q]W 3:L=V7@/AI]
MMFV 291?C+_%$^F"3L/<TU_%?%\H@73EB@^M%IY=Q.4[EAK:Z,4&4"OTZ'$X
MV3BOY*DZ1+ 3W[*2RH0 T@SN-5U3/^J^_Y*=),$.'B+CE<SO0B?GP[U"KKY:
M)/=RK)%7R,@H>'"QQ& @M<4C%'+U/GI&GQ_YFDF[7'LG1(F5-B6\W73Q38HD
M$&I:%,E-/J%&@O(M@ZS5QA<8;W1$N'=]S55WYE%S:)"ORW:Y<3(. L%M=;O=
M-!>9WZ(I=9TN?<XEG*B@_MG!74)S,6W /57 @N!9]F5@SI#$V+U!%Y]>I$-W
M.Q2]H]L=[)C;3=C0>%S.G=[5" N=/A!XP@<T;;_K]](N97WB_R.N>>E<'OJ2
M"9(709.E%CB8XJ--SF6G*!"?>DBZ^,:+C%R#!(>(2:\R=K?3FU0U+<2@IEM;
M>YI,&*-446[AY0*2;1O;H'5.44F,J==HU@E-M; =ND5X X EJ)I0TR&]1R7B
MX3C&LSPH\KMXSIWMM'60FX9LN@&M3*8/1<ZD!]\:?FC;56Y:)VFK[L7X)L)M
M]\AZ.2^2O0CO$L&)LL0X$8%=JN^%=HX--=\UZ;F:R!^,EUXM"4ETVY;HL>F"
M-I)&/%W %_,F:P/AFM<Z.S?*%.1 4^$"N=/-V_HU#3_4H'[(23N$1L\N_7#+
MG0]=+;DME<M)2?!YX"))^#9.8-/QB.#%!%5;70MX-<:(,9Q1%W*AXZ7A$%JK
M6%/\0^?B>C#LP:H"1>#?>K*UD5H#CH+7%?RV7..H;UR%P*7]GVO(7U^M!H2@
M[)[@(@Z>Z2*^QU ^D2UMC'0\KWNF462(*G,E?3YBX/,9J'?S54G>7&'Y>[,"
M.Q' 75XF>+%#1_=);+<]$JS 9>;36XS^BA_700(VC?7H?2P'U0XGR&3Y"2@!
MY%A]EX3,&5 @AQR323$EI:*V"-R^/2ACG 185]27C9/].'C#+0.QSR(UAL&.
M*?&RDA9M!4I=0M>E3M?"'.EWRWE\%VJ[4R=?C>YH\AZV.*V4A2@[9IN&+S#\
MN\X%+"M"]E9PMYU0W8;K>55I,&#;L[I\R6@T5V-0X3DO0*4 ;<FX_QA.U<N?
M<-;Q-80*''9=JFR*H-U/J-2S)EJ8K9M(T0AAN;D*U)*F+,6#Q-+)1Z,-:W"T
M/8*CC2EQ5&/*Q,AAAXD8NIVZSLT'LB;I5CHRKTOS-6FQI;;GX!Q?4I3=)-\B
MQ(:+F?C!:79H1LAB0@K]J/G@-+,VJBEV@"#;@ >HT_5^\(*M \RZ:HS6[7C#
MI;,VN<9)66+-8+^&QK:2@_S.4JNZ/-#P8LAED(32*HNHGV\NVR?MN0CWZ\SP
M591)CG2?8,YJ,"2:%F=2=N>:>TV#SM7^C2VH'B6^E)7IFLH.@B*CYMPI=2S!
M?VK3I(DP',=,UE1X="/%<^MTX.LJ+Y$41[U4Q/T]CZ]4+)1,I=+XE<&<665:
MT,+%BR&V%G^#;M^R\KJRUIZ8%LB):03]0IO(IN^2FM/!EE;27G<[NMD.-/38
M0Q"F=;@'@QFKDJ]H>MI*N_!&1I2(5NH-X9A\VOHH4]APZ]=SWW0O+=;^C;?&
M:3+AGZD'BPS:NVFWU3;U![>M.%Q]0AGPF?8:'[)/LY;F(9D/G,JO4=@I[(';
MTQY(/)Y,,#M=W*LHJ?#>3.HIK71CYG/W7GV VV);KGY#(6.X;'VWTV.W4@#T
M?*8^W1(L8>#7?C8^DG:19["063IGSR_J1M(N%CV(?%59EGJW$K/@O59IME'W
M=A=VY4P[-HR"I^]5^^ 7!0%8;_7E>:'#A^?)$6<?B>.K5P)#I.*%!@$B&R@]
MA2*L-ZHQB=AUW\=[K+Y.R,Q/J#,R[PT*31)CH".MBM80MS!?V5=/#M2*WU99
M)8J;UV]LLS<4.YY@P^.,W8Q.MB-J%W$5,RT+7KHJE*%P&>I@(4$P3,]@]B+*
MI!">^3N/J^L2KZ@1=.)^)=DM;FIMR50&C>04SB7$Y''9/?*<N0%4PINAHX*)
M4.)5:)H[AY(S&AK^@<HKMEJ4R@OATJ3ZJ*-=,F#,N.(E#ET7,3MB&]W0.$]%
M.SZ;99<:65Y@>8V34<K5'V*.F0EL#!75.)A8! G1M>1!QC 'CEP;S1O[\.&W
MKM>_X71KS1%;G^Y9<Y)$&B&@(Z,$&2__LZT7P'U;B7P5GO "BW0'VPOXMS[0
MDUXN,+.]%V"G:;V__J>>RD@:?,UP7W&&O2E]F$E8F]DO:<) U+!NR3ZZOBNI
M@@_8@#0")#ZE'11$IZ/4?8?U8,R"FYRMI&["7OJ:;;5=8U&'LR;=2R\DHLH9
MMW^C\DU3P6L9AYFG[V7G!21XZ23ZQ7YC#7A1.RIU\O.=+[3/?2Y-7FL,U*AU
MM0+=1L.\I_L]8GB95?7<@)!MOD[,;+E$E:$UHV5-!P#)8:."6%26T<*Y,F;5
MIQ-A[!#A#(@P]*F0SG=2R<:35;9 S0'N[HQ;=U++ XXDI'-)@HV7.G'FZR:0
MECO\')1,CI-9133&ZLPZ>=7X#YV(,B"NA,A+E37<I0A+?UE?-,%0)\A#6J*)
MA7K48%0S:NC#"11M;7W2F=<5<)%(6Z%E?BO]WV17;=-9J6L"2;S$X@G)GC&,
MF[?(/.WXU1Y>"7I)2E!DVG?!F=CT!Z,*U7$R&,;B[/5@A+@3# (Q&#EX/</H
M'Q>#(>%?6'@?>,S _HR"G=ZHVSF*7@P0&H->$(RB/H%*P+T+>H=GKZ-="[_!
M^!!'9P2VT3L_/WZ+WQ%\B($20OR*-Z\&_5<(7X$S.*?WCB[@<0*/>-'K#Q!8
M(42(BO&P=Q3A.X?1V$.I\C$M@C>]47 Q$J@/'AX_.HI>1\=GY_ YOGT8P83@
MMPB5\>:4L2AV>J?6'B4DQ&['3-8-&43_[$?G8YK^^-498G$04H:S6;3K!/01
M_0KC2L'1$;RV/^:=P!D?7HP&U,W$7\'S8.=0?N%O)ZN:<&[]\47O&/?D*#I!
MO)5A[Q!&[<'+^X-S0A%!2)3>L/^*'Z*5X]X^Q[]W^C(Z/'1Q/&94#MJYL^'?
M@T&W<QX-<7=E@0[2R2! F!8ZTL%I_VQX?C:$M]'IG"."R1A7=ABY7QZ%#%'B
M[Q!N.B.LG!"2"0*PT$D-@E>]UQ'\!#X:1S!!?!,2CCE>H..CB_XXQ'_T:?.0
M$(>O!_W(H)BT[-GY<(#4-AR,Q]$IH=0(L RMJ'<$=X/@6B+W12?G>%H..@P<
ME$?"<M(#6#10+$S\)(KX]70?@C[\+AH.>@*5%='6T5Z\@?<%1X-1__@,:16V
MQ$6#(\<E+%MVM0=GJ! Q0O%GFJ.E,#46C@8F.+J O931$=*/%@D' _07#5[#
M^P:T!P1ITH]0B?HCQZR>?H]9?>G\0.XLYH#A' _Z>",T'1#W_.)W)X7P$,9@
MF*/[)!$^.$A.7US[9]9NVJ>ZR;;Z)=^?=/]:)BI\4[09LLJX0M<H^UZIZF2R
M6HJ:CED=TNJ;K4'XFZ(ZI$TO0&-;&-]H6EHTAG79Y>F:&@H$G$NSFWQ^PZ$S
M+<-W/\/2$X+](.5/\#'T 4QX%%B>@;-<N\*8R_=,SV;3=U3Q$&J5 HU$V0?/
M,)' T= Y!]&[WK@&%IZ59YS\B,;)QLB.!+6R7/?*--H.O6,O:^=>JN&WIEJM
M9:-%5]_08[3U*"S<1%O8AJ;E1WV$/*2DCM.L-!)$NKU"OZ!-HXDG\0)^A_MW
M3?4\S?+6%I<'6 &R?6(KQ@T<!J>39P%/P9G'L(([26;S4_%M.:#>;K<>D/?5
M7&W.PK<;BZS!%!5R&V[;1;X9S$"#DW^"CENVQ-:$ 3:2#_MLE*V0Q:Y-9P.)
M1#KIM?P)%\$L""9B"284YN].$FK_?IUGB>_1GB9T5FP>:3D@YMG*SA=)M:*6
MQ.2L5)^RN-YLUJSKO#0%@NHEXY"O;GD9[ AT4KTV QF(O%;HB6J '6I"MC-!
MASC9G\W#6;@E\](+G?![]C'HD^3D/G2\RFP?:Y?4&O@F.0VT@C\T_H)0G 6A
MKBB11.^2GP,;LTBP-H:?G2[2C"U@^M86RV$,4.YJZ!754=[$-&'GI98%R5].
M>8OZ;]FSR0X$/&18XS2E>/6_5MQD&<=/JFJ>.&Y?<1$0U DZE%9%8:/['#)8
M2$HA^8VPC@0=$Z:K>JL_DOPMM5OGY0I@FV[+$6+Y%&G!*[1UN4:^(B^Q+4*,
M32=2.67Q!91L%@2S1&I8)CEB2XE/#\1;"K0ZFZ%,9%:9H!./T%0ECT$N=F8J
M0KP,;*U*ATTR\;N'+O%X1BK<4%2P:'PQ/+5ZF.AU+\PG1M4CJ\)1V$C+.Y%O
M>V3='&_2\5 S_$:4/!\),;*<[03+=H)("P&((AI?C[@PFM5"XR>H/];MF&$<
M:$3-!6"0,H$0=*'5'/Z+LJ' /!YD$JA &;Y;7:\6E\&T2&_PKT5^B4X^^783
M$AJ]H5Q@TI*R=<JXU@N^U3&9[&'/<@RI&JBX"@0##08"TA906';AR TJBM)Y
M[@=KMTYW^&/VC7@_;=\"PTQ7BJJ#D<ZYJ6E'OC>A !RNW F"$4LT9\"(1>[N
MNONT,;GX-KG<NXS+9*K[9&22(WLG\WPUY<=\\"4Y<)WC[C>B\@Y)L!-,C>I_
MYXJ\AI>AI: /GF% $-%L%: 2U;R\>,<Y1?622=A0SE9\I_$']UO6%4HM1*I7
M=.B;!YH04B2+G!(F$PXBHLVE%<]>-?GZ!+3D/6I;9;?3EH/6(^T"9HIY+*LE
MGA_G1%-PA(!.-F.[T6_:(LF8,5)6@2!XB>J3+A*C<9I"0XIJ<$%,/:YI,@!P
M+R@G@['++&19L(-$CZ7_TSNV*#*XCO-=*E=C"-5NAP JS1M@9$3T2N9E$K87
MG I=>)&G-G:T#4CG@TN^0V\>AB<Y07;\?@/3YTIVQ FP*&J*M*X J@,D(:)=
M";O4 3LI7R(&E19U]F1QF4]34Q7NA[7X6<LF*74..4"-*9#)!)K;+>5V4 @(
M%;P&'=LMA;.;IA7J_E.O])" 0B5Y!?]SF>?OG R5;D=25O ,\S*>$^Y#R1&;
M H- >28UU_6, 9L <SE?@862LB)I$F0T.1 'O\ZK_ IX)8:B)M>,\6C)W)@5
MO&Y#39RV(OF5:K-:_=/!HF-,N2UQ3_BD- DS6 G%F0:P]>O1:O>/]H,M*)--
M/LBZ*T+Q,SEQ<A2%P-:5WXBE ,9--L4C4J.YQ#3CN<GR<=,"O*2FAP]2]7VI
M80C3!ZTP'Z^_D^*":P7.]*T MCU]?)TZ1QRLP='!P\ <$U"(&%8HGE=BH'CW
MRW(2/HV:+7N3ST%H@UDVOW/%'5]I\N$)B:7W6;H6%PUD:;246@ZVL;%K@?']
M/W8)RH_?W?E?(9MSZ_4\5R)?3Z2D'JQ_3BTFUA&-AXY$J(7CV/@&(O-M+Z!2
M1<%\-ZA'=._P[YLTN37U)0I2E94@##Q B/:KWJJ\;$?=]3Q'5/@<2R&T2#*#
MQRF>.2J:J6NFP"BN\GP:S&+@>2[_X45I4L[GW,9Y/L$$F<948G2LI&  #-8]
MXBT9<25]'QE+.V"\F-BB94^95JO[9@#[@M0<VP-ZH:U2H6EP9%J.3L&N4+PG
MGCU?JOD^</%3D('B:LR)W#55=>2NF)DTN[.YCC:=$6=%>D?)CN $B<0Q]DC+
M5Y6>E\N^6=3H,JPRGJO10&Y23+>[DGQ>O:&>,Y4$5:IPOK9+0LB'1.^3D4S:
M'LTL)4_HAKY!+ (EPW&YRJ[08^8HU:D+XO+ EFDDZ+I!]!Z3D\Q*S[%\;'+G
M"MEMMJJ-NR1V+&!MN.^-P7R5U$<.<>%E],120D'[E^1/.5CGE\[#1KF340@M
M@S/9"Z._:M2#,5LI*]R#-?H<#("VH]NQ;'J6.VCKG"18UC0IW_[A>$:MN#VD
M''<)$AC6QX:, 'YRGFD38+[& S4'[7/R/!$1W0Y,MDB3&\+M+^%ISL=,LE)3
MOM'\CRD#V[V$:]D0 U*[\W$<4:B=HF"@AVQP%$T;RUP8/Z.2C&[7>=!"CYNV
MT>%ODBMM=W4?N3J!=@BJ(M,5 DY4G!2'^R.U1D&\FJ8"@D \1J-'PEZ$>]9S
MC9_I?>&(&6:RS]S^ -Y-Y.$T,X]9H0^PUO*";\/)_A,YV<?J9#<I.PV_>C0<
M#UX,^MZ7WVK'L(L/=&YY0L7U59E<_':G%?V;W<-CFW8.VA:1B[@;%/K#+_VL
M57[V<2N_B392?R&".-5H2O/0F[&7;D<?C]ZTMYF+AE\VJ>;3>\P)R---8I,;
MY@G>[6H=]E-(@L>I?7>Y$>F3FGC>TM?A#GCFK47NC2\%F6][I6D=KH@<-)YC
M>7J3DL^/XIC7U TF<WO[3*?H(^:@JHMX=8TC[CR57,L[T//+=;C:6U*(%&3;
MG1;VZ2"7 E;:NE!]Q(ZIC(,0"IT-,&Y-VL![%]Q^M:ORLY]C]CHZ[=ENBH&]
M0O6;,SYKBUI&XZC^8._TJ'G'[(]'^LGQH#\8WYLS/WA8LY_?8%5F19#H0,)(
M(J (-//7NIW6WC2U'@D*1.01\VTRA\N[<_!$R'D!T[PN/>9N.XZVU TM[KP4
MIJ:110D\!55H>)XTU7Y?HKHRY&(8S.Z8L6M57].F.#K#"$1F/R:\"NO["[WH
MCX\WH.RGSJ84#HIZL3(FU*^VV07%(;D_B2 EH^\!S,%TB07;BJEL(95M;HC)
M\XNSRN20A":O!)7H++ZBJK8K.BF3#$1X&2&SJIQ>F"]RK*6C:C:.HMC$$PMV
M2N 9>-8[DKV _\9@ Y:V>=AD&/4!<D _'5#!GW=Q" +N%C>\I)K=DN%-E4J<
MY$?Z'"%V:WV?J7'&31W9)WL3VNJ#7YX^)5TV!FJ<HN,TKV'['#S1(W%^';V?
M7,=@L,HPW0Z,\Z,[SBZW%UK3J2KDMH!@X< P#"Y_%6<">D5J.ON/,#,'HS3)
MLC3Q27E42;W>-.ARE<ZG"O=H6FXYW0I!+M(;V1.AIQQJ.$[/+< 8IBVA(D+1
M&BUSF-T.UD$S2+?@4VC^I=/&$,^H"5I! RT3K;]A  C)H.$"(),&:A#-"%<R
M.)2Q]GG%+[AJC&S%MM1"I[>D_WLG\,_5-]A1TI_\FLQ5$*"4;#KU,*S<9]RT
M5:SJD>>U+EOC]$U!*U*SK.>^ZA=<,F[C3Q/EQMI2XR;AK$B;^6J+BP5'!M\'
M&B_0,I#7?JV=LOFB=7NZ'<-Z3'6QO(.N"%;EX2M0BKR*%\L2DRK=5ENV"*R4
M"CZ>3ZVL;Q;T%B .)G'[]AK= LU*KZL?P@5-781YC_DX.-=&H7)\((Z\ND?R
M176;[Z&>I;D7(K^\9F13V8^/D%&F!Z;9.A.V-$7=;!M]@?WI=NZW00^W/?O!
MZ)IPX$W7GWI2^_W@QPUN*V*[?17%H^E-^'F_%W"W-RXT]"Q:]5F[392,<5)/
M2S%9[%DLEH,:##PYUVX).<<:&"<GJ8GAQ%Y)A5&75$[3GY!QC9;.>J<K \W-
M4?LRO31@MC B"IRJ;I\8ZIK&=Z6E"> )!?EGV)=5"S+_84.,S[Z'&+]*[[M@
M1##KE8D94#>R3_)F'3S]U,GM'.P&]P$-.,VS/7?^RC?1Y:OL6F,*CC^\W78"
M.?W%>)BU25I-*)S/O2TETSA.4B/(P\ %)X1JP-J3?,[XXFL4ZD)T+,(+UX(*
M1LU#2P@4H$O\KW!1353"(2D^RPW >!SKO,>JEU6FS-;4:NAYU $-2@Y^D0S%
MS35<3DNE)F0KIX0WZ):%B,>EWC.X\0)IX@F6%ZA\G';JULDT>HC+5@!;V _J
M>K*32&159%E8H\VZ ,*4E HE)2FFJHKK(L28F8:2M(;G(SURVE./VILR?WYU
M+)DDT_6DO@T[6IIO@9HU(-5)D\N,.TQFJ7$B>&=SKVN)6V:_ZX/5]QVNL59S
M#T#TQG.W=X>APG7Y@4YEM_<#/0 <D-HB-Q9^BZ!_DYP23DUFT6J)AU0J\ &#
M$U-35+:"T+Q@<[1OYLRJ6;*A)L>Z$KTY;@/&],*?FUIRU/,Z][:W"W%1SEN0
MN@TWAJLX==L<";VO(7=#XI)17(/&1E)D*.Q06BCI^Q0A&WE9Y?6CMH%<5KYR
MN(,)V])&%9LGZW"^US!Y(VO6X+ZW[ AOI(/H979(<N@QGS^E-6,L#BB"(K)Y
M89!%N5Y&NR5S'^9 UM/>G%-707B6KHS$I%HP<.85 KMJ5.^*NG+Q3G)^!L';
MX+#\2BZ36R8@4BII &/ S0G++!5]&J1I<O<A356^DI;QY).UC$B+QOXCM0R3
M?[FF>3P!_>/=Q*T11-5)L9)_QQ5VPF:K"!_L=EJ?)-^D9M36I#FF.VE,*BTV
MFZ1.6;.*F0U#._H2QM'7O]]7I5IT"YP@==C>@%G8[6R1;GK85LSIE!HNI<O$
M2733/"HE0T_T4F( 3=Q5"^9D6M[FP<X3+_"U7;3G&K:3\8V@LDS53W]5*,6M
M,H>'=0S8)&GA]<;J;LSL<RSO6V!(3S^9(9WAAO^'<R/#1I(,0V3DBL^UU6S#
M$)*G\?::YZ?2)(E:*:TWD' :ZOFFVI9,$B)TTK2(*5:UX6XQ7KKO#=_LV<I-
MOQ)!$Z1'Q#*KN-E0'G[ B,P&F5$,'"<EL8)9(G!TW!BK?<1U,*9M>W%_I;W^
MRZ:QY$[(A.5FB!]ZG5(,CN!C TQ7H/;JV@45S=1LRD$6BL?$&(E#%M7BN98@
MH[>VS^VJ_>9,)Z=MU#;;*=A@.C4NPGU-J/H/OYXI!?+G0VVI^F2WXC-^$7OJ
MVR@/ZED+AM+ZC%2I=[02WDR-(1C>@[SM>%WC^2K1C.\-W34=GSVV0.)4@&T[
M2X#@W,V/F'V^A%O,S9@-YH1"&UJG>PVR1LE];;LN^.5L-9_! K5_(864G:P=
MKVZH'DK=4F3I94!U.UF2TBS<YJ@9^_E1HFTG-O[U==PHW;4%LPJ,*^VJ!*3:
M6Y%MHK74='/Y2*2IOV;"4)?,6,-!*!)WN(NZ'68^I&N29F5ZZ_OV<<X\I7H0
M3#L*9OI]PHD<N$8F,^J@FN=3(L9:TSL]9DXE\\XXD<K=JX2K'L&*)FN7NJC9
MJZXJ9#-A;?ORR;TPB].B7EN" 31J/L#Q>\06H,K-F)%,X/4(PMGN',D2;0/I
M[>0&+5LZV?#*Z%!C-=Q;QK?Y!TX>OFUM3PD7TGV"+O@5T ,BV3@B3G. 9,\2
M)2/$,6;2:E.)E,8P3=V)NCH +1J +5O:VQ$,P!\Y\O73]\C79^[OY+3X,ZD:
MG(PO,0R^I?N!EQ3+UUTQ<FJ-BHG-_V8:=U*F(28;TG\D0HU_$:W:1'X,"B17
MK4FRFUZ';K[[OD_DVR)^GRY6"\6QLJC!#'A#SVA3)3;A4TQ[L+W;5);=XZ76
M,U%AZQ!,'ZM2J0!K65 H7DRL'7,!\#"3J+X]MI#/+3_@05DQE)[VTP\X$DP2
MHHPW0I%FIR:YI$J!R$/?@T&>JC44!0YV+9#P'[@_MNO.FO1?F__<[1@50ED<
M&6$"^HZ@1ZUI%W*.6[765CFV>25/\*^'5TT1)(@54?C72%L<:H*MX/R-*7M6
M/OI07<52,RH=5;%"_@ $@>VW*($(;JKIK6C>$E(")BI=1.^,%4])1VS8E9KF
MA;3LJAI RD&=.8FZ$MF43^<7[/Q'IP>]B6Y98SX-*&W6"!C,7B#6A%.8GZS;
M)R>BYFV4*E6S4(.F_P*20^6%_"+%95H5W'I,&B6$5#.Z*BKG^XHNWFQ5LFKN
M=OC!?6Y=7$FX*!3.P?0\U 22?+8KR/+TFU4F(TE=JBQQ1XMX\8>[=I.PP*R4
M6#8H+?0G*>02C+'L,W6V-L$KQ1:JF#B^[N]#"?KJ+PTH7!C!+1CQKW6A"/Z1
M<O\S7JA)D*053O4<&A4=I!5Y&)+W4U6['2$:@JPGOU2KFHR;V="2/4E3;_!D
M#\B9EW,* A-8DV'W>G'(O89A\^(RD8X]\D)O2MS1C; :ZQO&$ W.G-N(=9HG
M3!/)>VR\6XJY25CVVA$2BZHJO=6<J85)X S-,C"*N''\:-Y:D2SG\<14;H-9
MPPGL/C4SL&UAMU#KL?EYIP7+FL<91P<U>6 @5$X)*_=H%2&(4FY3B1\"9\@7
MZ21T4D!M!T+'\;1]WON_47Z1)!D]<.77+PBKW<!,W@"Y-Y"/!/C<?/Y2/K\8
M'$7'"!C_K1=_"9HF^QE #R"[.HBGU+E0@3[)#+,>10NEZ35%JEF-*0> J6,E
M ;'H*#6BU^?[BGI+K?FD+\_+58KUAQF"T?4V0?%HO\<MH[C-&ZG!ME.(>$1(
M[MJ,"7TTS?IS>#-Y7S:_1+J$B2P1D9"R;\KU+]\?"^BKW82#QS[TY#EV)S@=
MWQ\>_"&+7QNHSJW:;;VQDCJFG+1AVYY%J[:I(PM9&8PNX7RC.%A8E"XY6^@R
MBPL0\%JN9*!LFS6-&V""%W=U[R5AEJT?S_'*L+5EA(HZ5TVC/U;X?-AE'Z5"
MRUZTY7B:F1],U-<.2G&)/1$U!]D/;#3AH*5H]#[(VA5'OD@)Y=C7-/  VOVP
M&#5_=$K"[*IEWG1A\?TH([^1RW9 EZVG0N-H,/[6KUBKTU\Q.1Q_9N)#?3CH
M'&[NV69$B.93W4X-W[4W]X(XBIQ'GFP"%X75","7P1N:AJ2#A1;QZYXP7ZU3
MJF%4$&Z1VXPQ5.6[K6TC(8.@KA1Z:N"U*+#:\!LD%2$Y<.X5-RI68!W&T'-0
M<ZR=[Z.0,$)BR+:5P&34ZJ?24DL=IQIH(#=Q/JMNT7'=CH&IJ+9TS^K@$LU,
M/AV,W^1J!L[<V"^\92C[.U,':ZI\5#_=4[>2T4[3UD744%#VU^$#^C8@*DA3
M#HFO,MVZ$!O)F89D(648;(TB9WFVITO6CG8^[&U[G^LJF5QG^3R_NK/GO\7E
M Y2827H@94FCS#.G@NMSNJG5$8B<S6!C#2RU L4)Z3B*KV3W E.]#/'<=P4,
M_XH#W6O;]%T&QM>\$:1!<EG"K\JV\TPIJWQQYU?>W&F\JP5>JDYXP15Z8,AB
MERZ";0GE/DXFI7RB[,H23%Q!S./0(C1KO\G&ECCHZ20"N:<ZPXNV]+6O:98#
M;.P[305[]?.#$=D,+_.L!3QT9,1'X!1M@"/Z_ A#>1&L788!'PH,]A"Z1[XX
M^) 5'<5:%"+&M,+KFR13/QA8"ZE]%BRB;H?!B/[8X;6_? ^O?6E5<1'$Q(D;
ME_HZEEZC=VIE6+;MZ#*&L$$?B)><]S[#+')TCFLLA(N1%#5:WP#LE2KPJP)[
M<TP"Z:=-]^U35-!ZAX&Q=ULH$\%7W@QVFK(/QK U\(#&Q<V2H:[+$FZGT65Y
M+"?U_O,L(VP@V+DZ8R"-71B4/+XLT0"4UIU;4?_Q3.[1M #EH IP72W&67C^
M5G/'X42H!^C$K 2<>X*$(F#I\E&6W(*$AFU::D'_G0OV2-^4/ B.;/88ZRWX
M?$ T59281@;PKNVL32U;J?1M1H4:F5 7[ER[?XI%?CQ7NJQ1CJKJ2D'L@#8D
MI!*'NIND^:ID,'G"KS3S)M+^P*U&AT8.!TVM%Z1" ^\62&IDD08)7?45NWVJ
M6>D&FMQ05[J)V)_FM]D\CT$RU521FIQ'#PKAU^D+UVE#YCSYI?'\[M^)3'F)
MU0:%MM%!!C.YSG-. N;2&$X,P]YKV(J=F]!;<ZCE907UELA%X9\G5S![3*!T
M\E1%C?E&W I//+?"\' P'K;BF#D@2P:T[!\7@W'O\-@",AE7X/$@>N$UE_D<
M#HG/A*O4D[ ,A:RIL2XW#AT<14/3A_/D;1 1)ANUKL4&I&XWSK"]%>G9"7;_
MQ+:FLH\13.&XV[$C[7'SV"-LXGE^,8Y&//1)%%(K47@KM?(\IRZ].'YT.N(Y
MX=?<;?4P.HU>#,;PPM[@B'JT8@O@(Q@4WGP2U1J'!KUQ((Y9&@,6B]^^N!A?
M#"-4I:E;,/<[I<>QH^GQ,>[(&,:-AB-JV=L_[@U.1M02UDQ=>J2>]-YR=]?Z
M+G4[.X/3_O'%$34@AK%U2KP?$7:8??%BT(^&8< ]=,_@7^/AQ6@<<?=966IP
M?MRK]P,.926#8=#OG??Z@S',?<0=4N&7IADK<.+><#"B+J\7N*TA-_#%#\9G
M]!;NEXL?4,M<_^CI^V/V:6-;UOHB VFFZ_=Q[78^;!1<C;M3A\.HAPNI=W0.
M@]&K'O=\'5T<_@VVC%KS#D[YE_;Z!N<7P]%%[W2L38E?1$C>Q]XS/?CYSB_!
MQ?YHO[^/+9CW@X,@ I$0_6-_-]C!GYDL\!>]GM,K>9_'[/6$^+L=F YVIAX/
MJ,WO$;?Q/;K 5SHMJGGVT3]AK2-X\OAM\!)IC,F;VTG3UKRX@,=>G W[/%CT
MXH4LE;?#78/=&KN%>#NB4_K]"?4#IN:Y8[R0_;.+H;U=8SR<OUT @1P-N.DU
MSQ">?<M+B'! N&M1<XO/AF"_XRC^KLH-&_7@+I[T3D_AR@)A]LP)\ RXU;;L
M(KH<7L"G>+WM?0S-V<%N8,ODZ)\T7^X>/.9&R\>]-Z%<PL.ADH]'"&85P=DI
MMST^P?\/1L'@"/M-Z_5A%D1]O7&Z<.<&<)POZ,+8T,YKNIFP\./>: 3LYN20
M&D#3:X'FSL^&.#'Z%KC&&4R\KS^JC8-3'X$$$18FD]S'C"+#E3Q6ZG&GDQ-8
M&XR 'SW"7M$PZ 4PD+?"JF2#C\_ZO>.0SY[FH*? ^Z84$P:'P!QP[<<#V%OB
MI:$_$A[$:?2FVWG5.SF'2SR,^/4O89O@;+ K\W"@+."Y/A[8I_NPX<?!</#R
MU9AZ?<,S@_%Q%+P># QOJSV"GQ_\\M./+&^ H(:#?N]4A :\L7>(?=2!0=N'
M?WDL#[^,:G/"4W)8DAW^+_R+LV-<)C8+!Z9O6>_P;,S]X+N='O;GQD?YH:!W
M]#?@U2<J6H81'-3@%"GMU$%$#<S/7O2 6Q_W#OFX3H]ZPZ-1[=O^$*@ >ZPC
M(1$YZ]<J-/ UL)WT5FQ(?D+-X^$*HP#0-?WE1Z9F'O=D<,RD<P*#]_'P(^I&
MCD/+&3LRP=TDHJI1*/=<9?%.OS=Z%5)K>[PVAV>G%RP:7:D#?](M,/O ,Y+W
MP2Q?]8;P-;,N_Z3PQHU!>9$_W@S/3E\"#W!E# ]FQ02)ZQ[F(5#V7:C-['ND
MEU#[<<,O]N_/5^#,CT=GVVZCT0A\26NE'N\KOI+:OY_C\H2%$M=72FG(.^^=
M]I+:%QYJ7WAA]WPCWN(.OH:KSW_A:U[#?A[1OS>^(Y -1!9'-[+)R)C4/4[F
M\-@W/?A@&  =1(-3&6R?+RS\XES$&,D85%6$''#,NE[5W'1D]#@P'$_T3YS
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M\9>.NP*O>'3VHDV?<O4O8HCG\&XD+!)%PDZ&K,">H<;:(_\![50?C).7K0N
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MG%3"?W[XY?#_<+72'B@C;X!4PXVXAW&\.SH#]O'D] C82*I- ZC_AO'<T[2
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M/$UR54Z+F@D\%TNAE6*&/GJCOK# F^'+]><PG^YDI^;2Y!.A8^O@^BJS<KD
M,3.RTO;UEO6J;^QD'T)"LF%QN9R,):$87+:]11Q3,=X( 7S9$4K0;Q])47RR
M)5WS(NH<Q$L67W215].D[P;M,VV;8#<2=R*Y2ZXU6Y%J#;:DOR4E\MK2KB!>
M1N<LH>E34JV#["KW=%MVBTR(UC!?T.82(FTGJ;QI:.*TK84C==]YO/9\SBZV
M/G4:8V@=*/C1/R)HU& WZVA1,Z*J1O<I*&_*=TF>)[]$?PR085XS'"(DN1S2
M^PY%Y]DG+Y8+@.1 #3V:+)EB/"3>)+KK*<,ID *<]HE6GMD#8W'9 &C!LQWN
M^1%R@!*6<R"8D!&C7Y#-].TI=(J(D=$Q\OF]U[F]$PVWO;5N&7I.9'L%.@*P
M$%F53BQZ]A>/"\D%!\/T^?2WRERA8P[QLLZ*^D+[$+GS1FY%C=I(H*[X6,._
M!?B->8!QQR&"A[(D\L%2,[VC/;N\,D)_'<GM8MHW Y[P0_<\@A?62H"='Z2:
MT_<(>3"#&5S_.[W8@8JN]94NR@ETH!Q0 A46, H9/TM:<-@=FJ'':I(]0%3\
MO#-(\L%%[[$./E]/"*_E1/%=+#4 Z3)LV).%!D_63:BZ2$A\[2O-R-RR"FP@
MW-L50*0,2LX';1MR_?KHQYWL=5E5;/(@STX@ B-(L#+"'(23[&=_ U[B)SJ9
MJ,TEZPJ[L*;6CI-J[FW>4?"SE7<YMZQF6@K;;4A+G!@[0NW>BK@A]$0(X8F9
MW!TT7 ].U0PX,.VYL1!XUM5%.4VYTP>)^6/^*.H-4(%/GY MRJ2TD^N0,MA.
MT  "6S*LT\FMM53RB6'YM</[2/.$UVY1&,)HZWB+-T)%/K56_6^^_YWGY(W[
M@0V)5KOHHP$:/B$PK.LVQ-.S 2^SV[X!U+U0),VR-BUP1><MALV3[&76K(*[
M.<D+X#&915G@:HG,;\ <6'OPD"!, 1U\1#]=* NS-)^K%UZC;=QA<ABT'_3!
M@%6Q ':<P8E-S7:NLYDAOX&TFYR8:(6&(J463F4K&>.EU4T3BE!([R]KPE6L
M!:P>,U.2D;P.*EG$![23AW@':8*9MK;DRAEJ9;63_:Z^:^V<5]<B+#Q7Q*.-
M&P<74^O$%"B_BKM)>!C8!JS7L>.6;TQF:ZL$;V[#4C")X#8PKZ1&AZ 0ZFO?
M**-M4%%UM4@<]LB[YDU*$'_VQ-M;K&:^P^JW4:?SPT/P^ANM2CTZ/CC\[=A7
MY_BNS,& 'A;[DQ?[]Z/3O?WS/2K\/=T[.?QP?K1_ULN.CJG]\_I6WPYLE0#\
M^7%]_F*M(WNSZ<SWRFJO/_D0UI]\<-D*+6S-<6YV$//TN&9UJ)THM[>Z$R2/
MR,N!B4A <G1C.5O:(\H^Z(1BPOD 5Z/NBJZGXI+LP%C3.(?5X'JZ)J-WF98/
M/HA+0PJA0,E79&(6Q@3?6GF0[SZ_-VDZ/=P_.M][=[9)PA,W+?/3A5JO\<S>
M5W(P [+*N L/V8O6;"+KWKJ>6AGA>UX49/[![!N%L9A>U&)[>^NCN0ZC%3 U
MK!J"%,\6^DCC>I>0=T@2*O$>?8:V(1J;&>KH*^/J\MP7J2WDV#2_O,-"OF(:
MM*XLGHXP?J[CY"P8RZZQL^'Z0]G/96P]1-[_(S'2CHG)HGF!.?T'M3:ET'QP
MUZJH/[HNY#5AK="*/*^EN7%>3'0]Z*;A'+2M%+5'Z5.'V9K,>@.B@BG;:)BB
M8$I<@39W/^$I7E85-W.!R8?Z)AX")4G(TA^:_R[SA0EJ2;2Q[*"H!LLIS>=
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MPP^'+\5W ^L4HFDC(0#-AU;CT"-Y'0*N0A NJ3;B]Q>*T!0Y/>/EMO()%)&
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M&^8":;\)+-DEC>,P:@I!F <4'>0Z\A *-P0R&@1/?5E.[,EH75BJ[&H ,;
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M U8\(8]9@9!02@1K%@!S6;G8@LM<(ZNCR!6>9*:!;-LM 6]%R)$9<DC*<@6
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MVBA8RT2T= 19O)I9=Y3RMH/Y_>AT;_]\+SO_]?!T[^3PP_G1_EDO.SK>WX%
MN-F(9R*X2_!&OQX>O?WUW,[OBWA^@\_]B^Y^UWGW^YOG+SNWKZ]?NDELETBW
M]YI7N.'>2ID]I8_ZJ#'P'_V1 1:1_>T)_OM$[<9#_5S_QM(%1?_M"<!Q/C6?
M0P2^V(!/2\+-_.^=[*2<FBJ?+?Y?+_MMYV"E+OA6%NN<$A=?U6KM7^0%E:6J
M%0&T^">I[>@<^O(+OKYC<(^C 2\S7M_='YX]R\YVK(&=6\/KUZOK[.F3I[WL
MS)K4)MM]^F0]^V%]T_-Y=7_SWWTKN,5HU-O>VK?FO+5]9T6>_;S[Y,F/Z3EA
M_X^LT5_8=?D\9N]79.,^^U0;]\5?T,;=>WMZ>'B0G;_/]HX/LKW]_<.3\\.#
MEP\&[H.!^V#@_K4,W-_RZJ/]&\6B\ZZC)6L/C/WS'Z_?'_S;?OCK^6_O?OG_
M4$L#!!0    ( %!!,U6$EHVV,D   (45 0 1    9#0P,3@Q,&1E>#$P,BYH
M=&WM?>ES$UF6[W='^'_(H&<F3(1L;$-!L101LBV#>FS+(\G0O!?O0UI*6=E(
MF9K,E(W[KW_G=\ZY2RZ2H8 RS-#145A2YEW./?MV7[T=GIZ\?O6VTSYZO;GQ
M:M@=GG1>=_ZQO;>[L__JD7RD[Q_I \&K@][1A^#@S6'OI-?_X\'[M]UAY\'K
M8'.#'CJ,DB+*7K\ZZKX+!L,/)YT_'MS$XV+ZXO>=W^+D01#.XJODCP>S:%(\
MX+'.S6/S,+N*D^TB7;S8710O _U\F19%.I>O)FE2;.?QOZ(7>^[S))S'L]L7
MPW@>Y<%9=!/TTWE(,[5/NF_._GB0Q5=3FNK5P>O.IVE\&1<!MA6\>G3P^M6C
M<^RK:07[3[[A$D8,$U[#H'/>[K>'W=Y9T'[3[W1..V?#H'UV%/0[)YWVH'/7
MNO;V5ZRKB#X5VW$RIJE>//GW/[?.?R[S(I[</G@]G,9Y,(@68186<9H$[:LL
MBN8T=! FXZ ?S:(PCX*M__C;WI-G+^V/^/C[RX<!O3L/QU%P><N/7T;%310E
M0?<ZS6C"V[R@$?7=SJ=HM"SBZ\B\2R]L;KR+LW!4A,%P&F7A(J('1GDKZ":C
MG6"KF$:!O'N8SA=A<FO>W!JELUDTPF"SVR"+)E&61>.@2(,P#]Q;YV%6Q%$N
M;P6T(H)9?!V/E^&L_EKHO60FV@GN 6WZG</NL'TR^#'0X_W;3I^0M178XPMN
M"%K1?#%+;PEX=/  N!X0 !D7>7 XC:.)]TIO,HE'4?9R'3SO;3\Y<2G:29AX
MWW5X?TP&CB"BR420#MM,)T%[D<6S_T@N\\7+QZU@?W?O68LQB1X>TX @IN45
M32R/[.VW-C?V=_?W"+'3JXB@EK4\9&V:4=%0P-;,/N\?:G2<QSWB;$8"3.,B
MVLX7X2AZD:0W1-0/7K>+[??Q;/;J$1Y\[0&W18B33&(L,@YG1/:3-)LS'P(/
MN,;7@&*.R>1Y<)EV1JR]RJZ(<IAB;N)B6D+)$AMQD\7%[0I _V#XB;4]?6E(
MCA&DMD=BPY=1G%S16K)YG(0%G8S#5N+N132_C#)%Q.= UOU]ALSFAH#&DP!'
M]+H%".#]PV ?MJQ,G6"03\&ZLRA/9R#)1$00\?9@'.>+91&1(!G-PGB.?PE0
M]&=2Y$2$5UD<78?)B!^8TN+Q!TDAVCS]L8B*6/_$>..(UC2&6 D+7H C@7EX
M&TQ#S'U%0^=%F1-B+?0O\0E\K8*4%DX<8AQ-8A#/931+;UHDED:SY9B.KQ5<
M+HL@28M@%L_C@F53J[0SV4\09G&.XT[I<9J 11L_=Q-"L,U">7=SXTXLHE=S
M=_23+)W[N]BY][,_Z[UO!4,@P'&OWP&LZ"R3G*A8EZSPG2\+$NO!@C80YU&^
MN<%J"?%8(HM6[6#<&>()*"_@!#B:"6D6Z4W^8LW&OY?@/^R]ZYRUSX8_B.3?
MH\._>'WH _O5HXO7.\%@>?E/XBP@OCIZR1=I(HSC+L&0I,EV%EVG(QU>Y$,Z
MV=PHH)9:_MPJGYJ9C3"AB),EX3K3=PR:=LP1O# 7_/#'XJ$$(59(@Q?KQ,#3
MSX#]\Z^%?4BP[[X>1-<$>.SI/&22??6H2_ ?^LB,-><XB@51OD/KD+XJB!YH
M]Q@E"=XNDW'&\IK@"#.)ADF7.3[6'MC<.(XG!) CHH4PRX.M?WNV^WOKV6^[
M#^D<A,L1/D08_#@E;5E'L ,.;]+2?-71GCQK[=-@Q&FS8$Y@F;:"69035UO0
M&8["RYD<XC2=@2D2'R:M()C0(# MMO9^>RARC%_-'<^JB##F%>%HE&;C,EYX
MQ@20*(NNEK2PS0V"8$9K)!X"6<#2P;XSB3/B[PLY!OHW9O7._:*#!&:,,> C
MO(3%,N2&E<=8G6!AJKQ?Q=<\79*$,J*&_I-"2R1)1ZM/E[.Q2)M+@(&78,RM
MAMU;+"^O'.M::]7\)>A]R>C]-@IG!-[#,,.9 -6OO@[3!1F/\:W%Q3,2M!89
MA1]M;JSA2(/X4W&[31ALF)%!6TLI- 4<'XS(O[6>/]W?>=9 &,,I!(JC,1[V
M.%UFI0&9$G&"9L3'K=VG3W;V?O_6Q$%[_BKJ"'Y:XH H^3+JZ!)@QN-8K)"B
M$05)JYA?+C.:NJP1XBSPC5DL_4EC\RM&5@401KQT.RXI+=<Q+,:I4 06=Q/-
M)B",RR@A91&X<4TJ'U8$$@QG(A%G\20B*.5+%A,/ \+SB#B9ARNS\";8.NP=
M]-L/UV)*RZW";:<@0I[=!A%\+8*PO!N,XXM>)=T% 609)JP8\(R*(OER-'40
M8T#3$Y>1>([P2 QLB4&\6X]W=5ECS$2$E"\O2:/+5=6C14+?G9@C$XTY36B5
M,6D-U9]A&/$ !13BNZ9R&Z?7#69ZL%QDT3Q>SBW_?'34?4=ZFKI!-S<"_O^K
M19 7M[.HK+)%\QI;Q5<+ MSV91:%'[<O(X)K]"*<D0Z?PU_ZZFT_&'3_#S&J
MQP_,D.R&??&WY_R_!\'[[M'P[1\/]G9W_]URV</.V;#3_TM\M-]4*(Q8*!RD
MR3+_$N[_&3R=L&(;?'EL>/H0-E\1\%S!EF>0Q<*VFGPQ#RUQL^T\B?,129W;
M*,P(S6%%\&\TE;(9F.1D\%E6F"QA@0/-&-U\T9T79-,:0Z8ZN@J>D@7_>%<L
M^)W-C7/#=3WB*\2ERP:MFOP[(\)^8KU$=;E3WQOX_4$:9F.LY2C.Z*D4"IMS
MH/"OU@N;8G%!N"RF:4:'SEHXDUID-L///R3PBE^"35R"\56:CH-)&$.X,2OG
M(_8(+<K8$03!E/)JZ:QSQ^")PXVF9,.+?DE#3@*"%!U@2UB_;YD8^.?A/ +H
M94*&<I@DL!DO@08PS+/(OJ[L#4S H*"Z/"'YP'-H&TD:L$(@H,4SS.K\80%P
M'C,DMBOH ^.<\6 K5OXC@HCY,K%+XLS%]"$O5:$(AC4F?D6@)+L6[+HB/4>S
M-+<PKQRHCTJT9J*/D;)D62"ABL .KH"MV*SI-,Q&4T6>WZK3A;,H&=-X=P]Z
M_[KFF-G*>9H7VT-UCH$\"3^R$72'\RB+T[%PG*]<Z][CKUULS(OM?"JBQ$B\
MQH4VL49"ZU;-15W7K42EB?Y["9,WO"'Z)!$9%9L;1''P!R6P^DWXK V+WV<
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MM]/)]@PK9C^QO777WAYK$YFM,J5)MEXIGS ZU5,DY5-WXXD+&PE2FO4]Y:M
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M/1/0Y_GN@9?]?83'X<Y[1&P;(STQ*I*^>'(F72K_N2\^C"[_\;0'"Y707G.
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M1F'69*/CFI,!9R]5U-1ZW&L7!X)FB?#'J.EVOOMI=]<#!8&8D1L#==TY'GU
MEQ)F+]V.X/\.P<VJ1:960U[E=R*>/BJAQ_88A.%F>ZQ@:;4OL[E<.!I '+Z]
M%%>C_T7N^/M67))G/_M_>\'_VQ*_CHZOW[[<VMO=_7Z9$(8G9]<GE_]O!T/+
M?-7M((PGNH@TB]*'Q>,!9)Z,DA=UU;!CP/F[9\_7W $,-4GNN[W^S_[K<?@:
MQ93 7,+(K700O/]@&O!$?]CDN#@G@!@7U\--F0!?7;=#BBH3%M254+<FNU41
M]JWDN0)V&?/HQ)@*H47<O$FC:^DSD^A!9US;$&CMS-#D%%([YH<>2=2H^,;O
MU"0\+#108.]DN8N5>N!\2PU'$;M#X5C-DF\0O!9+O4--GGH;M10T*#>!N\$?
M5S.P=/&V)OI/[Q$_NU[)@">UQ2OPCDY3E(03Z?PN@XF%+/V[7D-14IJ5*M!J
M#/I4),YD59-(5PE7.N>Q-01GM#I% GE?:,IVQ*1H;7[S%;W+SY&AO1B4!49H
MYW155\P7Q*L:? <>$(,454DSD2&+/1F=79T,CI_VOQ$E'ZQV@RU:#7,L4[HG
M3ZQDJP$4/JN&?K';N=.;]I;=%L\'QG#<!*#F=:AYCATSE9 5LG&W>_W7Z,=,
MWD8"H8I(ER-S] UOZ+?ND(BB/>+1$0+W:7V?PK$#J+BBK(])6CU 3J@ *><N
MP)# D$!!6%UPR*>D)C,=SR9=#?W'  '%"HO1,/_5^9ZI;6A2.:*HMZ0E"N;B
M[8C9U,;TQ:^^65HA[CT0>B+G*.H-.P\3GYAEUDR[,F:@&4]$PYA[[S#QH4!B
M@T"#29,=N/VCZ!R;NEH?L4QJQ*D2Z)BP0!M)#6+:K'K3U.B7+Q!7-(8?L(S+
MWN()_02C&((!*_-!9E,J6TEF8/6GR]'X!L%^^BOB?44H31P(5).[(WDK=89&
M4Q'; 4Q1$!2B"@2"BL*3M\>#X5/ D4]E@)NQXMCR$0$/C1?-T&5]$Z>R,#F<
M1+J-@HA*[LRRBQIB&^?C9"1H,\<=%6H4%KA1W+12:"=AT H+$^]S'OQ4OU2I
MI[XHL#[.\VX.H;N-NWB"OO7IIEGM715 [ZSB+L(KC@!%7ZZG_"IV0!(8Z\)G
M\V;*@&#THB)<:>!ZNX( #H=/Z+"ASC8Y*7;7[;T"[>TM<4<U'QVEI;*-R!Q7
MBU*Q@3^ID6_L$3=;-<MY,34<YU939??T0M%\7-^:BG;W2;OG,ZH_K>BAYRM5
ML0UTJ2P<)SU#M^^(J?%*)/,R!;>%MBJ3)7J%':LF!"YC%P)R'EZ]O^<@\.?G
MWQ\(%!%&P#;+O8] VCKZC\,=O!".!.)LXG&#@)E]&)QN[SV-MH"_Y@I9UH^J
M25[O!1FT"F<.XYUG2[5HR!%F"PR+SQ3>J@!$ZEMS54G")\I9(1W7P44Q5<0+
M)>I104KRD(= \KD[^_D4#\<>F<)_V7SZ2; =W('MT%>Q;Y)C!S0R_*ASW]J^
MV/T^EL&YL5D:BY1, 2!1FA+].8>RIGBB(Q9D%(^5#5FK#T;-1S%,BRV/0W-3
M4 YW #>48$P8V^VT\ALOB<=,42>9,D[#C:]-EIFYSV=A13]7]+M91<,L?P8
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ME.8>#YC'73=GS#_S\"8>^1=02P$"% ,4    " !003-5)HR[-N(?   UK@
M#@              @ $     9#0P,3@Q,&0X:RYH=&U02P$"% ,4    " !0
M03-5]K6*T)6C  #B_P( $0              @ $.(   9#0P,3@Q,&1E>#$P
M,2YH=&U02P$"% ,4    " !003-5A):-MC)   "%%0$ $0
M@ '2PP  9#0P,3@Q,&1E>#$P,BYH=&U02P$"% ,4    " !003-5Z(&]?BL2
M   Y.P  $0              @ $S! $ 9#0P,3@Q,&1E>#DY,2YH=&U02P$"
M% ,4    " !003-52=G9?4,#  !%"P  $0              @ &-%@$ =FER
M>"TR,#(R,#DQ-2YX<V102P$"% ,4    " !003-54=Z]('H&  "[1@  %0
M            @ '_&0$ =FER>"TR,#(R,#DQ-5]L86(N>&UL4$L! A0#%
M  @ 4$$S54$)]+; !   -RP  !4              ( !K" ! '9I<G@M,C R
C,C Y,35?<')E+GAM;%!+!08     !P ' +X!  "?)0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
